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Abstract
After initially being infected with a virus, before an adaptive immune response can be
mounted, the innate immune system of a cell recognizes and responds to certain patterns
present in pathogenic molecules. I studied the role of two genes—PIR1 and CD200R1—on
the innate immune responses in two diﬀerent mouse models of viral infection, infection with
the picornavirus EMCV (encephalomyocarditis virus) and infection with HSV-1 (herpes
simplex virus) in a mouse model of herpes simplex encephalitis, respectively.
PIR1 is a putative RNA phosphatase that has been shown to play an important role in
antiviral small RNA processing in C. elegans. It has also been shown to interact with the
RIG-I-like receptor LGP2 in preliminary mammalian experiments. I sought to characterize
the eﬀect PIR1 has on the innate immune response to the virus EMCV in mice. By devel-
oping a PIR1-null mouse, I have found that the role of PIR1 in the progression of EMCV
in mice is limited. However, in vitro studies show that PIR1 might play an important role
in regulating foreign RNA recognition during the earliest time points post-infection.
CD200R1 is an anti-inﬂammatory signaling molecule that is expressed on myeloid-
derived cells, and whose ligand is highly expressed within the central nervous system. I
investigated the role of this receptor in an intracranial model of herpes simplex encephali-
tis. CD200R1KO mice show improved survival following direct intracranial infection with
HSV. I found this increased survival can be attributed to decreased levels of viral repli-
cation in CD200R1KO compared to wild-type mice. Further investigation has shown that
CD200R1 aﬀects the signaling and upregulation of the pattern-recognition receptor TLR-2
(toll-like receptor 2), and thus CD200R1 may impact HSV-1 replication by aﬀecting TLR2
signaling.
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1CHAPTER I: Introduction
21.1 The Virus and the Human
As humans, we encounter potentially pathogenic viruses on a daily basis. While some
pose little risk to our health, there are many which could be life-threatening if allowed
to take hold within our cells. Fortunately, humans have evolved with both innate and
adaptive immune systems, such that in an otherwise healthy host, viral infection may result
only in a self-limited illness. For example, the Inﬂuenza A Virus (IAV) will manifests
in an otherwise healthy person as several days of fever, myalgia, and lethargy, typically
without long-term sequelae. However, when the immune systems are compromised—such
as in the very young, the very old, pregnant women, those with chronic medical conditions
or immunodeﬁciencies, and those receiving immunosuppressive therapies— this same virus
can overwhelm the host, leading to severe disability and even death. For example, the CDC
estimates that in the 2015-2016 ﬂu season nearly 12,000 people died as a direct result of the
inﬂuenza virus, a number that has ranged from 4,000-20,000 over the past ﬁve years (when
accounting for secondary deaths from complications of infection, those ﬁgures balloon to
16,000-76,000 annually) [1]. While there is value in vaccine research and understanding the
role of the adaptive immune system in resolving viral infections, there is still much we do
not know about our most basic and vital innate immune responses, the ﬁrst defense against
infection from the viruses that surround us every day. Therefore, this dissertation explores
the important roles of two proteins that function within the innate immune system - PIR1
and CD200R1.
31.2 Host Responses to Viral Infection
As mammals, our very ﬁrst defense against any foreign virus or microbe in the envi-
ronment includes a number of physical barriers such as our skin. However, if a pathogen
overcomes this physical obstacle, infection can begin. In the case of viral infections, this
process depends on cell entry, viral gene expression, and the manipulation of host compo-
nents to promote self-replication. In order to combat this process and limit the negative
eﬀects of pathogenic viral infections, the host can mount an immune response. These many
coordinated reactions, when eﬀective, are capable of mitigating—if not eliminating—a viral
infection. If the host is naive with respect to the infecting virus, the adaptive immune re-
sponse can take a few days to weeks to develop and then reach a conclusion. Therefore, the
immediate innate immune response serves as a critical ﬁrst-line defense against pathogenic
infections in mammals.
1.2.1 Pattern Recognition by the Innate Immune System
Without having encountered a particular virus before, mammals are still capable of
recognizing and responding to a viral infection through the function of pattern-recognition
receptors (PRR). While pathogenic microbes are highly varied and constantly changing,
they possess certain structural patterns that a cell is able to recognize as foreign. These
pathogen associated molecular patterns (known as PAMPs) are themselves quite varied,
and range from cell-wall components of bacteria to RNA molecules generated as replication
intermediates during a viral infection. Animals have evolved to recognize these patterns as
being associated with pathogenic organisms or tissue damage and respond accordingly.
As shown in Figure 1.1, in the hours to days following an infection a naive host is able
to produce a range of cytokines, including the type 1 interferon (IFN) molecules IFN-β and
IFN-α. This initial response, triggered by the PRRs of infected cells, is critical in hampering
viral replication, and in aﬀording the host the 4 to 5 days required to generate a virus-speciﬁc
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Figure 1.1: A schematic representation of a viral infection in a naive host. The innate
(purple and pink curves) and adaptive (green curve) immune responses as well as the con-
comitant eﬀects on viral titer (light blue shaded area) are shown following the infection of
a naive host with a viral pathogen. Immediately upon infection, the PRRs of infected cells
or of cells located near the site of infection recognize PAMPs generated by the infection
and initiative the production of antiviral (IFN-α and IFN-β) and inﬂammatory (TNF-α,
IL-6, IL-12) cytokines. This response promotes and directs natural killer cells and other
innate lymphoid cells to begin targeting infected cells. These responses combine to halt the
increase in viral replication, resulting in a plateau of viral titer. The inﬂammation and in-
nate response also has the eﬀect of kicking oﬀ the adaptive immune response. After several
days of selection and expansion, virus-speciﬁc antibodies and cytotoxic T-lymphocytes are
produced in suﬃcient numbers to mount a targeted and eﬃcient removal of infected cells,
dropping the viral titer until the infection is cleared. Adapted from Janeway’s Immunobi-
ology [2].
5adaptive immune response, in the form of pathogen speciﬁc T-cells and B-cells.
Extracellular PAMP detection
The ﬁrst interaction most cells have with a pathogenic microbe is extracellular. Many
pattern-recognition receptors are located on the cell surface or the luminal side of endo-
somes. Some of the most well-studied surface PRRs are the Toll-like receptors, a family of
evolutionarily conserved transmembrane proteins that are capable to sensing highly varied
PAMPs, including bacterial or fungal cell-wall components, viral proteins, and nucleic acids
(review by O’Neill et al. [3]).
The ﬁrst TLR protein identiﬁed in mammals was TLR4, also known as the LPS (lipopolysac-
charide) receptor, for its signiﬁcant contribution to sepsis following the inoculation of mice
with LPS [4,5]. Subsequent work identiﬁed ten total TLR proteins in humans, and 12 in
the mouse. Of these TLR2, as an example, has been found to recognize various bacterial
and viral molecules.
Toll-like receptor 2 TLR2 is a known to be activated by bacterial lipoproteins as part
of a heterodimer with either TLR6 to respond to diacylated lipoproteins [6] or TLR1 to
respond to triacylated lipopoteins [7]. TLR2 has since been shown to bind and respond
to a wide range of bacterial and viral PAMPs including viral glycoproteins present on the
viral envelope of Herpes Simplex Virus (gH/gL and gB) [8]. This interaction also involves
an interaction on the cell surface with the the αvβ3 integrin [9–11]
Upon binding to its ligand, TLR2—with one of its recognition partners TLR1 or TLR6—
signals via the intracellular activation of MyD88 [12]. MyD88 activation then leads to the
phosphorylation of IRAK-1, IRAK-2, and IRAK-4 [13,14]. These IRAK proteins interact
with TRAF6 [15], leading to the production of IKK complexes capable of degrading IκB,
resulting in the activation of NF-κΒ which translocates to the nucleus and turns on the
expression of several proinﬂammatory cytokines which are able to bring about a larger
response against the infecting pathogen[16].
6Negative regulation of innate immune signaling
While pattern recognition receptors are capable of recognizing pathogens and initiating a
response, too much inﬂammation can be detrimental, and for this reason many mechanism
exists to negatively regulate inﬂammatory processes. Some of these mechanisms include
negative regulators of certain pathways, like the expression of decoy pattern recognition
receptors which capable of binding and neutralizing immunostimulatory molecules before
they activate [17,18]
Other mechanisms of negative regulation focus on the immune cells which normally
respond robustly to pathogenic stimuli. These cell-based negative regulators induce an
anti-inﬂammatory state within a given cell limiting its capacity to induced inﬂammation.
One such negative regulator CD200R1, is capable of inducing an anti-inﬂammatory state
within a cell prior to stimulation with a pathogenic ligand and plays an important role in
limiting inﬂammatory responses within the central nervous systems (CNS)
CD200:CD200R1 signaling CD200R1 is a cell-surface protein that is expressed on many
diﬀerent myeloid-derived cells including macrophages and neutrophils, but especially mi-
croglia within the CNS. Upon engagement with its ligand CD200, CD200R activates an
intracellular signaling pathway that ultimately limits the inﬂammatory capacity of these
myeloid-derived immune cells.
CD200R1 is the best understood of the putative receptors for CD200. Aside from an
extracullar domain responsible for ligand binding and a transmembrane region, CD200R1
has a cytoplasmic tail responsible for conveying it signal following ligand binding. When
CD200R1 binds it ligand, its cytoplasmic tail becomes phosphorylated, resulting in the
recruitment of the signal mediators Dok1, Dok2, and SHP-1 [19,20]. Ultimately the phos-
phorylation of Dok1 and/or Dok2 and the activation of SHP-1 stimulates RasGAP [21]
leading to a reduction in TNFα and NO production following TLR stimulation [22] and an
negative regulation of NF-κB activation [23].
7The result of these anti-inﬂammatory signaling events are macrophages and neutrophils
that are less capable of responding to pathogenic stimuli. In this way, CD200:CD200R1
signaling is an important limiting factor in the progression of several autoimmune disease
in mouse models of arthritis, multiple sclerosis, and inﬂammatory bowel disease [24,25].
However, in the case of pathogenic infections, this negative regulation can sometimes be
deleterious, as is the case with mice infected with L. amazonensis. In this case, CD200-/-
mice have improved disease outcomes and are better able to combat the infection, due to a
stronger oxidative response against this typically indolent pathogen [26].
The role of CD200R1 in limiting inﬂammation is most pronounced in regions where too
much inﬂammation can be detrimental, like the central nervous system. Within the CNS,
CD200:CD200R1 signaling is a critical factor in reducing inﬂammation and disease severity
in mouse models of both N. meningitidis septicemia and [27] and Toxoplasma encephalitis
[28]. In the case of both of these infectious, the anti-inﬂammatory signaling of CD200R1
within the CNS has the eﬀect of protecting the CNS from too much toxic inﬂammation,
resulting in less damage to brain cells and a less severe disease course. Molecules like
CD200R1 are critical moderators of the innate immune response, and as such help keep
inﬂammation from becoming too harmful.
Intracellular response and Cytosolic RNA Receptors
While TLRs are important in alerting cells to extracellular PAMPs, viruses and other
intracellular pathogens do inevitably ﬁnd a way to enter a cell. For this reason cells also ex-
press certain cytoplasmic PRRs capable of detecting intracellular signs of infection. While
there are exceptions, many of the intracellular PRRs recognize nucleic acids. Certain DNA
and RNA structures—like 5’-triphosphorylated RNA, long dsRNA, naked DNA—are com-
mon to pathogenic organisms, and when these are encountered within the cytoplasm they
are recognized as signs of an infection. Upon detection of foreign nucleic acids, these
receptors—much like the TLR receptors—kick oﬀ a signaling cascade to respond to the
8infection. Cytosolic sensors exist that recognize both DNA and RNA, and ultimately they
again induce the production of type 1 IFN signaling, to reprogram host cells and limit vi-
ral replication (cytosolic nucleic acid receptors are reviewed in [29]). I will focus on RNA
sensors here, as they play a signiﬁcant role in later parts of this dissertation.
During the course of replication, many viruses introduce virus-derived RNA molecules
into the cytoplasm of the infected cell. While the cytoplasm of a given cell is full of host-
derived RNA molecules (mRNAs, tRNAs, and others), certain sensors are able to properly
discriminate between endogenous RNA and foreign RNA and activate the type 1 IFN re-
sponse accordingly.
RIG-I-Like Receptors Foreign RNA present in the cytoplasm can be detected by the
RIG-I-like receptors. This family of DExD/H RNA helicases includes RIG-I, MDA5, and
LGP2 [30]. Together these proteins serve as sensors for foreign RNA, binding to speciﬁc
RNA structures like 5’-triphosphorylated RNA and dsRNA and setting oﬀ a signaling cas-
cade that culminates in the expression of antiviral type I IFNs. RIG-I and MDA5 each con-
tain two CARD (Caspase activation and recruitment domain) domains on their N-termini
which are used to induce downstream signaling. Upon binding to stimulatory RNA, these
sensors undergo a change in conformation, leading to the activation of their CARD domains.
Their CARD domains are dephosphorylated by PP1α/γ and the second of their 2 CARD
domains also undergoes K63-ubiquitination [31,32]
Upon activation, MDA5 and RIG-I both colocalize with their signaling adaptor MAVS,
located on the mitochondrial outer membrane [33–36]. The activated RLR CARD domains
interact with the CARD domain on MAVS to initiate the formation of MAVS ﬁbrils, which
then serve as scaﬀolds for the recruitment of subsequent molecules in the signaling cascade
[37]. Ultimately MAVS activation leads to the phosphorylation, dimerization, and nuclear
translocation of the transcription factor IRF3. IRF3 then binds to the promoter regions of
type 1 IFN genes—IFN-β and the many IFN-α genes. The expression and subsequent secre-
tion of type 1 IFN cytokines leads to the activation of the type 1 IFN receptor (IFNAR1),
9the induction of the type 1 IFN cascade, and the expression of hundreds of interferon-
stimulated genes (ISGs) (reviewed in [38]) (Figure 1.2). Ultimately the expression of ISGs
result in making the cell less hospitable for viral replication.
RIG-I can be stimulated by several diﬀerent RNA structures. The most widely studied
is 5’-triphosphorylated RNA (5’pppRNA), although various other motifs and secondary
structures found during viral infection have been shown to activate RIG-I as well (reviewed
in [39]). 5’pppRNA is often generated during viral replication, while endogenous RNA
in the cytoplasm is capped. This 5’ppp motif serves as marker of foreign RNA. Upon
binding to RNA, the RIG-I CARD domain is rearranged in such a way to activate it. This
conformational change, along with dephosphorylation and ubiquitination of RIG-I, leads to
the activation of MAVS. RIG-I has also been shown to bind longer RNA molecules and form
ﬁlamentous aggregates along their length. These ﬁlaments are also capable of activating
MAVS with polyubiquitination [40].
MDA5 activation occurs in a similar manner, with MDA5 forming ﬁlamentous aggregates
along the length of dsRNA molecules, leading to CARD domain aggregation and ultimately
to MAVS activation [41–43]. MDA5 has been shown to recognize long segments of duplex
RNA. It is thought that MDA5 regularly samples and moves along duplex RNA molecules
via ATP-hydrolysis [44]. When it encounters an RNA molecule that is particularly long,
it is able to reside on the molecule for long enough to nucleate a MDA5 ﬁlament capable
of signaling downstream. It should be noted, however, that the most commonly studied
ligands for MDA5, polyIC, is a synthetic homopolymer that does not actually form clean,
uniform duplexes. In fact, work by Pichlmair et al. have shown that polyIC exists as a
high-molecular weight RNA complex, thought to resemble a tangled string. Furthermore
these larger complexes actually are MDA5-stimulatory, with similar RNA structures isolated
from virus-infected cells giving a similar eﬀect [45]. This suggests that there is some role in
having dsRNA segments interspersed with other secondary and tertiary structural elements
for optimal MDA activation. Finally, while MDA5 is the predominant sensor for polyIC,
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Figure 1.2: The RIG-I like receptor pathway for the recognition of virus-derived RNA
molecules. Virus-derived RNA molecules carry certain structural patterns which are de-
tectable by the RLR proteins, serving as cytosolic PRRs. RIG-I is known to bind to
triphosphorylated RNA and small RNA molecules. MDA5 is known to recognize long
dsRNA and RNA with complex tertiary structures. LGP2, the enigmatic third member
of the RLR family, is currently thought to bind to dsRNA and promote the activation of
MDA5, while inhibiting RIG-I activation in certain contexts. Upon activation, both RIG-
I and MDA5 converge on the signal adapter MAVS, which is activated and subsequently
triggers the phosphorylation, dimerization , and translocation of the transcription factors
IRF3 and IRF7. These transcription factors turn on many important genes, chief among
them the type 1 IFN molecules IFN-β and IFN-α.
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it also appears that the helicase Dhx15 plays a small, though not yet fully deﬁned, role in
activating MAVS in response to polyIC stimulation in some cells types [46]. The function
of Dhx15 appears to be independent of MDA5.
LGP2 is the enigmatic third member of the RLR family. Missing the critical CARD
domains used by RIG-I and MDA5 for MAVS activation, LGP2 appears to play a role
in facilitating the activation of the other RLRs, depending on the ligand. Recent stud-
ies have suggested that LGP2 functions to stabilize MDA5 binding to dsRNA molecules,
when present at the correct stoichiometric ratio [47]. Too much or too little LGP2 binding
however results in negative regulation of MDA5 signaling. Because of its enigmatic role in
RLR signaling, several groups have sought to identify which RNA structures or motifs are
bound by LGP2. LGP2 has been found to bind to triphosphorylated RNA, blunt-ended
RNA, dsRNA, and ssRNA, among others [48–52]. Additionally, pulldown experiments have
demonstrated that LGP2 binds to certain speciﬁc segments of viral RNA. In the case of
EMCV, a well-studied agonist of MDA5 and LGP2 [53,54], LGP2 has been shown to prefer-
entially interact with the L-region of the EMCV genome on the anti-sense (negative) strand
of viral RNA [55].
While MAVS ﬁlament formation and signaling takes place near the surface of the mito-
chondria, the speciﬁc location where signaling occurs within the cells is still up for debate.
Some recent evidence has suggested that RLR signaling takes place in or adjacent to RNA
stress granules—punctate structures formed in the cytoplasm of a cell in response to stress-
ful stimuli (oxidative stress, heat shock, etc.). Stress granules are thought to serve as
important mediators of RNA regulation and processing. A number of recent studies have
found that RLR receptors relocate to stress granules upon stimulation with RNA ligands
[56,57]. However, at least one report has found that RLR localization to stress granules is
not required for MAVS activation [58], suggesting that stress granules might not be critical
loci of RLR signaling.
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1.2.2 Antiviral small RNAs
While the prominent antiviral signaling pathways in mammals revolves around the pro-
duction of type 1 IFN and other cytokines that are capable of signaling in an autocrine and
paracrine manner, another pathway dependent on small RNAs can contribute to the innate
response. Antiviral small RNAs are critical to the innate immune response in worms and
ﬂies, and while they are not as critical to mammals, their full role is still under investigation.
The antiviral small RNA response in C. elegans
The nematode C. elegans employs a small RNA pathway to combat viral infections.
Upon infection, small RNA processing enzymes DCR-1 and DRH-1 along with RDE-3 bind
to and process viral dsRNA into primary antiviral RNAs that average 23nts in length
and resemble canonical siRNAs [59]. These primary antiviral RNAs are then loaded into
complexes with the argonaute protein RDE-1. These complexes recognize long, unprocessed
segments of viral RNA and recruit RNA-dependent RNA polymerases (RdRPs). These
RNA polymerases then generate short, complementary RNA molecules using the length of
the targeted molecule as a template [60,61]. The small secondary antiviral RNA molecules
that are generated are called 22G RNAs since they are predominantly 22nts in length and
usually begin with a guanosine. These 22G RNAs are thought to be the eﬀector antiviral
RNA molecules responsible for targeting and inhibiting viral RNA replication [59].
In C. elegans, the RLR orthologue and Dicer-associated protein, Dicer-related helicase
1 (DRH-1), is essential for the Dicer-dependent cleavage of viral dsRNA into primary vsiR-
NAs. Guo et al. recently demonstrated that worms lacking DRH-1 are unable to mount an
antiviral RNAi response against Orsay virus [62]. Intriguingly, the antiviral RNAi response
in these DRH-1-null worms can be rescued with a chimeric DRH-1 protein consisting of the
helicase and C-terminal domains of human RIG-I and a worm-speciﬁc N-terminal domain
[62]. More recently it has been shown that DRH-1-mutant worms are able to produce some
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primary avRNAs, however instead of being dispersed along the length of the viral genome,
they were predominantly from the RNA termini, suggesting the DRH-1 plays a role in
facilitating dicer translocation along foreign RNA molecules [63].
Virus-derived dsRNA is cleaved by Dicer to create primary viral small interfering RNAs
(vsiRNAs). Dicer’s DExD/H helicase domain appears to be important for the processing of
siRNA from a dsRNA precursor, while being dispensable in the processing of pre-miRNAs
into miRNAs [64,65]. These primary vsiRNAs are then thought to recruit RNA-dependent
RNA polymerase (RdRP) complexes to viral RNA [60,66,67]. RdRP complexes produce
large amounts of single-stranded anti-sense secondary vsiRNA, which are then incorporated
in RISCs, where they can target viral RNA for silencing [68]. Worms lacking an active
Dicer-dependent RNAi pathway are susceptible to infection by several natural and non-
natural viral pathogens, including single-stranded RNA viruses such as insect Flock house
virus, mammalian vesicular stomatitis virus (VSV), and Orsay virus, which naturally infects
C. elegans [61,69–72].
The antiviral small RNA response in D. melanogaster
Like the worm, the antiviral immune response inD. melanogaster involves the production
of antiviral small RNAs that are capable of blocking viral replication and gene expression.
While similar in many ways to the avRNAi response in the worm, the antiviral response in
D. melanogaster has a number of important diﬀerences. Flies have two diﬀerent dicer genes
(Dicer-1 and Dicer-2) that each have a unique role in processing small RNA ligands. Dicer-1,
in association with its RNA-binding partner Loquacious, is known to process pre-miRNAs
into functional miRNAs [73]. Dicer-2, with its RNA-binding partner R2D2, is responsible
for cleaving in a processive manner long dsRNA ligands into siRNA molecules [74]. It is
in this capacity that Dicer-2 is thought to function in the antiviral response, by selectively
binding to the ends of virus-derived dsRNA and processively cleaving oﬀ antiviral siRNAs.
Flies lacking Dicer-2 are susceptible to viral infections and are unable to mount a proper
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Figure 1.3: Antiviral small RNA pathways in the model organisms C. elegans and D.
melanogaster. (A) C. elegans: Virus-derived dsRNA is processed by the dicer protein
DCR-1 producing primary antiviral RNA molecules that are short and double-stranded.
These primary avRNAs are then employed by the argonaute protein RDE-1 to target other
viral RNA molecules for RNA-dependent RNA polymerization. RdRP products derived
from all along the viral RNA molecule are produced. The secondary avRNAs are gener-
ally 22nt longs, single-stranded, and beginning with a G. The secondary avRNAs are then
used by other argonaute molecules to carry out antiviral inhibition of viral RNA. (B) D.
melanogaster: Virus-derived dsRNA is processed by Dicer-2 into primary antiviral RNA
molecules. These avRNAs can complex with an argonaute protein and form a RISC com-
plex to targets viral RNA. If this complex is taken up by a circulating hemocyte it can lead
to the reverse transcription of viral RNA in to DNA, and then the de novo transcription of
new RNA molecules capable of interfering with viral RNA.
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antiviral small RNA response [75–77].
Unlike worms, ﬂies do not have a bonaﬁde RdRP enzyme. However, ﬂies do appear
to utilize an ampliﬁcation step in order to enhance their antiviral RNA interference re-
sponse. This is accomplished through the synthesis of a cDNA intermediate generated by
reverse transcribing viral RNA as carried out by endogenous transposon-associated reverse
transcriptases [78]. This reverse transcription reaction is thought to occur selectively in
hemocytes, a class of circulating cells in the ﬂy. These hemocytes can take up viral RNA
and use it as a template to generate complementary viral DNA. This cDNA is then used as
a stable and persistent template from which secondary antiviral RNAs are transcribed. The
secondary avRNAs are then thought to be transported from the hemocyte to an infected
cell. Since these secondary avRNA molecules are de novo RNA products produced in the
cytoplasm, they are uncapped on the 5’-end [79].
Primary or secondary antiviral small RNAs, following synthesis, are then loaded into
an argonaute complexs [80]. Interestingly—as is the case in C. elegans— the avRNAi
pathway in D. melanogaster appears to be distinct from the exogenous dsRNAi pathway.
In the case of ﬂies, the avRNAi pathway engages Dicer-2 and leads to the production of
antiviral siRNA molecules, but it also induces the production of antiviral molecules which
activate Jak/STAT signaling [81]. This Jak/STAT signaling is not observed when non-viral
exogenous dsRNA is introduced, again suggesting that exogenous dsRNAi and avRNAi
pathways, while overlapping, are not identical.
A mammalian antiviral small RNA response As there is no known mammalian RdRP,
it was initially thought that mammals did not have a antiviral small RNA response, as
they lacked any mechanism for amplifying the antiviral eﬀect. It was also supposed that
as mammals adapted the type 1 IFN response, they evolutionarily lost the small RNA
response, given that the IFN response is capable of signiﬁcant signal ampliﬁcation at each
step along the signaling pathway, and is an eﬀective antiviral defense.
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However, several recent studies have shown that mammals—speciﬁcally mice and human
cells—do in fact utilize smalls RNAs to mount an antiviral response. The picornavirus
EMCV was used to demonstrate that under certain circumstances, antiviral RNA molecules
are produced and do have an important anti-viral role [82] in a mammalian system. Maillard
et al. showed that mouse stem-cells do produce EMCV-derived small RNAs, which can be
loaded into RISC complexes, suggesting that avRNAi could be used to mount an antiviral
response. More recent work by Li et al. shows that small RNAs derived from Inﬂuenza
A virus are associated with Argonaute proteins in mouse cells and have an important role
in regulating viral RNA [83]. In these somatic mammalian cells, small RNA molecules
generated from longer dsRNA molecules are able to inhibit viral replication.
Even more recently, it was demonstrated that the mammalian avRNAi response does
interact with the type 1 IFN response, with type 1 IFN signaling serving as a potent
antagonist to avRNAi production [84]. Antiviral RNAs derived from exogenous dsRNA
were detectable only after type 1 IFN signaling was abrogated (either by mutating MAVS
or neutralizing IFNAR). It was further demonstrated that type 1 IFN signaling negatively
regulates antiviral RNAi in mammalian cells. It has been found that type 1 IFN can
negatively regulate RISC activity by inducing the p(ADP)-ribosylation of Argonaute or
other RISC components [85,86].
Taken together, the literature to date suggests that mammalian cells have two competing
antiviral response pathways: the antiviral small RNA response pathway and a cytokine-
driven type 1 IFN response pathway. The evidence also suggests that the type 1 IFN
response is the dominant antiviral pathway, and is capable of suppressing the small RNA
pathway. Moreover, it is evident that the mammalian antiviral small RNA response is
not capable of compensating for a missing type 1 IFN antiviral response, as animals lack-
ing MDA5, MAVS, IFNAR, and others type I IFN signaling components are signiﬁcantly
more susceptible to many viral infections. This suggests that while active, the mammalian
small RNA antiviral response is insuﬃcient to protect against most common mammalian
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pathogens, at least in the context of laboratory infections of model organism with pathogenic
viruses.
However our interactions with viruses are not limited just to those that make us sick.
Just as the body of knowledge regarding the gut and the environmental microbiomes has
exploded in recent years, so has our understanding of the human virome, the countless
viruses and phages that we encounter on a daily basis (well reviewed in [87]). Eukaryotic
viruses, phages, and endogenous retroviruses are prevalent in our genome, gut, and else-
where throughout out bodies. These indolent sources of viral RNA might be a reason why
mammals have held on to the avRNAi pathway.
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1.3 Conclusions
The innate immune response to viral infections in mammals is multifaceted, with cells
expressing a repertoire of PRRs, waiting to raise the alarm and launch an IFN response,
and with a small RNA response that can process and utilize viral RNA to launch a more
widespread, cytokine-driven type 1 IFN response. However, we are still just understanding
the varied and intricate interactions that lead to this common innate response. In this
dissertation, I will present my work on two such important aspects of the innate immune
system in mammals. The ﬁrst examines the role of the phosphatase PIR1 in the early viral
detection of mammals (Chapter 2). The second explores the surprising role of the anti-
inﬂammatory molecule CD200R in viral replication, speciﬁcally during HSV encephalitis
(Chapter 3).
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CHAPTER II: Investigating the role of PIR1 in the innate
immune response to EMCV
In addition to contributing to the design, analysis, and interpretation of the experiments
herein, I was assisted in processing experimental samples and carrying out certain assays.
Michael King helped perform the western blot analysis on cell lysates, ELISA tests on
serum and tissue culture supernatant, and genotyping of mice by complementary DNA
and genomic DNA. Anna Cerny assisted in mouse husbandry and genotyping of mice by
complementary DNA.
I designed the PCR primers presented in Table 2.2 and Table 2.4. I also developed the
PCR protocol used in Figure 2.6 and Figure 2.8 and generated the samples analyzed in
each. I performed the PCR experiments presented in Figure 2.8. I generated the visual
representation of the SNP data generated by Jackson Laboratories (www.jax.org) displayed
in Figure 2.5.
I generated the samples and performed the assays presented in Figure 2.9, Figure 2.10,
Figure 2.11, Figure 2.13, Figure 2.14, and Figure 2.16. I generated the samples analyzed in
Figure 2.12 and Figure 2.15.
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2.1 Introduction
2.1.1 PIR1 - protein that interacts with RBP 1
PIR1 (Phosphatase that interacts with RNA/RNP-1) is a member of protein phos-
phatase family known as dual-speciﬁcity phosphatases (DUSP), and is highly conserved in
animals as far ranging from nematodes to humans. While PIR1 (also known as DUSP11)
shares a conserved HCXXGXXRXG catalytic active site motif with other DUSP family protein
phosphatases [88], PIR1 is unique for its ability to bind with high aﬃnity to in vitro tran-
scribed mRNA molecules[89]. Additionally, PIR1 stands out from other atypical DUSPs as
it shares signiﬁcant sequence homology with the RNA phosphatase RNGTT/MCE1 (RNA
Guanylyltransferase And 5’-Phosphatase, or mRNA Capping Enzyme 1), homology that is
not shared by any other members of the DUSP family [90].
Beyond homology, PIR1 can function as an RNA phosphatase, while the other DUSP
family members are exclusively protein phosphatases. In solution, human PIR1 acts as a γ-
and β-phosphatase for short RNA molecules, producing 5’-monophosphorylated products
from 5’-triphosphorylated substrates [91]. Experiments performed by Deshpande et al.
using human PIR1 showed that in solution PIR1 has a several orders of magnitude greater
activity for dephosphorylating RNA molecules than it does for dephosphorylating peptides
[91]. These ﬁndings suggested that PIR1 could potentially act as an RNA phosphatase
within the cell.
As seen in Figure 2.1, the PIR1 protein has a catalytic domain, N- and C-terminal
arginine rich motifs (ARM), and a proline rich motif (PRM). PIR1 also has a predicted
nuclear localization sequence (NLS), and 2 predicted α-helices [89,92]. The ARMs have been
suggested to serve as RNA-binding domains [89] and might facilitate viral RNA recognition.
Likewise, the PRM has been hypothesized to function as an SH3-binding domain [89], and
could facilitate protein-protein interactions critical for the assembly of an RNA-detection
complex.
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Figure 2.1: A domain schematic of the mouse PIR1 protein, demonstrating two arginine
rich motifs (ARMs), a catalytic domain, the catalytic phosphatase active site, and a proline
rich motif (PRM).
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PIR1 is a well-conserved protein present throughout the animal kingdom, with the
human and worm version sharing substantial similarity. When aligned with one another
these two proteins show a 60.8% similarity (138 of 227 aligned amino acids) and 41% identity
(93 of 227 aligned amino acids) (Figure 2.2). Of note is the high degree of conservation
around the catalytic active site (C152 in the human gene, shown in blue in Figure 2.2), with
this region of the enzyme showing a high degree of identity between the worm and human
version of the protein (shown in red in Figure 2.2).
This level of conservation between the worm and human versions of the PIR1 protein,
especially around the catalytic domain suggests that its catalytic function is also conserved
between these two species. The human protein, as seen in Figure 2.2 does have a substantial
C-terminal domain, that the worm protein is lacking which might suggest diﬀerences in
how these two proteins interact and in which pathways they function in. More work will be
needed to better isolate and characterize each of the potential domains in the mammalian
PIR1 protein, including the C-terminal domain.
PIR1 in C. elegans
Work by Duchaine et al. ﬁrst hinted at a role for PIR1 in C. elegans in small RNA
processing. Using a proteomic approach, they sought to identify what proteins were inter-
acting with DCR-1, the dicer protein found in worms. PIR-1, among other proteins, was
found to interact with DCR-1 [93], leading the way for further investigation into what role
PIR1 might have in small RNA pathways.
Using a pir-1 mutant, Daniel Chaves Ph.D. (working in the lab of Craig Mello Ph.D)
in his doctoral dissertation demonstrated that, in the nematode, PIR1 plays a critical roles
in spermatogenesis, animal development, and antiviral immunity [94]. Speciﬁcally, with
respect to the its role responding to viral infection, Chaves showed that pir-1 mutant worms
are unable to control replication of the natural nematode pathogen Orsay virus. Without
PIR1 expression, this RNA virus is able to replicate to levels that are several orders of
23
C. elegans pir-1    1 MSNYHHNHNYQHRPRGY------ERLPGKRLPDRWNIYDNVGRDIDGTRF     44
                      ||.:||..:...|.|.:      ::..|..:|:||..|..||:.:.||||
H. sapien PIR1      1 MSQWHHPRSGWGRRRDFSGRSSAKKKGGNHIPERWKDYLPVGQRMPGTRF     50
C. elegans pir-1   45 VPFKTPLDSSFFDGKNMPVELQFGVKTLISLAQQANKQIGLVIDLTNTDR     94
                      :.||.||..||  .|.:..|..|....|.:..::.|:::||:||||.|.|
H. sapien PIR1     51 IAFKVPLQKSF--EKKLAPEECFSPLDLFNKIREQNEELGLIIDLTYTQR     98
C. elegans pir-1   95 YYKKTEWADHGVKYLKLNCPGHEVNEREDLVQDFINAVKEFVNDKENDGK    144
                      |||..:..: .|.|||:...||:|.:.|.:.: |.:||..|:.:.:::.|
H. sapien PIR1     99 YYKPEDLPE-TVPYLKIFTVGHQVPDDETIFK-FKHAVNGFLKENKDNDK    146
C. elegans pir-1  145 LIGVHCTHGLNRTGYLICRYMIDVDNYSASDAISMFEYYRGHPMEREHYK    194
                      ||||||||||||||||||||:|||:.....|||.:|...|||.:||::|.
H. sapien PIR1    147 LIGVHCTHGLNRTGYLICRYLIDVEGVRPDDAIELFNRCRGHCLERQNYI    196
C. elegans pir-1  195 KSLYEAERKKKYGKSSGKSSGNSADSTISSEQLHRNNSQ-----------    233
                      :.|.....:|.:..|..:|| :..||....:.:|....:           
H. sapien PIR1    197 EDLQNGPIRKNWNSSVPRSS-DFEDSAHLMQPVHNKPVKQGPRYNLHQIQ    245
C. elegans pir-1  234 --------------------------------------------------    233
                                                                       
H. sapien PIR1    246 GHSAPRHFHTQTQSLQQSVRKFSENPHVYQRHHLPPPGPPGEDYSHRRYS    295
C. elegans pir-1  234 -----------------------------------    233
                                                        
H. sapien PIR1    296 WNVKPNASRAAQDRRRWYPYNYSRLSYPACWEWTQ    330
Figure 2.2: A pairwise alignment of the human and worm PIR1 protein sequences. The
sequences were aligned using a global pairwise alignment algorithm and the BLOSUM62
substitution matrix. The highly similar alignment positions are denoted by a : and identical
alignment positions are denoted by a |. The catalytic active site (C152) is shown in blue, and
the highly conserved region adjacent to the catalytic active site is shown in red. Sequences
used are the human NCBI reference sequence: NP_003575.2 and the C. elegans sequence
WP:CE48135 from wormbase.com (http://wormbase.com). The sequences are aligned using
the Needleman–Wunsch algorithm with the EBLOSUM62 substitution matrix, a gap-open
penalty of 10.0, and a gap-extend penalty of 0.5.
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magnitude greater than wild-type animals. Deep sequencing studies showed that the pir-1
mutant worms are capable of generating many virus-derived small RNA. The pir-1 mutant
animals also had signiﬁcantly higher levels of primary antiviral small RNAs (these are
dsRNA molecules that average 23nt in length, and show hallmarks of being produced by the
Dicer cleavage of viral dsRNA). However, the pir-1 mutant animals had signiﬁcantly lower
relative levels of 22G RNAs (secondary avRNAs that carry out antiviral RNA inhibition,
as described in Section 1.2.2 on page 12), relative to the amount of viral RNA within the
cell [94]. Since these 22G RNAs, being RdRP products, are initially 5’-triphosphorylated,
one potential role for PIR1 in this pathway might be in the dephosphorylation of these
triphosphorylated 22G RNAs.
Taken together the data presented by Chaves demonstrates that PIR1 plays a critical
role in facilitating a robust and eﬀective antiviral small RNA response. Chaves suggests that
PIR1 exerts its eﬀect by promoting the production of eﬀective secondary 22G avRNAs early
on in the course of an infection [94]. How the RNA phosphatase activity of PIR1 aﬀects
this process is not yet well understood, but it could be that PIR1 facilitates the detection,
shuttling, or processing of triphosphorylated 22G avRNAs thereby promoting their eﬃcacy.
It is also possible that the processing of triphosphorylated 22G avRNA molecules into their
monophosphorylated form by PIR1 renders them better suited to carry out antiviral RNAi
either by increasing the eﬃciency of loading 22G avRNAs into their appropriate Argonaute
protein complexes or by increasing the inhibitory activity of these argonaute complexes once
formed. When ﬁrst discovered, it was noted that PIR1 binds to RNA molecules with high
aﬃnity [89], raising the possibility that the function of PIR1 might not be directly linked
to its phosphatase activity, but rather to its RNA-binding activity. Further investigation is
needed to better understand the true mechanism for the PIR1 phenotype in C. elegans.
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PIR1 in the mammalian system
Human PIR1 is similar in sequence to C. elegans PIR1, with 75% amino acid similarity
along the length of the expressed protein. Human PIR1 has been shown to bind RNA
with high aﬃnity and dephosphorylates the 5’-end of RNA molecules [89,91]. The crystal
structure of the core phosphatase domain of human PIR1 was recently solved and showed
that PIR1 does share many structure and ligand-bindings similarities with other RNA
phosphatases, further supporting the hypothesis that PIR1 functions as a RNA phosphatase
[92].
A number of additional studies have implicated PIR1 in RNA metabolism pathways.
In the study ﬁrst describing the PIR1 gene, Yuan et al. showed by confocal microscopy
that a labelled PIR1 protein is expressed in the nucleus, where it colocalizes with the the
splicing factor SC35 [89]. This same study also showed PIR1 interacting with the splicing
factors 9G8 and SRp30C using yeast two-hybrid analysis [89]. Another study, looking at the
regulation of PIR1 by the tumor suppressor p53, showed PIR1 interacting with yet another
splicing factor, SAM68 [95].
There are several sources of triphosphorylated RNA in a mammalian cell, with the most
well-studied being virus-derived RNA molecules. Many viruses produce triphosphorylated
RNA as a product of RNA-dependent RNA polymerization. These 5’-ppp-containing RNA
molecules are recognized as foreign since the vast majority of host RNAs found in the
cytoplasm have a 5’ cap or are monophosphorylated. Ultimately, these 5’-ppp viral RNA
molecules activate the RLR:IFN antiviral pathway. Since RLR proteins are orthologous to
the helicases DRH-1 and DRH-3, which are known to interact with PIR1 and are critical
for antiviral siRNA production in C. elegans, the link between RLR signaling and PIR1 was
investigated, again by the Mello Lab. Expression and co-immunoprecipitation experiments
by Darryl Conte Ph.D. showed that in unstimulated human HEK293T cells, PIR1 selectively
interacts with the RLR protein LGP2 and Dicer (Figure 2.3).
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Figure 2.3: Initial human PIR1 overexpression and co-immunoprecipitation experiments
performed by Darryl Conte Ph.D. show that PIR1 selectively immunoprecipitates with
human LGP2. (reproduced with permission from Darryl Conte Ph.D. UMass Medical School
Worcester, MA)
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Aside from a potential role in RLR signaling, PIR1 has recently been shown to have an
eﬀect on the production or maturation of certain RNA polymerase III products, including
miRNAs produced from viral DNA and various host RNAs [96]. These recent ﬁndings point
to a role for PIR1 is the maturation of atypical miRNAs or other small non-coding RNAs.
Therefore, for this dissertation work I set out to examine the critical roles of PIR1 in
the innate immune response to viral infection using a PIR1KO mouse.
2.1.2 The replication cycle of Encephalomyocarditis Virus
Given PIR1 was shown to interact directly with the RLR LGP2 by co-immunoprecipitation
(Figure 2.3), I sought to investigate the role of PIR1 in the mouse innate immune response
to encephalomyocarditis virus (EMCV), a response that is known to be dependent on LGP2
[54].
EMCV is a picornavirus (positive sense, single-stranded RNA, unenveloped), that nat-
urally infects rodents. EMCV also is known to infect pigs, a potential threat to livestock,
but a more serious threat to humans as porcine xenotranplantation continues to be exam-
ined as a potential solution for a broad range of human disease [97]. In the study of the
mammalian innate immune response, EMCV is widely used as a selective agonist of MDA5-
dependent, but not RIG-I-dependent, IFN induction. Groundbreaking work by Kato et al.
used EMCV to show that MDA5 and RIG-I detect and respond to diﬀerent RNA ligands
and infections, and therefore are not redundant despite the fact that they both activate the
the signaling-adaptor molecule MAVS [53].
EMCV infection begins with viral entry into a host cells. The mechanism of entry is
not well understood, but it is clear that EMCV has tropism for certain tissues—including
the heart, brain, and the pancreas—and that this tropism can be virus strain speciﬁc [98].
VCAM-1, which is highly expressed within the heart, is one of several molecules implicated
in EMCV entry [99]. Following the introduction of the positive sense EMCV genome into
the cytoplasm of the host cell, the genome recruits host translation machinery and begins
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producing viral protein. This process is cap-independent given an internal ribosome entry
site (IRES) in the 5’-UTR of the genome [100]. In total, the EMCV genome is roughly
7.8kb in length and encodes for 13 proteins, with at least one of them being in a diﬀerent
reading frame (called 2B* [101]).
The EMCV genome is covalently linked on the 5’-end to the viral protein VpG (a.k.a.
protein 3B). However, during ribosome binding this VpG protein cap is removed by the
host protein TDP2 [102]. The requirement of VpG removal for viral gene expression is virus
speciﬁc, but for several picornaviruses, it has been shown that VpG removal increases the
eﬃciency of viral translation [103]. Translation generally occurs along the entire length of
the genome, generating a polyprotein that is subsequently processed by the protease 3C
into mature proteins. The protease 3C is an active and promiscuous protease capable of
cleaving many host proteins including RIG-I [104].
Following viral gene translation, genome replication takes place. Replication occurs in
the cytoplasm in membrane vesicles formed through the rearrangement of the endoplasmic
reticulum. In order to generate negative strand molecules via RNA-dependent RNA poly-
merization (RdRP), translation must stop on the positive strand [105]. Once translation
has ended, the positive strand is positioned to allow for the template-driven addition of two
uridine bases to a VpG molecule [106]. The subsequent VpG-pUpU is then used as a primer
for RNA synthesis by the RNA polymerase 3Dpol, beginning at the poly(A) tail on the
3’-end of the positive strand. As the negative strand is synthesized a double-stranded RNA
intermediate—known as the replicative form (RF)—is generated [107]. Each negative-sense
genome is then used as a template for the synthesis of several positive-sense genomes simul-
taneously. The resulting RNA molecule, which consists of a single negative-sense molecule
associated with several positive-sense molecules at various stages of synthesis, is known as
the replicative intermediate (RI).
The ﬁnal steps of replication involve the formation of viral capsids around a viral genome.
While the exact mechanisms of viral assembly are not yet well understood, it is known
29
that only VpG-linked positive strand genomes are loaded into virions [108]. After virion
maturation, the exact mechanism by which mature, infectious virions egress are also not
well understood. As described by Carocci et al., several hypotheses have been put forward
explaining EMCV egress, including direct physical membrane rupture by an overabundance
of virions or the formation of membrane pores using viral proteins [109].
2.1.3 EMCV Pathogenesis in Mice
Rodents are thought to be the natural host of EMCV, especially rats, in which infection
can result in an asymptomatic and prolonged infection [106]. In mice, the illness caused
by EMCV is dependent on the strain of virus used and amount of inoculum administered.
Several strains, including EMCV-D, are well studied for their ability to induce diabetes.
EMCV is also capable of infecting many other organs in the mouse, but generally most
strains of EMCV cause encephalitis, limb paralysis, and myocarditis. Viral infection of
the mouse myocardium leads to necrosis of the myocardium and an inﬁltration of immune
cells. It is thought that NF-κB-mediated inﬂammation during the subsequent immune-cell
inﬁltration reaction leads to more severe disease in the heart [110–114]. The type I IFN
response has been shown to help slow the loss of cardiac function, following EMCV infection
[53], suggesting that viral damage and the resulting inﬂammation together contribute to the
observed myocarditis.
In the central nervous system, EMCV causes encephalitis and focal lesions within the
spinal cord. With a high dose of virus, paralysis is evident by 3 to 4 days post infection
regardless of the route of infection. In the brain, necrosis and gliosis are present, along with
cellular inﬁltration and perivascular cuﬃng typical of central nervous system inﬂammation
reactions [115–117]. The ultimate cause of mortality in the mouse is likely a combination
of the encephalitis and myocarditis, however certain strains of EMCV strains are capable
of replicating in the heart without causing encephalitis [115], and some strains will infect
the mouse pancreas and cause diabetes before the either encephalitis or myocarditis can
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manifest [118].
EMCV Detection by the Innate Immune System
EMCV was found to be a potent agonist for MDA5 [53], and subsequently LGP2 [119],
and much work has been done investigating how EMCV induces MDA5 activation and type
I IFN production. The exact mechanism of how EMCV activates this pathway, however,
is still not completely understood. RNA isolated from EMCV-infected cells and analyzed
for MDA5-stimulatory activity, showed that high molecular weight RNA complexes were
potent agonists of MDA5 signaling [45]. Further studies demonstrated that viral replication
is required for viral MDA5 ligand production. Additionally isolated RI and RF viral RNAs
were found to induce MDA5 activation [120]. Finally, using immunoprecipitation, it was
shown that a small segment of the antisense sequence of the Leader protein was bound
with high aﬃnity to LGP2 and was capable of activating IFN signaling in primary mouse
ﬁbroblasts [55]. Together it appears that during virus replication, EMCV generates several
RNA species that can be detected by MDA5 and LGP2.
At the same time, EMCV actively antagonizes these RLR:MAVS-driven detection mech-
anisms. The viral protease 3C cleaves RIG-I, rendering it inactive [104]. Expression of a
un-cleavable RIG-I variant results in RIG-I activation following EMCV infection and a more
robust IFN response. How EMCV activates RIG-I is unclear, and it is unknown whether
this activation is through the generation of EMCV-derived triphosphorylated RNA, short
dsRNA, or another RIG-I ligand. The Leader protein also actively antagonizes type I IFN
activation by directly interfering with IRF3 dimerization, preventing proper IRF3 activation
and translocation to nucleus [121]
2.1.4 Investigating the role of PIR1 in the mammalian innate immune response
Given that PIR1 was previously shown to interact selectively with LGP2 (Figure 2.3),
and that the type I IFN response to EMCV is dependent on LGP2 [119], I sought to
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Figure 2.4: A schematic representation of the replication cycle of encephalomyocarditis
virus (EMCV). (A) viral entry. (B) polyprotein synthesis. (C) negative strand synthesis.
(D) positive strand synthesis. (E) polyprotein processing and cleavage. (F) viral assembly.
(G) viral egress.
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investigate the role of PIR1 in the mammalian innate immune response by examining EMCV
infection in a PIR1-null mouse. I also examined here the eﬀects of loss of PIR1 on RLR
signaling using PIR1-null bone-marrow-derived dendritic cells in vitro. Finally, I began
investigations into the role of PIR1 in small RNA regulation.
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2.2 Materials and Methods
2.2.1 Generating a PIR1 gene trap mouse strain
Embryonic cells containing a putative null allele containing a gene-trap insertion within
the Dusp11 locus were purchased from the International Gene Trap Consortium (gene-
trap.org). The strain purchased was identiﬁed as Dusp11Gt(BB0198)Wtsi. The 129P2/OlaHsd-
derived cells carried a gene trap insertion in the Dusp11 locus on chromosome 6. This allele
is called the PIR1KO allele going forward.
A mouse strain was generated from the embryonic cells by the Transgenic Mouse Core
Facility at the University of Massachusetts, ultimately resulting in mice heterozygous for
the gene trap allele, which were then crossed with C57BL6/J mice for up to 11 genera-
tions. Unless noted otherwise, all experiments presented herein were conducted with N=11
backbred PIR1KO mice and C57BL6/J bred in house as wild-type control.
2.2.2 Genotyping the PIR1 gene trap
Genotyping via complementary DNA
A blood sample was collected via tail bleed from weanling mice. Approximately 6 drops
of blood were collected directly into 50 μL of heparin 50 U/mL, and stored on ice until
processing. Blood samples were centrifuged at 800×g for 5 minutes at room temperature.
The supernatant was removed, the cell pellet was resuspended in 500 μL of Red Cell Lysis
Buﬀer, and cells were incubated for 5 minutes at room temperature. The cells were collected
by centrifugation for 10 minutes. The supernatant and the top layer of the pellet were then
removed. The cell pellet was again resuspended in 500 μL of Red Blood Cell Lysing Buﬀer
(Sigma Aldrich; sigmaalrich.com; cat: R7757), and incubated at for 5 minutes as room
temperature. The cells were spun at 500×g for 10 minutes, and then washed in PBS. The
cells were pelleted a ﬁnal time at 500×g, and the pellet was resuspended in 350 μL of RLT
lysis buﬀer (Qiagen RNeasy RNA Isolation Kit).
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RNA isolation was then carried out according to the manufacturers speciﬁcations for
the RNeasy RNA Isolation Kit (Qiagen). Following isolation, the RNA was eluted once
with 30 μL of RNase free H20.
Complementary DNA (cDNA) was made using the Quantitect Reverse Transcription
Kit (Qiagen). 12 μL of RNA sample was used as starting material. PCR ampliﬁcation
of a wild-type transcript (expressed from a wild-type Dusp11 allele) and a gene trapped
transcript (expressed from a gene-trap allele) was conducted, along with ampliﬁcation of
a housekeeping gene as a control. The PCR master mix included, per reaction: 1 μM
forward primer, 1 μM reverse primer, 25 μL of HotStart Taq 2x Master Mix (Qiagen), 2.5
μL of cDNA, and H20 to bring the reaction volume to 50 μL. PCR was performed with the
following conditions: 95°C for 5 mins; 38 cycles of 94°C for 30 seconds, 60C for 30 seconds,
and 72C for 1 minute; 72°C for 10 minutes, and 4°C indeﬁnitely.
PCR samples were then analyses via a 1.2% agarose gel. 5.56 μL of 10× loading buﬀer
was added each samples, and 20 μL of this mixture was loaded into each lane. 10 μL of
ethidium bromide was added to the gel box, and the gel was run at 100 V for 30 minutes.
The gel was then imaged using a UV gel box.
Genotyping via genomic DNA
Tail tissue samples were collected from weanling mice. DNA was extracted from this
tissue using the DNeasy kit (Qiagen, qiagen.com, cat: 69504) according to the manufacturers
instructions. The DNA as eluted in 100 μL of AE buﬀer as supplied by the kit.
For each animal three reactions were set up: a control reaction, a wild-type reaction and
a gene-trap reaction. A master mix was made consisting of: 25 μL of HotStarTaq Master
Mix (Qiagen; qiagen.com; cat: 203443), 500 nM forward primer, 500 nM reverse primer, 2
μL of tail DNA, and enough H2O to bring each reaction to 50 μL. PCR was run with the
following conditions: 95°C for 5 mins; 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds,
and 72°C for 1 minute; 72°C for 10 minutes, and 4°C indeﬁnitely.
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Table 2.1: PCR primers used for PIR1 mouse genotyping by complementary DNA. To
detect the wild-type allele, the primers used are: DUSP11 F1, and DUSP11 R1. To detect
the gene-trap allele, the primers used are: DUSP11 F1, and Genetrap R2.
Primer Sequence Target
Dusp11 F1 AGAAGGGCAGAAACCACATC dusp11, exon1
Dusp11 R1 GTAGGATCTGCTGAGTCTTC dusp11, exon8
Genetrap R2 GTAGCCAGCTTTCATCAACAT LacZ gene, in pg101xr plasmid
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PCR samples were then analyses via a 1.2% agarose gel. 5.56 μL of 10× loading buﬀer
was added to each sample, and 20 μL of this mixture was loaded into each lane. 10 μL of
ethidium bromide was added to the gel box, and the gel was run at 100 V for 30 minutes.
The gel was then imaged using a UV gel box.
Sequencing Intron 1
Primer sequences were designed using NCBI Primer-BLAST [122]. The target se-
quence used was NC_000072.6 (Mus musculus strain C57BL6/J chromosome 6, GRCm38.p2
C57BL/6J, NCBI Reference Sequence) from position 85,961,962 to position 85,958,583,
which is a 3379 bp segment of the Dusp11 locus on chromosome 6. The primer query
included checks against the remainder of the M. musculus genome to reduce the risk of
spurious PCR products when gDNA is used. The other Primer-BLAST parameters are
listed in Table 2.3. The primers generated are listed in Table 2.4
2.2.3 Mouse cell line generation
Bone-marrow-derived dendritic cells
Bone-marrow-derived dendritic cells (BMDCs) were generated from 6 to 8 week old mice
using a protocol adapted from the one used by Lutz el al. [123] and Brandt et al. [124].
Mice were euthanized then, rinsed with 90% ethanol to reduce fur contamination, then
dissected to isolated the tibias and femurs. Each bone was cut on either end using sterile
scissors, and ﬂushed with RPMI1640 media using a 25G needle. Bone marrow was then
passed through a 70 μm cell strainer, and centrifuged for 5 minutes at 300×g at room
temperature. The supernatant was discarded, and the cell pellet was resuspended in 1 mL of
Red Cell Lysing Buﬀer (Sigma Aldrich; sigmaalrich.com; cat: R7757), and incubated at for 5
minutes as room temperature. After incubation for 1 minute at room temperature, 15 mL of
RPMI1640 was added, and the cells were centrifuged again for 5 minutes. This was repeated
37
Table 2.2: PCR primers used for PIR1 mouse genotyping by genomic DNA. To detect the
wild-type allele, the primers used are: dusp11intr1–4F, and dusp11intr1–4R. To detect the
gene-trap allele, the primers used are: dusp11intr1–4F, and Genetrap R2.
Primer Sequence Target Reaction
dusp11intr1–1F AACCAGCATTATGGCCGACA dusp11, exon1 control
dusp11intr1–1R CTCAAAGGACACCTCCGCTT dusp11, intron1 5’ side control
dusp11intr1–4F ACGAGGCTGGGTTTGTTAGG dusp11, intron1 3’side wild-type, gene trap
dusp11intr1–4R TGAAACGAGTCCCAGGCATC dusp11, exon2 wild-type
Genetrap R2 GTAGCCAGCTTTCATCAACAT LacZ gene, in pg101xr plasmid gene trap
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Table 2.3: A table of parameter used with the program Primer-BLAST to generate over-
lapping PCR primers that span Intron 1 of the mouse Dusp11 gene.
Parameter Value
Min total mismatches 2
Min 3’ end mismatches 2
Deﬁned 3’ end region length 5
Mismatch threshold to ignore targets 4
Misprimed product size deviation 4000
Max number of Blast target sequences 50000
Blast E value 30000
Blast word size 7
Max candidate primer pairs 50
Min PCR product size 200
Max PCR product size 1000
Min Primer size 15
Opt Primer size 20
Max Primer size 25
Min Tm 57
Opt Tm 60
Max Tm 63
Max Tm diﬀerence 3
Repeat ﬁlter AUTO
Low complexity ﬁlter Yes
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Table 2.4: Primer pairs used in Figure 2.6 to determine the insertion location of the gene
trap plasmid. These primer pairs target Intron 1 of the Dusp11 gene on chromosome 6 of
the mouse genome.
Pair Number Primer Name Sequence (5’→3’) Product length
Primer pair 1 dusp11intr1–1F AACCAGCATTATGGCCGACA 464
dusp11intr1–1R CTCAAAGGACACCTCCGCTT
Primer pair 2 dusp11intr1–2F GCAGGCTGACAAACCCTACT 225
dusp11intr1–2R TGTCGGCCATAATGCTGGTT
Primer pair 3 dusp11intr1–3F GTCAGCCAGTGTGTAGGCAT 483
dusp11intr1–3R CCTAACAAACCCAGCCTCGT
Primer pair 4 dusp11intr1–4F ACGAGGCTGGGTTTGTTAGG 309
dusp11intr1–4R TGAAACGAGTCCCAGGCATC
Primer pair 5 dusp11intr1–5F GATGCCTGGGACTCGTTTCA 519
dusp11intr1–5R CCACTTGAAGCCCTGTAGCA
Primer pair 6 dusp11intr1–6F AAGCGGAGGTGTCCTTTGAG 414
dusp11intr1–6R GCAAGCTGTCAGGCAAGTTC
Primer pair 7 dusp11intr1–7F GAACTTGCCTGACAGCTTGC 701
dusp11intr1–7R ATGCCTACACACTGGCTGAC
Primer pair 8 dusp11intr1–8F CCCTTTCTCCTGCCCACATT 346
dusp11intr1–8R AGCCTAACAAACCCAGCCTC
Primer pair 9 dusp11intr1–9F ACCCTACTTTCAGTGCGACG 985
dusp11intr1–9R CCACTCTGGGAAGGGAGAGA
Primer pair 10 dusp11intr1–10F GAGGCTGGGTTTGTTAGGCT 800
dusp11intr1–10R GAAGCCCTGTAGCACACGAT
Primer pair 11 dusp11intr1–11F ACATCCCCGAAAGGTAAGCG 711
dusp11intr1–11R TCCACTCTGGGAAGGGAGAG
Primer pair 12 dusp11intr1–12F ACTTTGCCCATGTTCACCCA 436
dusp11intr1–12R GAGCACACAGGTCTCCACAA
Primer pair 13 dusp11intr1–13F TTCAGGATGGACGTGATGGC 892
dusp11intr1–13R TGGGTGAACATGGGCAAAGT
Primer pair 14 dusp11intr1–14F TTGTGGAGACCTGTGTGCTC 597
dusp11intr1–14R GTTTGTGTCTCCCTGCCTGA
Primer pair 15 dusp11intr1–15F TGAACCCTTTACTTGCGGCT 251
dusp11intr1–15R GCCATCACGTCCATCCTGAA
Primer pair 16 dusp11intr1–16F TCTCCTGCCCACATTTTGCT 333
dusp11intr1–16R AAACCCAGCCTCGTGTCAAA
Primer pair 17 dusp11intr1–17F GTCCCTTGATCTCCGAAGCC 220
dusp11intr1–17R AGCCGCAAGTAAAGGGTTCA
Primer pair 18 dusp11intr1–18F ATTTGACACGAGGCTGGGTT 662
dusp11intr1–18R TGTTTGTGTCTCCCTGCCTG
Primer pair 19 dusp11intr1–19F CTTTCAGTGCGACGTGTGTC 289
dusp11intr1–19R CGCTTACCTTTCGGGGATGT
Primer pair 20 dusp11intr1–20F TCAGGATTCGGAAAGCGGAG 258
dusp11intr1–20R GGGCAGAGCATTCTGTCGAT
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as necessary until the cell pellet is no longer red. Finally, the cell pellet was resuspended
in RMPI R10 media—RPMI 1640 Dutch Modiﬁcation with sodium bicarbonate, 10% heat-
inactivated FBS, 2 mM L-glutamine, 50 μM β-mercaptoethanol, 100 U/mL penicillin, 100
μg/mL streptomycin, 20 ng/mL recombinant murine GM-CSF (Peprotech; peprotech.com;
cat: 315-03)—, and placed in the appropriate size tissue culture ﬂasks with the appropriate
volume of media: roughly 300 cm2 per animal. The ﬂasks were then incubated at 37°C with
5% CO2.
After 3 days, the non-adherent cells were removed by swirling the ﬂasks, removing the
media, and replacing with a half-volume of fresh RPMI R10 media. The removed media
was centrifuged at 350×g for 5 mins at room temperature, and then a half-volume of the
old media was returned back to the culture ﬂask. The remaining media and non-adherent
cell pellet was discarded. The ﬂasks were then incubated again at 37°C with 5% CO2.
After 3 more days, the non-adherent cells were removed again, as described above. The
ﬂasks were then incubated again at 37°C with 5% CO2.
After 2 more days, half of the media was exchanged while preserving non-adherent cells.
Half of the media from each ﬂask was removed and centrifuged at 300×g for 5 minutes. The
supernatant was discarded, and the non-adherent cell pellet was resuspended in an equal
volume of fresh R10 media. The ﬂasks were then incubated again at 37°C with 5% CO2.
After 1 or 2 more days, the cells were harvested, counted, and plated for stimulation.
The media and non-adherent cells were removed from each ﬂask, centrifuged at 350×g for
5 minutes, the supernatant was saved as conditioned media. 5mL of fresh RMPI1640 was
added to each ﬂask, and the cells were then scrapped oﬀ the bottom of the ﬂask, and
centrifuged at 350×g for 5 minutes at room temperature. The cells were then resuspended
in 5mL of conditioned media and counted using a hemocytometer. Cells were plated at the
appropriate for the experiment at hand in conditioned R10 media and incubated overnight
at 37°C with 5% CO2. The following day, the media was removed, and cells were stimulated
per the stimulation protocols.
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2.2.4 Preparation of EMCV stocks
The strain of encephalomyocarditis virus (EMCV) used was original purchased from
ATCC (American Tissue Culture Collection, atcc.org): VR-129B. The strain was passaged
four times on BHK-21 cells (ATCC).
To generate a highly-concentrated stock of EMCV, a monolayer of BHK-21 cells was
inoculated with EMCV at a multiplicity of infection (MOI) of 0.01, and incubated for 24
hours at 37°C and 10% CO2. At the point that roughly 90% of the BHK-21 cells exhibited
cytopathic eﬀect (CPE), the culture ﬂasks were freeze-thawed three times. From this point
the cell lysates were collected, centrifuged at 3,500×g for 15 minutes at 4°C. The supernatant
was removed and passed through a 0.2 μm ﬁlter.
EMCV was then puriﬁed by pelleting through a sucrose cushion. Brieﬂy, the ﬁltered
supernatant was placed in a 1 inch ultracentrifuge tube (Beckman Coulter; beckmancoul-
ter.com; cat: 344058) and then underlaid with 2 mL of sterile 30% (w/v) sucrose in PBS.
The samples were then ultracentrifuged using the SW32Ti ultracentrifuge rotor (Beckman
Coulter; beckmancoulter.com; cat: 369650) at 174,900×g (32,000rpm) for 2 hours at 4°C.
After ultracentrifugation, the supernatant and sucrose were aspirated oﬀ, and the EMCV
pellet was resuspended in PBS with 50 mM MgCl2. This viral stock solution was then
dispensed into 10 μL aliquots that were then stored at -80°C. One day later, two or three
aliquots were thawed on ice and titered by a plaque assay on BHK-21 cells in order to
determine the concentration of infectious EMCV by measuring plaque forming units per
mL.
2.2.5 EMCV plaque assays
BHK-21 cells (ATCC) were seeded in a 12-well plate at a concentration of 5×105
cells/well in 2mL of DMEM complete (DMEM, 10% heat-inactivated FBS, 2 mM L-glutamine,
100 U/mL penicillin, 100 μg/mL streptomycin), and incubated overnight at 37°C in 10%
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CO2. The next day, the media was removed from the BHK21 monolayers, and 1 mL of
10-fold serially-diluted EMCV-containing sample (virus stock, tissue lysate, cell-culture su-
pernatant, etc) was added to the cells, and incubated at 37°C in 10% CO2 with hand-shaking
every 20 minutes. After the one hour of inoculation, the virus-containing media was re-
moved, and 1mL of agarose overlay was added on top. The overlay consists of 1× MEM
and 2% low-melting-point agarose (w/v), which has been melted and then held at 42°C in a
water bath prior to overlaying BHK-21 cells. The cells were then incubated at 37C in 10%
CO2. After 36 hours, the 0.5 mL of a 0.5% crystal violet (w/v) and 4% paraformaldehyde
(w/v) in deionized H2O was added on top of the agarose, and allowed to stain the cells for
at least 2 hours at room temperature. At this point, the agarose overlays were removed, and
the ﬁxed monolayers were rinsed with water. The plates were then air dried, and plaques
quantiﬁed using a light box to illuminate the monolayers for visual inspection.
2.2.6 SNP analysis of mouse lineages
Tail samples from weanling mice were collected in a microcentrifuge tube, and shipped on
ice to the Jackson Laboratory (Bar Harbor, ME; jax.org). Personnel at Jackson Laboratory
performed the gDNA isolation and SNP sequencing. SNP sequences were compared to those
of both parental strains: C57BL6/J and 129.
The SNPs tested are listed in Table 2.5
2.2.7 Infection of mice with EMCV and collection of samples
For survival studies, 6 to 10 week old mice were inoculated via intraperitoneal injection
with 1×105 pfu/mouse of EMCV in 200 μL of sterile PBS. After infection, the mice were
then monitored once ever 12 hours for death or moribundity. Moribund mice were counted
as dead, and euthanized.
For time point sample collection, mice were infected with EMCV via intraperitoneal
injection. At the speciﬁed time points (6, 24, and 48 hours) mice were euthanized and
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Table 2.5: Positions and rsID numbers for SNPs tested to assess backbreeding.
Chr Location Ref SNP ID Chr Location Ref SNP ID Chr Location Ref SNP ID Chr Location Ref SNP ID
1 5215199 rs3708040 4 86563736 rs3659971 9 16021041 rs3719348 14 48792639 rs3659053
1 15968979 rs3684370 4 91021367 rs4136370 9 32541782 rs3716314 14 63543331 rs3702501
1 25731275 rs3666554 4 105891733 rs3664701 9 34646174 rs3659084 14 70097369 rs4230429
1 29774142 rs3695988 4 108237002 rs3664065 9 45669748 rs4227612 14 76489669 rs3664973
1 45504098 rs3654040 4 122489120 rs3702270 9 52358773 rs3654569 14 86443660 rs3666728
1 59272438 rs3687432 4 122489120 rs3702270 9 59238251 rs3685575 14 102295849 rs3686670
1 64459042 rs3697376 4 134927851 rs3679734 9 76102534 rs3685573 14 105343852 rs3656066
1 76386671 rs3699038 4 142898789 rs3718220 9 76938604 rs3676260 14 106254320 rs3677639
1 87687980 rs3678377 4 155091989 rs3680364 9 89297541 rs3709387 14 121343810 rs4230603
1 90636912 rs3670389 5 10671078 rs3676096 9 98249448 rs3692530 14 123545419 rs3685710
1 103425685 rs3720366 5 4082306 rs4225033 9 105983686 rs3657415 15 3219262 rs3687235
1 120375151 rs3680832 5 15336887 rs3673475 9 113824128 rs3721068 15 17000043 rs3726451
1 124137123 rs3676992 5 24922231 rs3664933 9 123551657 rs3706619 15 20138467 rs3662097
1 135256759 rs3022833 5 30708181 rs3023765 10 6998239 rs3724192 15 31846034 rs3023416
1 143991782 rs3663996 5 45444992 rs3663092 10 3496425 rs3090968 15 42657298 rs3667271
1 151052601 rs3710036 5 52211200 rs3655838 10 14976369 rs3701746 15 46631272 rs3024123
1 163725177 rs3706326 5 67053321 rs4225249 10 22906845 rs3665690 15 59162786 rs4230758
1 166321951 rs3707309 5 67053321 rs4225249 10 34297659 rs13480578 15 74316084 rs3724474
1 179305169 rs3668273 5 79046996 rs3678094 10 42421803 rs3716113 15 90278319 rs3724956
1 192267912 rs3699344 5 82943584 rs3705373 10 53462955 rs3696307 15 101641254 rs3023429
1 193617817 rs3715125 5 92720835 rs3704889 10 70714406 rs13480646 16 5596485 rs4153115
2 3151175 rs3713997 5 108807704 rs3656524 10 72243080 rs13480647 16 12604654 rs4162874
2 11988388 rs4137557 5 108807704 rs3656524 10 82455611 rs3717445 16 19883172 rs4165081
2 20293400 rs4139548 5 120432371 rs3670250 10 92728249 rs4228405 16 38174909 rs4174474
2 30268356 rs3689602 5 127277828 rs3705399 10 102471129 rs3716716 16 49089580 rs4184376
2 40450275 rs3697051 5 137912435 rs3141573 10 116830927 rs3670118 16 57292597 rs4189277
2 45047811 rs13476470 5 141533535 rs3717290 10 127890188 rs3719409 16 63792299 rs4195412
2 60302386 rs3714030 5 150598041 rs3722801 11 4408733 rs3659787 16 75143255 rs4205499
2 60302386 rs3714030 5 150598041 rs3722801 11 5684650 rs4222040 16 90383864 rs4217372
2 75946661 rs3699089 6 3416870 rs3661828 11 14903307 rs3703198 16 95329654 rs4221067
2 77028245 rs3670874 6 15441783 rs3658616 11 24386229 rs3673413 17 5885430 rs3694565
2 94918939 rs13476645 6 17673652 rs3023064 11 39780701 rs3717967 17 5079178 rs3667161
2 99962752 rs3686727 6 28731469 rs3706286 11 46666864 rs3686921 17 14468498 rs3664721
2 103824484 rs3697882 6 44823195 rs3706944 11 55679273 rs3671065 17 24105207 rs3673763
2 118811005 rs3691456 6 62010344 rs3706318 11 69560965 rs3668244 17 27244878 rs3684506
2 121850773 rs3726142 6 75345544 rs3671401 11 82677260 rs3663879 17 44300074 rs3677240
2 134586818 rs13476785 6 82284691 rs3707989 11 89314273 rs3682081 17 58335285 rs3710084
2 138397679 rs3726475 6 89242512 rs3708822 11 99441451 rs4229088 17 67755219 rs3023456
2 150727187 rs3704224 6 105174947 rs3665833 11 110246168 rs3712384 17 79284189 rs4231670
2 150727187 rs3704224 6 121990121 rs3727110 11 121116553 rs3675603 17 84394009 rs3707550
2 160792944 rs3693259 6 135557845 rs3684061 12 3701820 rs3675632 17 93598958 rs3023460
2 164979405 rs3661349 6 148260469 rs3711088 12 15131892 rs3709592 18 5207638 rs3706767
2 180489599 rs3680965 7 4796809 rs4226386 12 28835162 rs3712523 18 22098944 rs3707236
3 11297853 rs3680834 7 16621522 rs3675839 12 30739722 rs3091105 18 22098944 rs3707236
3 26231610 rs3698991 7 30566471 rs4226520 12 46426114 rs3701242 18 34759922 rs3701931
3 32477107 rs3659585 7 31508107 rs3662246 12 48020093 rs3665793 18 43083464 rs3676196
3 37166987 rs3141019 7 47576838 rs3675009 12 59053677 rs3706319 18 44777584 rs3675819
3 52508729 rs3685081 7 51751706 rs3710949 12 67818222 rs3677704 18 54721426 rs3715080
3 65133735 rs3022960 7 62576551 rs3671564 12 74706281 rs3683927 18 56780585 rs3721446
3 72409948 rs3681493 7 75671284 rs3710266 12 75826388 rs3655558 18 67794075 rs3657976
3 80234955 rs3672565 7 81780013 rs3672773 12 90384551 rs3711162 18 77973654 rs3725940
3 87174449 rs4224040 7 88680105 rs3656205 12 99535606 rs3719660 18 78443851 rs3686065
3 95750438 rs13459185 7 102503409 rs3670440 12 106091063 rs3663596 18 89629192 rs3663208
3 109572245 rs3712218 7 104479593 rs3710857 12 114496728 rs4229611 19 003490564 0
3 109572245 rs3712218 7 120464651 rs3680026 12 119290434 rs3686631 19 18669375 rs3691881
3 118532449 rs3721089 7 123671703 rs3654689 13 4160601 rs3695486 19 21510766 rs3692864
3 130432706 rs3089257 7 134811064 rs3697227 13 14446330 rs3680731 19 31481029 rs3681148
3 135357403 rs4136498 7 151765715 rs3664224 13 23788316 rs3679575 19 38517304 rs3695591
3 150231659 rs3725806 8 3189168 rs3701395 13 31508761 rs3654710 19 45627210 rs3160376
3 150231659 rs3725806 8 15191287 rs3709624 13 44496918 rs3023382 19 48212356 rs3023496
3 159329523 rs3665134 8 27414184 rs3684251 13 60682856 rs3713287 19 60842385 rs3023498
3 159329523 rs3665134 8 31235216 rs3691295 13 67941214 rs3023384 X 17889948 rs13483721
4 3649668 rs3694594 8 47006288 rs4137370 13 74990455 rs3667493 X 36252886 rs13483729
4 15072175 rs3090919 8 55938034 rs3661085 13 87813907 rs3666540 X 68674333 rs3161045
4 23212481 rs4138316 8 70607462 rs3089230 13 105301661 rs3687254 X 82748657 rs3664154
4 30384672 rs3707198 8 83509096 rs4227271 13 120254901 rs3710370 X 100102202 rs13483918
4 30384672 rs3707198 8 89791885 rs3706660 14 8613747 rs3701221 X 114022081 rs3690903
4 47160354 rs3654185 8 95465749 rs3089148 14 10592844 rs3689508 X 131483758 rs3702256
4 59942679 rs3654495 8 109771826 rs3683511 14 18484813 rs3678171 X 150081739 rs13484074
4 63785765 rs3656076 8 125471593 rs3693295 14 29772395 rs3719262 X 162753251 rs3698078
4 75302622 rs3655623 9 4020321 rs3694533 14 47715833 rs3661783
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organs were collected. For tissue lysates, pre-weighed 5 mL tubes with 500 μL of sterile
PBS were prepared for each organ. Organ hemisections were dissected and place into each
tube, which were then stored on ice until further processing. Each tube was then weighed
again, to determine the mass of organ contained within. At this point each organ sample
was homogenized using the Qiagen TissueRuptor (qiagen.com). The homogenates were
then clariﬁed by transferring to a 1.5 mL microcentrifuge tube, and centrifuged at 12,000
rpm for 10 minutes at 4°C. The supernatant was then removed to a clean microcentrifuge
tube, and stored at -80°C for future analyses.
For RNA sample collection, a 5 mL tube with 500 μL of Trizol reagent (Thermo Fisher
Scientiﬁc Inc; thermoﬁsher.com; cat: 15596018) was prepared for each organ sample. Organ
hemisections were placed into 500 μL of Trizol reagent on ice. (Thermo Fisher Scientiﬁc
Inc; thermoﬁsher.com; cat: 15596018). The tissue samples were then lysed in Trizol and
homogenized using a Qiagen TissueRuptor. Total RNA extraction proceeded according to
the manufacturers instructions, with the ﬁnal RNA pellet being resuspended in 50 μL of
RNase-free H2O.
2.2.8 ELISA
IFN-β ELISA was done using the Mouse IFN Beta ELISA Kit from PBL Inc (pblas-
saysci.com; Piscataway, NJ; cat: 42400-2). Serum samples were diluted either 1:5 or 1:10 in
the provided dilution buﬀer, and the assay was conducted at half the recommended volume.
Otherwise the assay was performed as instructed by the manufacturer.
ELISA tests for murine IL-6 were purchased as BD OptEIA kits from BD Biosciences
(bdbiosciences.com; cat: 555240), and performed as per manufacturer’s instructions. ELISA
tests for murine RANTES (CCL5) were purchased from R&D as the Mouse CCL5/RANTES
DuoSet ELISA (rndsystems.com; cat: DY478) and performed as per the manufacturer’s
instructions.
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2.2.9 qRT-PCR
Quantitative reverse-transcriptase PCR (qRT-PCR) was performed on total RNA sam-
ples collected from organ samples.
Complementary DNA was generated using the Quantitect Reverse Transcription Kit
(Qiagen; qiagen.com; cat: 205310). 1 μg of total RNA was processed for removal of ge-
nomic DNA, and then reverse transcribed using random hexamer primers. The resulting
cDNA, was then assayed for several genes using SYBR® Green PCR Master Mix (Qiagen;
qiagen.com; cat: 4309155).
PCR primers speciﬁc for the M. musculus genes Il6, Ifnb1, Isg15, and Gusb were pur-
chased from Qiagen (qiagen.com; cat: QT00098168, QT00249662, QT00322749, QT00322749).
PCR primers for the EMCV genome and mRNA have been previously validated by Car-
rocci et al. [115] and ordered as custom DNA oligos from Euroﬁns Genomics (euroﬁnsge-
nomics.com). The sequence for the forward EMCV primer is GGGATCAGCTTTTACGGCTTT ,
and the sequence of the reverse EMCV primer is TGCATCCGATAGAGAACTTAATGTCT.
Reaction mixtures were run on Eppendorf MasterCycle RealPlex qRT-PCR machines,
according to the SYBR Green protocol.
2.2.10 Western blotting
To blot for phosphorylated proteins, stimulated cells ready for lysis were ﬁrst washed
with PBS. Cells were then lysed with RIPA buﬀer (10 mM Na2HPO4 pH=8, 150 mM
NaCl, 1% NP-40 (v/v), 0.5% sodium deoxycholate (w/v), 0.1% SDS (w/v)) containing
fresh protease inhibitor cocktail (Sigma Aldrich; sigmaaldrich.com; 11697498001) and fresh
phosphatase inhibitor cocktail (Sigma Aldrich; sigmaaldrich.com; P0044). Cells were lysed
for 5 mins at 4°C, and lysates were collected by pipetting into microcentrifuge tubes. Lysates
were clariﬁed by spinning for 5 minutes at 12,000 rpm in a microcentrifuge. The supernatant
was removed and stored at -20°C prior to blotting.
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Protein levels in lysates were determined by microBCA assay (ThermoFisher; ther-
moﬁsher.com; cat: 23235), to ensure that a consistent amount of protein was loaded for
each sample. 8 to 10 μg of protein was loaded into each well of a freshly made 10% SDS-
PAGE gel, using a mini-gel casting system.
Preparing polyacrylamide gels
To prepare a 10% PAGE gel, a polymerization solution was made: 3.3 mL of Proto-
gel (30% (w/v) acrylamide: 0.8% (w/v) bis-acrylamide stock solution (35:5:1) National
Diagnostics; nationaldiagnostics.com; cat: EC-890), 4 mL of H2O, 2.5 mL of 1.5 M Tris so-
lution (pH 8.8), 200 μL 10% (w/v) SDS, 83 μL ammonium persulfate (BioRad; biorad.com;
cat: 161-0700), and 10 μL of TEMED (BioRad; biorad.com; cat: 161-0800). Prior to
polymerization this solution was poured into 2 assembled mini-gel cassette casts. Once the
polymerization solution was added to each cast, approximately 300 μL of butanol was added
as an overlay at the top of each. The gel casts were then incubated for an hour at room
temperature to allow for complete polymerization.
Running a loaded gel
Samples were prepared by mixing normalized samples with 2× Laemmli Sample Buﬀer
(BioRad; biorad.com; cat: 161-0737) at a 1:1 ratio. Samples were then heated at 95°C for 5
minutes. Samples were then placed in wells, and the gel was run at 90 V until the loading
dye reached near the bottom of the gel. The running buﬀer was: 3 g Tris-Base, 14.4 g
glycine, and 1.0 g SDS in 1.0 L of ddH2O.
Gel transfer
After the gel is done running, proteins were transferred onto a membrane for im-
munoblotting. A transfer sandwich of blotting pad, blotting paper, membrane, blotting
paper, and blotting pad was prepared. All but the membrane was submerged in transfer
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buﬀer, while the membrane was submerged in 100% methanol. The polyacrylamide gel was
then place on top of the membrane at the center of the sandwich, and all bubbles were re-
moved from between each layer. The transfer was then run on a semi-dry transfer machine
at 25 V (maximum of 300 mA) for 45 to 60 minutes. The transfer buﬀer consisted of: 3 g
Tris-Base, 14.4 g glycine, and 100 mL of 100% methanol in 1.0 L with ddH2O.
Immunoblotting
After transfer, the membrane was blocked with 3% (w/v) bovine serum albumin (BSA)
in TBS with 0.1% Tween 20 (TBS-T) overnight at 4°C. Blocking buﬀer was removed, and
primary antibody diluted in blocking buﬀer was added. Membranes were incubated with
primary antibodies overnight at 4°C. Membranes were then rinsed three times with TBS-T,
and then incubated with secondary antibody diluted in blocking buﬀer for 2 hours at room
temperature. Primary antibodies against phosphorylated proteins were used at a dilution of
1:1000, and primary antibodies against non-phosphorylated proteins were used at a dilution
of 1:2000. The secondary antibody used as an anti-rabbit IgG-HRP conjugate used at a
dilution of 1:30,000. Each of the primary antibodies were purchased from Cell Signaling
(cellsignal.com): phospho-IRF3 cat: 4947S, IRF3 cat: 4302S, phospho-STAT1 cat: 9167S,
STAT1 cat: 9172S. The secondary antibody was from Vector Laboratories (vectorlabs.com)
cat: PI-1000.
2.2.11 Confocal microscopy
Cells were plated into an 8-well chambered slide (Lab-Tek 8-chambered slide; Thermo
Fischer; thermoﬁsher.com; cat: 70411) at a concentration of 6×104 cells/chamber. After
incubation overnight, growth media was removed and replaced with media containing the
stimulant or media alone. After the indicated time, the stimulation media was removed, cell
were washed with PBS, and then ﬁxed with 4% paraformaldehyde (w/v) for 20 minutes at
room temperature. Cells were washed again with PBS, and permeabilized with 0.1% Triton
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X-100 in PBS (v/v) for 10 minutes at room temperature. Cell were once again washed
with PBS, then blocked with 3% BSA in PBS (w/v) for 1 hour at room temperature.
After washing with PBS, cells were incubated with primary antibody diluted in 1% BSA
in PBS (w/v) overnight at 4°C. The next day, the cells were washed with PBS, and then
incubated with secondary antibody diluted in 3% BSA in PBS (w/v) for 1 hour at 4°C.
Cells were washed a ﬁnal time, overlayed with ProLong® Gold Antifade Mountant with
DAPI (Thermo Fisher; thermoﬁsher.com; cat: P36931). A glass coverslip was place on top
of each slide, and sealed on the edges with clear nail polish, at which point the slides were
ready for confocal imaging on a Leica SP8 scanning confocal microscope.
2.2.12 miRNA nanostring
miRNA expression by Nanostring was conducted using the oﬀ-the-shelf miRNA code-
set (Nanostring; https://nanostring.com; cat: 150406, GXA-MMIR-24), according the the
manufacturers speciﬁcations. 100 ng of RNA was used for each sample, as measured by
UV/Vis absorbance.
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2.3 Results and Discussion
2.3.1 Generating a PIR1-deﬁcient mouse
In order to generate a PIR1 knockout mouse model, embryonic cells containing a putative
null allele containing a gene-trap insertion within the Dusp11 locus were purchased from the
International Gene Trap Consortium (genetrap.org). The strain purchased was identiﬁed
as Dusp11Gt(BB0198)Wtsi. The 129P2/OlaHsd-derived cells carrying a gene trap insertion in
the Dusp11 locus on chromosome 6. This allele is called the PIR1KO allele going forward.
The insertion is the linearized pGT0lxr plasmid, which contains a splice-acceptor site, a
stop codon, and a LacZ reporter.
These embryonic stem cells were used to generate transgenic pups that were then crossed
with C57BL6/J mice. Initially, to follow the PIR1 KO allele, a reverse-transcription cDNA
ampliﬁcation protocol was used. Backbreeding of the PIR1KO-allele onto a C57BL6/J
background was carried out for 5 generations, at which point tail DNA from several candi-
date oﬀspring were analyzed to determine what percentage of the original 129 background
strain persisted. The pup with the highest percentage of C57BL6/J-derived SNPs was
chosen to continue backbreeding. This was carried forward until generation 11. During
this time a genomic DNA genotyping protocol was established, allowing more reliable and
faster turnaround of genotyping results. At the 11th generation backbreeding, several pups
were once again chosen for SNP testing, by the same procedure. The panel of SNPs tested
were distributed across all 19 chromosomes, and were compared to the 129 and C57BL6/J
genomes.
The results of this analysis, as seen in Figure 2.5, show that at generation 5 (N=5) there
remained several background-derived loci scattered across several chromosomes. One region
of note is on chromosome 4, near the mouse type I IFN cluster, which overlaps with one of
these loci of parental-origin [126]. Additional loci of 129P2/OlaHsd-derived polymorphisms
were present on chromosome 16 and chromosome 19. By generation 11, all but one SNP
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N=11
Chromosome:
Figure 2.5: PIR1 KO mice nucleotide polymorphism analysis. Mice heterozygous for the
PIR1-gene-trap allele were brackbred to C57BL6/J mice for 5 (N=5) and then 11 (N=11)
generations. At these generations, DNA samples were collected and analyzed by polymor-
phism analysts. Each blue box represents a mouse chromosome. Each black line represents
a SNP that was sequenced and identiﬁed to be derived from C57BL6/J. Each white line
represents a SNP that was sequenced and identiﬁed as being derived from the background
strain of the original embryonic cells (129P2/OlaHsd). SNPs found to have been derived
from the background strain are also highlighted with red arrows.
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locus was C57BL6/J-derived. The remaining 129P2/OlaHsd-derived locus was present on
chromosome 6, and is adjacent to the Dusp11 gene. Taking into account the location of
the nearest ﬂanking C57BL6/J-derived loci, I can conclude that the N=11 mice have a
C57BL6/J-derived genome, with the exception of a region surrounding the Dusp11 gene
that can be no larger than 6 Mbp.
As female mice were bred to male C57BL6/J mice at several points during backbreeding
the Y chromosome was assumed to be be completely C57BL6/J-derived. The X chromo-
some, while not pictured, was also tested, and showed no 129P2/OlaHsd-derived SNPs at
N=5 or N=11.
2.3.2 Characterizing the gene-trap allele
Information provided along with the ES cells from the International Gene Trap Con-
sortium included the sequence for the interrupted transcript generated by the gene-trap-
containing allele which encodes a truncated Dusp11 transcript consisting of most of Exon 1.
From the sequence of this transcript provided, it was possible to surmise that the location of
the gene-trap insertion was somewhere upstream of Exon 2; however, this was not enough
information to develop a gDNA-based genotyping assay.
In order to pinpoint the location of the 5’-end of the gene-trap insertion, I designed a
series of PCR primers that would amplify adjacent, overlapping regions of Intron 1. These
primers were designed to amplify regions no larger than 800bp, since the inherent complexity
of this exon made ampliﬁcation of longer sequences diﬃcult. The results of this experiment
can be seen in Figure 2.6. Of the 20 primer pairs that were used, only four failed to amplify
a segment of the genome in PIR1KO gDNA. These 4 pairs targeted the ﬁnal 400 bps of
Intron 1, narrowing down the insertion to this small region just upstream of Exon 2.
In order to sequence the intron:gene-trap junction, I PCR ampliﬁed this region using the
forward primer from primer pair 4, and a reverse primer targeting the LacZ gene present
in the gene trap insertion. Sequencing this product gave the exact position of the 5’-end of
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Figure 2.6: PCR analysis of intron 1 of the Dusp11. 20 PCR primer pairs were designed
along the length of intron 1 to amplify in an overlapping manner the entirety of the intron
and its ﬂanking exons while ensuring that no single amplicon was larger than 1kb. Using
this method, I was able to identify exactly where the gene-trap insertion is located within
intron 1 in the PIR1KO allele. Primer pairs 4, 10, 14, and 18 produced no PCR products
when incubated with genomic DNA derived from a Dusp11-KO mouse. This pinpointed the
gene trap to within last last 400 bp of intron 1. Further analysis allowed for the sequencing
of the point of insertion.
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Figure 2.7: A exon schematic of the wild-type and null alleles of the murine Dusp11 gene.
The gene-trap insertion containing a splice-acceptor site (SA) and stop codon is positioned
toward the end of intron 1. Splicing of exon 1 to the gene-trap insertion results in a null
allele, producing truncated mRNA transcripts.
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Figure 2.8: A robust genomic DNA PCR protocol was developed, which allowed for easy
and reliably genotyping of the Dusp11-KO allele. Primers amplifying the upstream junction
of intron 1 and the gene-trap insertion are used to identify the presence of the gene-trap
allele.
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the gene trap insertion. With this information, I was able to develop a robust and reliable
gDNA-based genotyping protocol, the results of which can be seen in Figure 2.8.
2.3.3 EMCV infection in vivo
To test whether PIR1 plays a role in the pathogenesis of EMCV in mice, I infected wild-
type C57BL6/J mice and PIR1KO mice (backbred to N=11) with 1×105 pfu of EMCV by
intraperitoneal injection, and collected tissues at various time points.
EMCV titers from heart and brain samples
EMCV was recovered from heart and brain homogenates at 6, 24, and 48 hours post
infection. Tissue homogenates were serially diluted onto monolayers of BHK-21 cells to
measure the concentration of plaque-forming units per mL of organ lysate. The results of
these studies are shown in Figure 2.9. The progression of EMCV infection in wild-type and
PIR1KO mice is demonstrated by steadily increasing levels of infectious EMCV virions in
the heart and brain as the infection progresses from 6 hours to 48 hours.
EMCV infection of heart tissue was detectable at 6 hours post infection. Of the wild-
type mice infected with EMCV three of ﬁve had detectable levels of virus ranging from 15
to 250 pfu/mL. Of the PIR1KO mice infected for 6 hours, 3 of the 4 mice had detectable
levels of virus, which averaged 40 pfu mL/mL. By 24 hours all of the infected mice had
detectable levels of virus in their heart, and by 48 hours these titers reached an average
of approximately 250 pfu/mL. Infection of brain tissue was not detectable until 24 hours
post infection, when 3 out 5 wild-type and 4 out of 6 PIR1KO mice had detectable levels
of virus. In these mice the titers ranged from 80 to 300 pfu/mL. By 48 hours, all the mice
tested had detectable levels of EMCV in their brain, with values ranging from 200 pfu/mL
to 2000 pfu/mL with an average around 950 pfu/mL for each genotype.
In this model of EMCV infection, EMCV was seen to infect the heart and reproduce
to detectable levels much more quickly in the heart than in the brain. However the rate
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of change of viral titers from 6 hours to 48 hours shows that viral replication in the brain
might be faster. With respect to the comparison of wild-type and PIR1KO mice, these data
show that PIR1 does not aﬀect EMCV replication to a signiﬁcant extent during the ﬁrst
two days post-infection.
Inﬂammatory and viral RNA expression levels in heart and brain samples
In order to test whether PIR1 aﬀected viral RNA production or the transcription of
type I IFN and inﬂammatory cytokine genes, I isolated RNA from the heart and brain of
infected mice. cDNA was prepared for qRT-PCR analysis of mRNA expression levels of
IL-6, ISG15, IFN-β, and EMCV genome/transcript RNA.
In the heart (Figure 2.10), several RNA expression patterns can be seen. First, the
amount of viral RNA increases between 6 hours post infection and 24 hours post infection.
At 24 hours post infection PIR1KO heart tissue had a higher concentration of viral RNA
than the heart tissue of wild-type mice. Interestingly, organ homogenates did not show
a signiﬁcant diﬀerence in viral titers (as shown in Figure 2.9) in the heart at 24 hours
post infection, suggesting that PIR1KO hearts had more viral RNA per infectious particle
when compared to wild-type hearts. Between 24 to 48 hours, the amount of viral RNA
in PIR1KO mice remains high and relatively constant, while the wild-type mice show an
increase in viral RNA such that there is no longer a signiﬁcant diﬀerence between the
knockout and wild-type.
In infected hearts, mRNA levels of the cytokines IL-6 and ISG15 are upregulated from
6 hours to 24 hours post infection in both mouse genotypes. However, again, at 24 hours
PIR1KO mice exhibit higher levels of both IL-6 and ISG15 in the hearts when compared to
wild-type mice. These diﬀerences are gone by 48 hours in the case of IL-6, and diminished
in the case of ISG15, with both cytokines not showing much more upregulation between 24
to 48 hours post infection.
In contrast, IFN-β expression in the heart follows a unique kinetic pattern from 6 hours to
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Figure 2.9: Measurement of EMCV titers in the heart and brain of wild-type and PIR1KO
mice. EMCV titers of brain and heart homogenates form wild-type and PIR1KO mice.
Mice were infected with 1×105 pfu by intraperitoneal injection. Bisections of whole brain
and whole heart were isolated at the designated time points post infection, lysed, and super-
natants collected by centrifugation. EMCV was titered on BHK-21 cells. Each represents
a wild-type mouse, and each represents a PIR1KO mouse. Wild-type and PIR1KO groups
were compared using the Mann-Whitney U test. No signiﬁcance was detectable in any of
the comparisons.
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Figure 2.10: Gene expression in the heart following infection with EMCV. qRT-PCR was
used to measure gene expression from total RNA isolated from heart lysates. Mice were
infected with 1×105 pfu of EMCV by intraperitoneal injection, and organs were collected
at 6 hours (A, D, G, J), 24 hours (B, E, H, K), and 48 hours (C, F, I, L) after infection.
The expression of the EMCV 3dPol gene (A, B, C), IL-6 (D, E, F), ISG15 (G, H, I), and
IFN-β (J, K, L) were normalized to the housekeeping gene GUSB. WT and KO groups were
compared using the Mann-Whitney U-test. Each represents a wild-type mouse, and each
represents a PIR1KO mouse. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
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48 hours post infection. In wild-type mice IFN-β gene expression remains fairly unchanged
until 48 hours at which point it decreases, presumably because of downregulation. The
PIR1KO mice, however, show an early decrease in IFN-β expression at 24 hours, and then
a subsequent increase at 48 hours post infection. On account of these opposing changes, the
PIR1KO mice have signiﬁcantly less IFN-β gene expression at 24 hours and signiﬁcantly
higher levels of IFN-β gene expression by 48 hours.
In the brain, the same genes were analyzed at 6, 24 and 48 hours post infection (Fig-
ure 2.11). In the brain homogenates, the amount of EMCV RNA is seen to increase dra-
matically at each time point, but no diﬀerences between mouse genotypes are observed.
Additionally, IL-6 and IFN-β levels can be seen increasing up to 48 hours post infection,
but I did not observe any signiﬁcant diﬀerence between the wild-type and PIR1KO mice.
In contrast, ISG15 mRNA expression levels appear to drop between 6 and 24 hours post
infection in the PIR1KO mice. ISG15 expression levels in wild-type mice were equivalent at
6 hours and 24 hours post infection and decreased between 24 and 48 hours post infection.
Together, this data from heart homogenates (Figure 2.10) and brain homogenates (Fig-
ure 2.11) show that PIR1 may play a dynamic and tissue-speciﬁc role in modulating com-
ponents of the immune response. EMCV is known to have diﬀerent pathological eﬀects
depending on the tissue that is infected. This is consistent with my ﬁndings from RNA
expression analysis of brain and heart homogenates which show diﬀerent patterns of gene
expression. Furthermore these data show that PIR1 appears to aﬀect the progression of the
EMCV infection in the heart, between 6 hours and 24 hours, by partially controlling viral
RNA production, but the diﬀerence between wild-type and PIR1KO animals disappears by
48 hours post infection. In the brain, PIR1 appears to not aﬀect viral replication, with only
ISG15 expression at 24 hours showing a diﬀerence between the two genotypes.
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Figure 2.11: Gene expression in the brain following infection with EMCV. qRT-PCR anal-
ysis of gene expression from total RNA isolated from brain lysates. Mice were infected with
1×105 pfu of EMCV by intraperitoneal injection, and organs were collected at 6 hours (A,
D, G, J), 24 hours (B, E, H, K), and 48 hours (C, F, I, L) after infection. The expression
of the EMCV 3dPol gene (A, B, C), IL-6 (D, E, F), ISG15 (G, H, I), and IFN-β (J, K, L)
were normalized to the housekeeping gene GUSB. WT and KO groups were compared using
the Mann-Whitney U-test. Each represents a wild-type mouse, and each represents a
PIR1KO mouse. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
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IFN-β expression in sera samples
In order to test whether PIR1 has an eﬀect on the global expression of IFN-β protein in
EMCV-infected animals, I collected sera from each mouse at 24 and 48 hours post infection
with EMCV. I then measured the amount of IFN-β protein expression by ELISA analysis.
As seen in Figure 2.12, there is was no signiﬁcant diﬀerence in the circulating levels of IFN-β
in the wild-type and PIR1KO mice at 24 hours and 48 hours post infection.
PIR1KO mice do not have a diﬀerence in survival rates following infection with EMCV.
Finally, I wanted to investigate whether PIR1 plays a role in protecting mice from lethal
disease following infection with EMCV. Previous work had demonstrated a role for MDA5
and LGP2 in protecting mice from EMCV [53,54]. In these studies, loss of MDA5 or LGP2
resulted in a dramatic acceleration of death following infection with EMCV. I hypothesized
that PIR1 might play a role in this response due to its interaction with LGP2 (Figure 2.3).
I hypothesized that PIR1KO mice would succumb to infection much faster than wild-type
mice.
As can be seen in Figure 2.13, there was no observable diﬀerence in the rate of death
when comparing wild-type to PIR1KO mice. Both genotypes showed 100% mortality by
100 hours post infection, with the majority of mice from each group succumbing to infection
by 75 hours post infection.
2.3.4 Investigating the role of PIR1 in vitro
In an eﬀort to better elucidate the role PIR1 plays in type I IFN signaling in vitro, I
generated bone-marrow-derived dendritic cells from wild-type and PIR1KO mice and stim-
ulated them with viral stimulants. After overnight incubation (18 hrs), supernatants were
assayed by ELISA for IFN-β levels. The combined data from three independent experi-
ments can be seen in Figure 2.14. The results from these replicated experiments do show a
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Figure 2.12: Measurement of IFN-β from the serum of EMCV-infected mice. Serum was
collected from wild-type and PIR1KO mice infected with 1×105 pfu of EMCV by intraperi-
toneal injection at 24 and 48 hours post infection. The concentration of IFN-β was then
measured by ELISA. Wild-type and PIR1KO samples were compared using the Mann U-
test.
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Figure 2.13: Mortality of mice to EMCV. Wild-type and PIR1 KO mice were infected with
1×105 pfu of EMCV by intraperitoneal injection, and monitored for death. PIR1KO mice
show no survival advantage following infection with EMCV.
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diﬀerence in IFN-β production between the two cell types. The wild-type BMDCs induce a
15-fold change in the amount of IFN-β in the culture supernatant when compared to back-
ground. In contrast, the PIR1KO BMDCs only yield a 7-fold increase in IFN-β production
following overnight stimulation with EMCV. While both cell types produced substantial
amounts of IFN-β in response to EMCV, the PIR1KO cells produce less. Both cell types
responded to Sendai virus, suggesting that the IFN-β defect seen in the PIR1KO cells is
EMCV-speciﬁc.
PIR1-deﬁcient cells show diminished RLR pathway activation
As the 18-hour stimulation of BMDCs showed that PIR1KO cells have a modest defect
in their ability to produce IFN-β, I sought to investigate whether PIR1 was playing a
role at earlier time points post stimulation. I transfected wild-type and PIR1KO BMDCs
with the synthetic MDA5/LGP2 ligand and viral RNA mimetic polyIC. In order to monitor
MDA5/LGP2:MAVS pathway activation, I looked at IRF3 phosphorylation by western blot.
Following RLR activation and the initiation of RLR:IFN signaling, the transcription factor
IRF3 undergoes phosphorylation, dimerization, and then translocation into the nucleus
where it can turn on the expression of the type I IFN genes (Figure 1.2 on page 10). I also
assessed the phosphorylation status of the type I IFN receptor signaling molecule STAT1.
Phosphorylated STAT1 serves as a marker for how much type I IFN cytokine has been
released and subsequently bound to its receptor on the cell surface.
Using lysates collected from BMDCs stimulated for 2 and 4 hours with transfected
polyIC, I looked for phosphorylated IRF3 and phosphorylated STAT1 by western blot (Fig-
ure 2.15). I found that at 2 hours post stimulation the PIR1KO cells had substantially
more phospho-IRF3 and phospho-STAT1, when compared to the wild-type cells. This dif-
ference was gone, however, by four hours, with both cell lines showing equivalent levels of
phospho-IRF3. At 4 hours post stimulation phospho-STAT1 appears to be absent in both
cells lines (while total STAT1 is consistently present). It is possible that by 4 hours post
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Figure 2.14: IFN-β ELISA on BMDC cell supernatants. The data shown are mean ± SD
of duplicate determination of IFN-β from three independent replicates of BMDC diﬀer-
entiation and stimulation. Cells were stimulated for 18 hours, supernatant collection, and
measurement of IFN-β by ELISA. EMCV was used at an MOI=10, Sendai Virus was used at
80 HA/mL. Signiﬁcance was tested using a ratio paired t-test testing wild-type to PIR1KO.
ns = not signiﬁcant.
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stimulation STAT1 has become inactivated and dephosphorylated. This is consistent with
previous ﬁndings that STAT1 inactivation is a fairly rapid process with active, phospho-
rylated STAT1 being absent from the nucleus by 4 hours in human ﬁbroblasts stimulated
with IFN-γ [127].
2.3.5 The eﬀect of PIR1 on small RNA pathways
Since PIR1 plays a prominent role in facilitating the production of antiviral small RNAs
in C. elegans [94], I sought to investigate whether PIR1 aﬀects small RNA processing or
expression.
PIR1KO cells appear to have increased baseline expression of many miRNAs
As PIR1 is known to interact with the dicer molecule Dcr-1 in C. elegans, I wanted to
see if PIR1 plays any role in global miRNA regulation. Using a miRNA Nanostring codeset,
I measured the expression of the annotated miRNAs relative to housekeeping genes. Fig-
ure 2.16 shows that in wild-type mice, following stimulation with EMCV, several miRNAs
increase in expression level. However, this stimulation-induced increase in miRNA expres-
sion is absent in PIR1KO cells. Instead, as can be seen in Figure 2.16-C, at baseline—
without any stimulation—the PIR1KO cells have a global upregulation of many miRNAs.
This is an intriguing result, and suggests that PIR1 might be having global regulatory
eﬀects on the miRNA expression pathway. PIR1 has been shown to promote the stability
of certain non-canonical miRNAs and other small RNAs [96]. It is possible that I observed
a similar eﬀect. With a loss of PIR1, as other small RNAs are destabilized, canonical
miRNAs, which are detected by the Nanostring-miRNA assay, could be upregulated.
<div class="added" remark="add-generation"">
It should be noted that this experiment was conducted with not yet full backbred
PIR1KO mice (N=6) and littermate wild-type mice as controls. While polymorphisms
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Figure 2.15: PIR1 appears to play a role in the earliest stages of RLR signaling. (A) Whole
cell lysates from WT and PIR1KO BMDCs show that PIR1KO BMDCS have greater accu-
mulation of phospho-IRF3 2 hours after transfection with polyIC. However, this diﬀerence
is gone by 4 hours, as the wild-type and PIR1KO cells appear to have equally high levels if
phospho-IRF3 at this time point. Additionally, the PIR1KO cells appear to have increased
levels of phosphorylated STAT1 at 2 hours. A diﬀerence that once again is absent by 4
hours. (B) Biological replicate, showing decreased IRF3 phosphorylation at 2 hours post
transfection with polyIC.
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Figure 2.16: PIR1KO-derived BMDCs appear to have higher expression of certain miRNAs
in an unstimulated state. This results in a failure to properly upregulate these miRNAs
following infection with EMCV. Cells were stimulated for 6 hours with EMCV or media
control, and total RNA was assayed via the Nanostring miRNA reporters. (A-D) Dot plots
showing the expression level of each miRNA. (A) Wild-type cells before and after infection
with EMCV. (B) PIR1KO cells before and after infection with EMCV. (C) A comparison of
miRNA expression levels in unstimulated wild-type and PIR1KO cells. (D) A comparison
of miRNA expression wild-type and PIR1KO cells following infection with EMCV. (E) A
heat map showing the log transformed fold induction of the 50 most diﬀerentially induced
miRNAs, following stimulation with several stimuli. Mice used in this study were N=6
backbred PIR1KO mice and littermate wild-type controls.
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in the genetic background could account for the observed diﬀerences here, the ﬁndings by
Burke et al. [96] point to PIR1 playing a role in the production or stability of certain
classes of miRNAs. More rigorous study of a global miRNA eﬀect or PIR1 is needed to bet-
ter understand if PIR1 is playing such a role and what consequence it might have following
stimulation.
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2.4 Conclusions
While PIR1 plays a critical, albeit not fully characterized, role in the antiviral small
RNA response in C. elegans, the role of PIR1 in mice is not nearly as dramatic, at least not
in the context of an EMCV infection. However, data presented here hints at a potential
role for PIR1 in the earliest steps of RLR signaling, and in early EMCV infection.
2.4.1 Role of PIR1 in RLR signal transduction and/or ligand production
PIR1 appears to have a subtle role in the kinetics of type I IFN signaling at the earliest
moments of infection with EMCV or stimulation with polyIC. Generally, following viral in-
fection in an immuno-competent mammalian host, the type I IFN response is considered the
dominant antiviral response. While studies looking at the eﬀect of type I IFN genes and the
type I IFN receptor (IFNAR) have demonstrated this, the feedforward and self-enhancing
nature of the response have made it diﬃcult to evaluate whether other intracellular antiviral
mechanisms exist.
I have shown here that PIR1 has tissue-speciﬁc eﬀects on the innate immune response
to infection with EMCV, with IL6 and IFN cytokine production being altered in the hearts
of PIR1KO mice at 24 hours post infection, when compared to wild-type. The eﬀects of
the knockout were less pronounced in the brain. Furthermore this eﬀect did not seem to
alter the global progression of the infection, with EMCV viral titers and mortality being
unaﬀected by a loss of PIR1.
My in vitro studies show that PIR1 antagonizes MDA5:LGP2 ligand recognition in
BMDCs stimulated with transfected polyIC, limiting IRF3 phosphorylation and STAT1
phosphorylation 2 hours after stimulation. This phenotype is notable at 2 hours, but is
gone by 4 hours, once again suggesting PIR1 is most critical in the early innate immune
recognition of viral RNA, but ultimately has minimal consequence upon the downstream
manifestations of innate immune signaling. This could be explained by the feed-forward
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nature of type I IFN signaling. The stimulation of the RLR:MAVS:IRF3 pathway results
in the secretion of IFN-β which can then bind to the IFNAR receptor on the secreting cell
to further activate IRF genes. As a result, once this process it set in motion it is diﬃcult to
discern how much stimulant was responsible for starting the whole process. Consequently,
if PIR1KO cells are delayed by a hour or so in activating RLR:MAVS:IRF3 signaling, it
could be possible for these cells to appear equivalently stimulated several hours later.
PIR1 might be antagonizing early dsRNA recognition events by processing RNAmolecules
to render them non-stimulatory. As a 5’ RNA phosphatase, it is possible that the mecha-
nism by which PIR1 antagonizes RLR signaling is via the dephosphorylation of stimulatory
RNA rendering it inert. However, this mechanism would need to be minimal or short-lived,
since I did not notice any major diﬀerence in type I IFN signaling between wild-type and
PIR1KO cells. Furthermore, the work by Daniel Chaves in C. elegans suggests that PIR1
might be doing more than simply deactivating immunostimulatory RNA. It is possible that
PIR1 is processing stimulatory RNAs as part of a small RNA antiviral immune response.
In the worm, Chaves showed that PIR1 is required for eﬀective processing of viral RNA
molecules into antiviral 22G molecules. In the mammalian system, PIR1 might be promot-
ing a similar processing of viral RNA molecules. When PIR1 is absent, as is the case in
the PIR1KO BMDCs in Figure 2.15 (Page 67), this might result in a higher initial con-
centration of immunostimulatory RNA resulting in a faster initiation of the IFN signaling
cascade, resulting in the noticeable surge in phospho-IRFs at 2 hours post stimulation.
The role of PIR1 with respect to its RNA phosphatase activity, and its antiviral role in C.
elegans
Recent work by Burke et al. has demonstrated that PIR1 is important for dephospho-
rylating special subclasses of non-coding RNAs and certain RNA-polymerase-III-derived
miRNAs expressed by the host, as well as DNA viruses human adenovirus and bovine
leukemia virus [96]. Burke et al. have also shown that, when left phosphorylated, the 5p
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arm of these miRNAs are less stable and less eﬃciently loaded and used by Argonaute
complexes.
I hypothesize that PIR1 promotes the small RNA processing of polyIC. Commercially
available polyIC exists in a bi-phosphorylated state (there are β and α phosphates present
on the 5’ of many molecules as a consequence of the synthetic process) [128]. It is possible
that the presence of these phosphates promotes PIR1 recognition and the initial processing
of polyIC following transfection. However, over time, the amount of polyIC introduced
directly into the cytoplasm may overwhelm PIR1 processing in favor of RLR signaling. One
can imagine that if this small RNA processing pathway were less eﬃcient in the absence of
PIR1—as is the case in the C. elegans model—then transfected polyIC would activate RLR
signaling more rapidly.
2.4.2 Combining the small RNA and IFN pathway phenotypes: a proposed
model
My ﬁndings for a limited and transient role for PIR1 in the earliest moments after
intracellular stimulation with dsRNA, when combined with Daniel Chaves’ ﬁndings for the
antiviral role of PIR1 in C. elegans, along with the growing body evidence that mammalian
cells are capable of responding to viral RNA via both a type I IFN and avRNAi response,
suggests that PIR1 plays a role promoting the avRNAi response over the RLR:IFN response.
I propose a model where, after an initial infection with a virus, in the earliest moments
of replication, a limited pool of immunostimulatory RNA is sorted into one of two compet-
ing pathways. This RNA can either be processed by Dicer and directed into an avRNAi
pathway, or recognized by MDA5:LGP2 to trigger a type I IFN response. Once the type
I IFN response is triggered, any the avRNAi pathway is antagonized by the poly(ADP-
ribosylation) of argonaute proteins.
In this model, PIR1 may have the eﬀect of shunting immunostimulatory dsRNA toward
the avRNAi pathway, and away from RLR:IFN pathway. During the initial moments of
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infection this might slow down the activation of RLR signaling (as seen in Figure 2.15),
but would not necessarily increase viral susceptibility since the avRNAi pathway is itself an
antiviral pathway.
It should be noted, however, that the functional role of this pathway and PIR1 in
the course of a viral infection is likely to be limited. Pathogenic viruses have evolved
alongside their hosts for millennia, and as result are capable of subverting antiviral processes,
especially when those process are themselves ancient—as the avRNAi pathway is. This
combined with the fact that the avRNAi pathway appears to have been superseded by
the type I IFN response in mammals, suggests that the global consequence of PIR1 on
mammalian viral infections is likely to be limited.
Should the model put forward in Figure 4.1 prove to be correct, PIR1 and the avRNAi
pathway it promotes would be an antiviral innate immune response that every RNA virus
would encounter immediately after infecting a cell. Furthermore, continued investigation
into the interaction between these two antiviral pathways and the role of PIR1 in antago-
nizing one and promoting the other would allow for a better understanding of how viruses
interact with infected cells and their small RNA machinery following infection, furthering
our understanding of the intricate interactions between virus and host.
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CHAPTER III: CD200R1 supports HSV-1 viral replication
and licenses pro-inﬂammatory signaling functions of TLR2.
The majority of this work has been peer-reviewed and published in the journal PLOS One
[129]. This chapter discusses the rationale for this work, and presents the results. It also introduces
additional pieces of data that were generated after this publication which elucidate further the role
of CD200R1 in HSV infections. Both the published data and unpublished data are included, and
both are considered in the discussion and conclusions. The reproduction of any ﬁgures and text is
authorized under the Creative Commons Attribution (CC BY) license.
In addition to contributing to the design, analysis, and interpretation of the experiments herein,
I was assisted in processing experimental samples and carrying out certain assays. Michael King
helped perform the plaque assays on samples generated from in vivo and in vitro experiments. Anna
Cerny assisted me in conducting the intracranial infections. Glennice Ryan helped in the stimulation
of peritoneal exudate cells and the transduction and stimulation of PECs and BMDMs.
I trained in brain histopathology with Thomas Smith M.D. and developed the novel histological
scoring system described in Figure 3.4, processed the tissue samples for histological analysis, and
served as the blinded scorer on the histology scoring data presented in part B of Figure 3.5. I also
generated the data presented in Figure 3.7, parts A and B of Figure 3.8. I generated the cells and
produced the lysates for the western blots in Figure 3.13 and titers in Figure 3.11. I generated the
cells, developed the assay, and produced and analyzed the data in Figure 3.15. I assisted in the
mouse infections, tissue harvesting, and processing for the samples used in Figures 3.2, 3.6, and 3.5.
Finally I assisted in the mouse husbandry of the CD200R1KO mouse used in this work.
[129] Soberman RJ, MacKay CR, Vaine CA, Ryan GB, Cerny AM, Thompson MR, Nikolic B,
Primo V, Christmas P, Sheiﬀele P, Aronov L, Knipe DM, Kurt-Jones EA. CD200R1 supports
HSV-1 viral replication and licenses pro-inﬂammatory signaling functions of TLR2. PloS one.
2012;7(10):e47740. PMCID: PMC3474780 DOI: 10.1371/journal.pone.0047740
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3.1 Introduction
3.1.1 Herpes Simplex Encephalitis
Herpes Simplex 1 (HSV-1) is an enveloped, double-stranded DNA virus that is a very
common human pathogen worldwide. In developing countries greater than 95% of the
population tests positive for HSV-speciﬁc antibodies by adulthood [130], with developed
countries reaching a seroprevalence of 40% to 60% by 30 years of age [131]. Clinically,
HSV-1 infection most often manifests as perioral lesions, known as herpes labialis, more
colloquially known as cold sores. These lesions are generally self limited, and resolve within
a few days to a few weeks. Despite the outward resolution of the cold sore, the HSV-
1 infection is not over; the virus will persist in a latent state within the nuclei of sensory
neurons of the face, most commonly in the ganglia of the trigeminal nerve (cranial nerve V).
As a result of local injury, stimuli, or other stressors [132], HSV-1 can sporadically emerge
from its state of latency and begin self-replicating, emerging from the axonal termini of the
latently-infected sensory neurons to form new perioral lesions.
However, the cosmetic concerns of these outward lesions are small when compared to a
greater and more deadly risk of HSV-1 latency and reactivation. When HSV-1 enters the
CNS, it can result in encephalitis, an infection and inﬂammation of the brain parenchyma
associated with acute focal brain deﬁcits [133] and a high fever [134]. Herpes simplex
encephalitis (HSE), while rare, is the most common cause of sporadic encephalitis in the
United States (10 to 20 percent of the 20,000 viral encephalitis cases annually), and if left
untreated has a 70% mortality rate [135]. Because of the wide prevalence of HSV-1, the
rapid progression of disease once encephalitis is present, and the high risk of mortality, HSE
must always be considered during the treatment of patients presenting with the signs and
symptoms of meningitis or encephalitis [134]. PCR testing of CSF samples can rule out
HSV-1 infection, but frequently empiric treatment with the antiviral acyclovir is initiated
before test results are available [134].
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While this antiviral treatment can be eﬀective in limiting the progression and conse-
quences of HSE when initiated early enough in the course of the infection, the mechanisms
by which HSV-1 causes its damage are not fully understood. There appears to be a com-
plicated interplay between the pathogenic replication of virus in host neurons and the host
antiviral immune response. The CNS typically exists in a highly anti-inﬂammatory state,
but the HSV-1 infection is able to trigger a robust immune response. This inﬂammation
and the subsequent inﬁltration of immune cells into the otherwise immune-privileged space
of the CNS can itself be detrimental, often leading to substantial cell damage and neuron
loss. Yet, at the same time, HSV-1—if left unchecked—will damage and kill host neurons
via repeated lytic infections. The combination of these two opposing, yet equally damaging
mechanisms likely lead to the life-threatening CNS pathology seen in HSE [136].
The HSV Replication Lifecycle
Upon entering a cell, the HSV replication lifecycle begins, as the vhs protein starts to
degrade host mRNA molecules [137]. The viral capsid is then transported to the nucleus
where gene expression commences. HSV gene expression is triphasic, with each of the three
rounds of gene expression relying upon the previous. First α genes are expressed, which lead
to the expression of β genes, which then turn on γ genes. The expression of γ genes, many of
which encode for virion structural proteins, leads to virion assembly and viral egress [132].
The lifecycle depicted in Figure 3.1 only describes the lytic lifecycle of HSV-1. Under
certain circumstances, instead of initiating a lytic infection, the virus will enter into a latent
infection (reviewed in [138]). During a latent infection, the viral DNA associates with
nucleosomes and forms a circular episome within the nucleus of the infected cell [139,140].
During this time, viral protein expression in repressed, while several noncoding latency-
associated transcripts (LATs) are produced [141].
At some point, by a mechanism that is not well understood, HSV can transition from a
latent infection into a lytic infection, produce virions, and egress. Usually this will manifest
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Figure 3.1: A schematic representation of the HSV replication cycle during a lytic infection.
Upon entering a cell, the HSV vhs protein will begin inhibiting a number of host processes.
The viral capsid will then be transported to the nucleus where gene expression begins. While
simpliﬁed, HSV gene expression can be considered triphasic, with each of the three rounds
of gene expression relying upon the previous. First α genes are expressed, which in turn
turn on β genes, which ultimately turn on γ genes. The expression of γ genes, which encode
for many structural proteins, then leads to virion assembly and viral egress. Adapted from
Field’s Virology [132].
78
as new cold sore lesions, as virions travels via anterograde transport along the axon of
sensory neurons to emerge in the skin, leading to a localized infection and inﬂammatory
reaction. However, it could manifest as a life-threatening encephalitis.
There are three potential opportunities for HSV-1 to enter the central nervous system
(CNS). First, during a primary infection, the virus is able to travel via retrograde transport
into the CNS via sensory neurons in the trigeminal nerve, from the skin around the mouth,
or in the olfactory nerve, from the nasal mucosa. Second, during recurrent outbreaks, as
latent virus is reactivated and replicating, the virus again has the opportunity to move via
retrograde transport into the CNS. Finally, around one–third of cases of HSE are seen in
patients without a known primary or recurrent infection, suggesting that the virus was la-
tent, and was able to reactivate and spread inward either from a latently infected peripheral
ganglion or previously infected CNS neurons [134].
HSV and the Innate Immune System
In the case of latent HSV-1, we know there are interactions with the host’s adaptive
immune system, as both HSV-1 speciﬁc T-cells and antibodies can be detected following an
initial infection. This adaptive immune response appears to be important for controlling
recurrent infections and maintaining latency [142,143]. However, we also know that HSV
interacts extensively with the innate immune system, including during CNS infection, and
it is this interaction that our laboratory has studied.
HSV-1 virions ﬁrst interact with host cells at their cell membrane, where virions bind
to cell surface receptors to initiate entry into the cell. However, glycoproteins present
on the viral envelope (gH/gL and gB), can also be recognized by the pattern recognition
receptor TLR2 [8]. This interaction may also involve an association with the αvβ3 integrin
[9–11]. HSV-1 recognition by TLR2 then leads to the activation of NF-κB, in a MyD88-
dependent manner [144], and a strong inﬂammatory response. This TLR2-driven response
is problematic within the CNS in the case of HSE [145]. In fact, TLR2-/- mice exhibit
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improved survival as compared to wild-type mice following HSV infection, likely due to
decreased levels of intracranial inﬂammation [145].
Within the endosome, TLR3 can recognize and respond to dsRNA produced during the
HSV infection to induce inﬂammatory and antiviral responses. Double-stranded RNA has
been found in HSV-1 infected cells [146], and speciﬁcally within the CNS, TLR3 is activated
by HSV-1 infection, triggering an important defense against encephalitis [147,148]. Yet, how
HSV-1 induces this TLR3 activation is unclear, as we do not know how the stimulatory
dsRNA ends up within the endosome to engage TLR3.
TLR9 is also activated during an HSV-1 infection, as it recognizes and responds to
dsDNA [149], within the endosome. HSV-1 activation of TLR9 appears to be cell-type
speciﬁc, with plasmacytoid dendritic cells responding to HSV-1 DNA [150]. TLR9-/- mice
are still able to control infection, and other cell types such as macrophages and conventional
dendritic cells are still able to produce type I IFN in response to HSV-1, suggesting that
TLR9 signaling might be redundant to other defense pathways in these cells [151].
Within the cytoplasm, several pattern recognition receptors are activated by viral DNA,
to stimulate innate immune processes. The DNA sensor DAI was found to recognize HSV-1
DNA and inhibit infection [152–154]. HSV-1 DNA has also been found to activate RIG-I
signaling via RNApolIII transcription of DNA into triphosphorylated RNA [155]. Viral
DNA in the nucleus or cytoplasm can activate the DNA-binding protein IFI16, which leads
to the activation of the type 1 IFN signaling and ASC inﬂammasome activation [156].
HSV-1 DNA has also been shown to activate cGAS, leading to the production of the second
messenger cGAMP and type I IFN activation via STING [157].
Despite these varied methods for host sensing of the virus, HSV-1 has evolved many
mechanisms to antagonize these processes (well reviewed by Su el al. [158]). The HSV
protein ICP0 is a well-studied virulence factor responsible for negatively regulating many
antiviral responses within an infected cell. ICP0 inhibits MyD88 signaling following TLR2
activation [159], inhibits NF-κB translocation to the nucleus [159], interferes with DNA
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recognition by inhibiting the signal mediator STING [160], and interferes with the the
ability of IFI16 to induce a response to viral DNA [161].
Other HSV-1 viral factors interfere with innate immune signaling by directly modifying
or interacting with host defense proteins, reducing their ability to mount a response. UL36
deubiquitinates TRAF6, inhibiting the activation of TBK1 and ultimately blocking type I
IFN stimulation [161]. US11 interferes with formation of RIG-I and and MDA5 signaling
complexes, limiting the ability of infected cells to respond to foreign RNA [162]. US3 down-
regulates TLR3 expression, while also inhibiting the polyubiquitination of TLR2, leading
to deceased signaling capacity for both of these TLR pathways [163,164]. US3 has also been
found to hyperphosphorylate IRF3 and the p65 component of NF-κΒ, preventing both from
properly activating and translocating to the nucleus to activate the expression of type 1 IFN
genes [165,166]. ICP34.5 appears to bind and sequester the kinase TBK1, thus preventing
it from activating IRF3 and inducing a type I IFN response [167,168]. Viral tegument pro-
tein VP16 blocks IRF3-mediated gene activation, preventing IRF3 from interacting with
its coactivator CREP-binding protein [169]. UL41 (aka vhs) actively degrades many host
mRNA transcripts including those that encode for the antiviral proteins vipirin [170], ZAP
[171], and tetherin [172].
In the immune-privileged environment of the CNS, HSV-1 infection can evade some
innate defenses to progress quite rapidly, but such an infection will trigger a signiﬁcant
host inﬂammatory response. It is thought that the clinicopathologic features of HSE are a
result of these combined damaging eﬀects. As mentioned previously, the current standard
of treatment for HSE is antiviral therapy with acyclovir alone, which is eﬀective in reduc-
ing both the morbidity and mortality of the infection [173]. However, co-therapy with an
anti-inﬂammatory agent in addition to acyclovir has been shown in small cohort and case
studies to improve treatment outcomes [174,175]. Current studies are underway investigat-
ing whether steroidal anti-inﬂammatory agents are useful in treating HSE inﬂammation.
Yet, more speciﬁc treatment options will only come with a better understanding of the
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factors that drive the balance toward inﬂammatory and/or antiviral processes during HSE.
Mouse models of Herpes Simplex Encephalitis
Since HSV is able to latently infect a host, and infection of the CNS typically follows
reactivation at some undeﬁned time point, studying the natural course of HSE is diﬃcult.
However, several mouse models exist that attempt to approximate a natural HSE infection,
such as the intranasal administration of virus [176], or direct inoculation via corneal scarring
[177], and dental pulp injection [178]. Each of these models approximate the PNS to CNS
course of HSE, but each has their own limitations and confounders. Most importantly,
peripheral inoculation of HSV at the mucosa, such that there is a natural progression of
HSV from the PNS into the CNS, aﬀords the adaptive immune response ample opportunity
to develop a CD4 and CD8 T-cell response, complicating any study of the direct innate
immune response within the brain.
Therefore, in order to study the innate immune response of the CNS to HSV-1 in iso-
lation, without this added complexity of an adaptive immune response, the Kurt-Jones lab
established a model of HSE that involves the direct inoculation of HSV-1 into the CNS, via
an intracranial injection at the lambda point on the back of the mouse skull. HSV-1 virions
are delivered intrathecally, allowing for immediate primary infection of the cells within the
CNS and the induction of an inﬂammatory response [179].
3.1.2 CD200:CD200R Signaling
Due to the tight junctions that constitute the blood-brain barrier, monocytes and lym-
phocytes very rarely enter the central nervous system. Yet, during infection signiﬁcant
inﬂammation does occur, with chemokines and chemoattractants recruiting neutrophils,
macrophages, and other eﬀector cells through the blood-brain barrier to the site of infec-
tion. However, it is not just this barrier to entry that renders the CNS immune-privileged.
Upon entering the CNS, immune cells encounter various anti-inﬂammatory signals, which
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reduce or limit their inﬂammatory response.
A signiﬁcant component of this anti-inﬂammatory signaling milieu is the CD200 signal-
ing pathway. CD200 is a cell-surface protein that is expressed on neurons, astrocytes, and
other glial cells within the CNS [180]. It has been shown to be an important mediator of mi-
croglial and macrophage inactivity within the CNS, helping to prevent spurious activation
of these cells that might lead to neuronal loss [24]. However, CD200 is not itself anti-
inﬂammatory, but instead functions as a ligand for the anti-inﬂammatory CD200 Receptor
1 (CD200R1) [181]. CD200R1, also a cell-surface protein, is expressed on many diﬀer-
ent myeloid-derived cells including macrophages and neutrophils, but especially microglia
within the CNS. Upon engagement with its ligand, CD200R activates an intracellular sig-
naling pathway that ultimately limits the inﬂammatory capacity of myeloid-derived immune
cells.
CD200R1, the most well-studied receptor for CD200, has a cytoplasmic tail responsible
for signaling after the binding of the receptor with its ligand CD200. Upon binding CD200
on the cell surface, the cytoplasmic tail of CD200R1 on myeloid-derived cells undergoes
tyrosine phosphorylation, leading to the recruitment of the signal mediators Dok1, Dok2,
and SHP-1 [19,20]. Phosphorylation of Dok1 and/or Dok2 and the activation of SHP-1
subsequently activates RasGAP [21]. RasGAP then antagonize inﬂammatory processing by
several mechanisms. In macrophages it has been shown that RasGAP negatively regulated
ERK signaling, leading to a reduction in TNFα and NO production following TLR stimu-
lation [22]. RasGAP has also been shown to interfere with the activation and translocation
of NF-κB to the nucleus [23].
CD200:CD200R1 Signaling in CNS Infections
The majority of the evidence supporting CD200R1 as a negative regulator of inﬂamma-
tion derives from the ﬁndings that CD200-/- or CD200R1-/- mice have worsened inﬂamma-
tion compared to wild-type in several mouse models of inﬂammatory diseases. For example,
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models of autoimmune arthritis and autoimmune encephalitis are both worsened in CD200-
/- mice compared to wild-type [24]. Similarly, the pathologic inﬂammation of Dextran
Sodium Sulfate Induced Colitis is exacerbated when CD200 or CD200R1 are knocked out
[25]. Conversely, in one study of allograft survival in transplanted mice, the upregulation
of CD200 was protective, showing increased rates of tissue survival [182].
In the context of an infection, the eﬀect of an the anti-inﬂammatory pathway driven by
CD200:CD200R1 signaling is pathogen and disease speciﬁc. For example, following infection
with inﬂuenza (IAV), CD200-/- mice have increased levels of inﬂammation and inﬁltration
within their lungs, resulting in a more severe illness [183]. A similar result in seen in
CD200-/- mice infected with meningococcus, with CD200 signaling being required to limit
inﬂammation following N. meningitidis septicemia [27]. In a mouse model of Toxoplasma
encephalitis, CD200-/- mice again have a worsened disease progression due to unregulated
inﬂammation within the CNS [28]. However, by contrast in the case of L. amazonensis,
CD200-/- mice have improved disease outcomes and are better able to combat the infection,
due to a stronger oxidative response against this typically indolent pathogen [26].
CD200R1-/- mice are protected from HSV-1 encephalitis
In our direct inoculation model of HSE, HSV in the CNS induces a strong inﬂammatory
response, contributing to the observed mortality of infected mice [179]. For this reason we
sought to investigate the role of CD200R1 anti-inﬂammatory signaling in HSE. The ﬁrst
experiment conducted was a survival study, where wild-type and CD200R1-/- mice were
infected via intracranial injection with 1×105 pfu of HSV-1. The results of this experiment
(Figure 3.2) showed that CD200R1-/- mice had a signiﬁcantly higher rate of survival when
compared to wild-type mice. Wild-type mice began dying as early as 3 days post infection
and continued to die until day 9, at which point approximately 25% of the mice survived
the duration of the study. The CD200R1-/- mice, however, were much more resistant to
the disease process, with only approximately 25% of the mice dying around day 5 or 6, and
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Figure 3.2: CD200R1-/- mice are protected from HSV-1 encephalitis. CD200R1+/+ (WT)
and CD200R1-/- (KO) mice were administered 1×105 pfu HSV-1 by intracranial injection.
Survival was monitored for 15 days. Data includes a total of 3 separate experiments (n = 20,
WT; n = 16, KO). An unpaired, two-tailed Student’s t-test was used to determine statistical
signiﬁcance.
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75% surviving the duration of the experiment.
Knowing a signiﬁcant portion of the lethal damage to the CNS during HSE derives
from the inﬂammatory response, and understanding CD200R signaling as an important
anti-inﬂammatory pathway within the CNS, I hypothesized that CD200R1-/- mice have
reduced levels of inﬂammation in brain leading to a less severe disease, and ultimately
greater survival. Surprisingly, however, my investigation revealed instead that CD200R1-/-
mice have less death following infection because of a reduced capacity of HSV-1 to replicate
within the CNS in CD200R1-/- mice. Here, I will present my work demonstrating that
CD200R1 is an important host factor that promotes HSV-1 replication.
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3.2 Methods
3.2.1 In vivo intracranial infection
Virus was diluted to the appropriate concentration in sterile saline. 6 to 8 week old
mice were anesthetized with isoﬂurane, and the head was sprayed with isopropanol. Using
surface landmarks, a 30G needle was inserted into the lambda point (intersection of the
lambdoid suture and the sagittal suture). A spacer was placed on the syringe to assure
that the needle was inserted only about 5 mm deep into the skull. The spacer allowed for
consistent intrathecal injection in pilot studies using dextran blue as a marker. For each
inoculation 20 μL of solution was injected.
3.2.2 Immunohistochemistry staining for HSV
Whole brains were extracted from euthanized mice by dissection. The entire brain
was then either processed whole or bisected along the sagittal plan and then processed.
Brains were then placed in cassettes and submerged in Bouin’s ﬁxative (5% acetic acid,
9% formaldehyde, and 0.9% picric acid 0.9) for 18 hours. Brains were then transferred
to 1× PBS pH 7.4, and then delivered to the DERC facility (University of Massachusetts
Medical School, University Campus) for cutting, paraﬃn embedding, microtome slicing, and
placement on glass slides. Before being embedded in paraﬃn, the brains were cut along a
coronal plane into 5 segments, and oriented so that each slice of the parraﬁn block contained
a section from each segment.
The paraﬃn sections were then either stained in the traditional manner with hematoxylin
and eosin, or processed further for immunohistochemistry.
87
Figure 3.3: Intracranial infection method. A schematic of the location of infection, including
surface landmarks used. Using a 30G needle, 20 μL of diluted virus was infected at the
lambda point, where the sagittal suture and lambdoid suture meet.
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3.2.3 Culturing Mouse Embryonic Fibroblast
Isolation of Mouse Embryonic Fibroblasts
Pregnant mice were euthanized at 14 to 16 days postcoital using CO2 or isoﬂurane
followed by cervical dislocation. The uterus was dissected out and placed into a 100 mm
tissue-grade dish ﬁlled with sterile PBS on ice for 5 minutes. Each embryo was separated
from its placenta and surrounding membranes. For each embryo, the head was separated for
genotyping, and the internal organs were removed to avoid non-ﬁbroblast contamination.
The embryos were then moved to a second 100 mm dish and swirled to remove small loose
pieces of debris and as much blood as possible. The embryos were then transferred to a 15
mL conical tube containing 5 mL of 0.25% trypsin (GIBCO, contains EDTA), and incubated
at 4°C overnight to allow diﬀusion of trypsin into the embryo.
After overnight incubation the tubes were incubated at 37°C to activate the trypsin.
After 15 minutes, the excess trypsin was poured oﬀ, and 4 mL DMEM/FCS (DMEM with
10% Hyclone FCS, 1% L-glutamine, 1% Pen-Strep) were added. The embryos were then
dispersed by pipetting up and down using a large-bore pipette, until only small clumps
remained. Any debris and connective tissue was allowed to settle out of solution.
The cell suspension for each embryo was then plated into a 100 mm dish—with this
plating being referred to as passage zero—and an additional 4 mL of complete DMEM was
added. Cells were then incubated overnight at 37°C and 10% CO2 to allow cells to adhere.
The next day, the media was changed and the cells were split if conﬂuent.
Splitting MEFs Whenever the cells were conﬂuent, they were promptly split. To split
MEFs for passage 1, the growth media was removed from the monolayer, and the monolayer
was then washed twice with PBS, ensuring that any remaining clumps and debris from MEF
isolation were also washed away. After washing, 2 mL of trypsin were added to each plate
and incubated for at 37°C in a 10% CO2 incubator. After 5 minutes, the trypsin was
neutralizes with an equivalent amount of DMEM medium supplemented with 10% FCS
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(DMEM complete), and the cells were dislodged by pipetting. The cell suspension was
then transferred to a conical tube and centrifuged for 4 min at 300×g. The cells pellet was
resuspended in fresh DMEM complete and plated at a 1:4 or 1:5 ratio into a new dish with
8 ml of DMEM complete. This is equivalent to splitting the cells at an approximate density
of 1×104 cells/cm2 every 3 days.
Freezing MEFs At each passage, aliquots of MEFs were cryogenically preserved. After
collecting cells and pelleting, cells to be frozen were resuspended in 1 mL of freezing medium
(90% HyClone FCS, 10% DMSO (v/v)) and transferred into a cryovial. Cells were placed in
an insulating container and stored at -80°C for 2 weeks, at which point they were transferred
to liquid nitrogen.
Thawing MEFs To thaw MEFs previously stored in liquid nitrogen, the cryovial was
removed from refrigeration and placed directly into a 37°C water bath. While swirling
the tube continuously, the cell suspension was allowed to melt half way (meaning half the
volume of the vial was liquid and half was still frozen solid). At this point the vial was
removed from the water bath, and 1 mL of DMEM/10% FCS was added to the cryovial
and mixed well by pipetting to ﬁnishing thawing the cells. The cells suspension was then
transferred to a 25 cm2 tissue-culture ﬂask along with 5 mL of additional DMEM complete
and incubated at 37°C with 10%CO2.
If cells did not appear to grow well the next day following thawing, half the media was
discarded and replaced with DMEM supplemented with the following: 15% FCS, 1% of
nonessential amino acid, 1% HEPES buﬀer, 1% sodium pyruvate.
3.2.4 Infection with GFP-expressing viruses, and measurement of infection by
ﬂow-cytometry
Cells were plated in a 24-well plate at a concentration of 1×105 cells/well, and incubated
for 4 hours at 37°C. The growth media was then removed and replaced with serum-free
media. The cells were inoculated with GFP-expressing HSV at the speciﬁed MOI. The
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virus was allowed to adsorb for 1 hour at 37°C with intermittent swirling. After the hour,
the media and virus were removed, the cells were washed once with sterile PBS, and then
incubated with 500 μL of DMEM complete supplemented with 165 μg/mL of pooled human
IgG (Sigma; https://sigmaalrich.com; cat: I2511) to neutralize extracellular virions.
At the speciﬁed time point post infection the cells were collected for ﬂow-cytometric
analysis of GFP expression as a measure of virus replication. The growth media was re-
moved, and 200 μL of trypsin 0.25% was added to each well. After incubation at 37°C for
3 minutes the cells were lifted out of each well by pipette and placed into a microcentrifuge
tube. The cells were pelleted by centrifuge for 5 minutes at 300×g and 4°C, and the cell pel-
let was washed once with sterile PBS. The cells were pelleted a ﬁnal time, and resuspended
in 100 μL of sterile PBS. Once resuspended, 100 μL of 8% formalin in PBS was added to
each samples. Cells were then stored in the dark at 4°C until they could be analyzed by
ﬂow cytometry.
3.2.5 Analysis of HSV protein expression by western blot
Cells were infected with HSV-1 for 24 hours, at which point the cells were washed and
lysed with 1× Laemmli Sample Buﬀer (BioRad; biorad.com; cat: 161-0737). Once lysed
samples were stored at -20°C until thy could be processed. Samples were heated to 95°C for
5 minutes, the loaded in a SDS-PAGE gel. The gel was run at 90 V until the loading dye
reached near the bottom of the gel. The running buﬀer was: 3 g Tris-Base, 14.4 g glycine,
and 1.0 g SDS in 1.0 L of ddH2O.
After the gel was done running, proteins were transferred onto a membrane for im-
munoblotting. A transfer sandwich of blotting pad, blotting paper, membrane, blotting
paper, and blotting pad was prepared. All but the membrane was submerged in transfer
buﬀer, while the membrane was submerged in 100% methanol. The polyacrylamide gel was
then place on top of the membrane at the center of the sandwich, and all bubbles were re-
moved from between each layer. The transfer was then run on a semi-dry transfer machine
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at 25 V (maximum of 300 mA) for 45 to 60 minutes. The transfer buﬀer consisted of: 3 g
Tris-Base, 14.4 g glycine, and 100 mL of 100% methanol in 1.0 L with ddH2O
After transfer, the membrane was blocked with 3% (w/v) bovine serum albumin in TBS
with 0.1% Tween 20 (TBS-T) overnight at 4°C. Blocking buﬀer was removed, and primary
antibody diluted in blocking buﬀer was added. Membranes were incubated with primary
antibodies overnight at 4°C. Membranes were then rinsed three times with TBS-T, and
then incubated with secondary antibody diluted in blocking buﬀer for 2 hours at room
temperature. Primary antibodies were used at a dilution of 1:2000. The primary antibodies
were all purchased from Abcam (abcam.com): ICP4 cat: ab6514, ICP8 cat: ab20194, ICP27
cat: ab31631, VP16 cat: ab110226.
3.2.6 Antibodies
Anti-CD200R1 and anti-CD200 for cell surface staining were purchased from AbD
Serotec. Goat anti-CD200R1 intracellular domain-speciﬁc antibody was from Santa Cruz.
Anti-IL-1β was goat polyclonal anti–mouse IL-1β (AF-401-NA; R&D Systems). The pri-
mary antibody used in immunohistochemical studies was rabbit polyclonal anti-HSV2 (B0116;
Dako) and the secondary antibody used was biotin-conjugated goat anti-rabbit (H+L) IgG
(656140; Invitrogen). The secondary anti-rabbit antibody used in blotting studies was
rabbit anti-goat (H+L) IgG HRP conjugate (172–1034; Bio-Rad).
3.2.7 PCR Primers and Screening for CD200R1 Gene Targeting
CD200R1-/- mice used had been backcrossed to generation N9 or N10 on the C57BL/6
background. To identify the knockout allele in genomic DNA, tail vein DNA was puriﬁed
using the DNeasy kit (Qiagen). PCR was then performed using the forward primer Neo1,
located in the 5’-promoter region of the neo gene cassette (5’-TGCGAGGCCAGGCCACTTGTGTAGC-
3’) combined with the reverse primer CD200R1-rev, located outside the short arm of the
knockout construct (5’-GGGATGCAGAACATAGGAGGCAG-3’) corresponding to a sequence within
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the ﬁrst third of intron 1 of the CD200R1 gene. The PCR product yields a 1.5 kbp prod-
uct. To identify the wild-type allele primer WT1 (5’-CAGTAGTTTTGGAGAATGTGACAG-3’) was
combined with WT-rev (5’-GATAGCCCTTGCTCCTATGACTGAG-3’) to yield a 1.4 kbp product
corresponding to a region of intron 1 that is present in WT DNA but is deleted by insertion
of the targeting construct. The PCR conditions for both sets of primers were: (95°C, 15
min; 94°C, 30 sec; 62°C, 1 min; 72°C 2 min; 35 cycles using Thermo Start ReddyMix PCR
master mix (Thermo Scientiﬁc).
3.2.8 Exon-Speciﬁc screening.
The following forward and reverse primers were combined to probe the expression
of CD200R1 exons in peritoneal macrophages: exon 1F (5’-ATGTTTTGCTTTTGGAGAACT-3’)
and exon 7R (5’-CTAGATTCCAATGGCCGACAA-3’) to amplify the full length cDNA; exon 1F
(above) and exon 5R (5’-CACCTCTACTCAGTTCTATGG-3’) to amplify exons 1–5; exon 5F (5’-
TGAAGTAACCTACTTTCCAGA-3’) and exon 7R (above) to amplify exons 5–7. RNA was prepared
using RNeasy (Qiagen) and RT-PCR was performed using 1 unit Taq polymerase, and Q
solution (Qiagen). The PCR conditions for all pairs of primers were: (94°C, 20 sec; 62°C,
20 sec; 72°C 2 min; 35 cycles).
3.2.9 Preparation and Stimulation of Peritoneal Macrophages
Mice were injected with 4% thioglycollate and peritoneal exudate cells were routinely
harvested 3–4 days later [6]. Peritoneal exudate cells (> 90% macrophages) were plated
at 1×106 cells per well in 24-well plates in DMEM containing 10% FCS. Lipopolysaccha-
ride (LPS) was obtained from Sigma and phenol extracted as previously described [184].
Pam2CSK4 was obtained from EMC Microcollections (Tubingen, Germany).
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3.2.10 Immunohistochemistry and Viral Particle Detection
For immunohistochemistry, ﬁxed brain sections from CD200R1+/+ and CD200R1-/- mice
were deparaﬃnized by rinsing three times in xylene for 5 minutes each, and then for 5
minutes each in 100% ethanol, 90% ethanol, and 70% ethanol. The slides were then gently
rinsed with tap water.
To permeabilize the sections the slides were submerged in 0.2% Triton X 100 in PBS at
room temperature for 10 minutes. Antigen retrieval was carried out using a pH 5.7 sodium
citrate solution. The retrieval solution was pre-heated to just below boiling, and then slides
were added. The slides in retrieval solution were then heated by microwaving for 50% power
for 5 minutes, and allowed to cool to room temperature on the bench top.
Slides were then blocked. To block endogenous peroxidase activity slides were incubated
in 2% H2O2 93.3% methanol in H2O for 20 minutes at room temperature. Slides were then
washed twice with PBST, and then blocked 90 μL of avidin blocking per slide (Vector;
https://vectorlabs.com/; cat: SP-2001). A paraﬃn ﬁlm coverslip was added to each slide
and they were then incubated in a humid container at room temperature for 15 minutes.
Slides were once again washed twice with PBST. 90 μL of biotin blocking solution was then
added to each slide, followed by a paraﬃn ﬁlm cover slip, and 15 minutes of incubation in
a humid container at room temperature. Slides were washed twice again with PBST, and
then blocked with blocking solution solution (1% dehydrated milk, 1% BSA, and 5% goat
serum in PBST). 80 μL of this serum blocking solution was added to each slide, followed by
a paraﬃn ﬁlm coverslip, and a 1 hour incubation in a humid container at room temperature.
After blocking, slides were washed twice with PBST, and incubated with primary an-
tibody diluted 1:100 in the blocking solution without serum. Antibody was added to each
slide, followed by a paraﬃn ﬁlm coverslip. The slides were then incubated in a humid con-
tainer at 4C overnight. At this point, the slides were washed twice with PBST, and then
stained with secondary antibody. The secondary antibody was diluted 1:100 and added
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to the slides in the same manner as the primary antibody. The slides were then incu-
bated in a humid container at 4C for 1 hour. The slides were washed twice with PBST,
and then incubated with avidin-biotin complexes (Vector; https://vectorlabs.com; cat: PK-
4005). Complexes were formed by mixing avidin-DH with biotinylated-HRP in PBST at a
ratio of 1:1:50 and incubating them for 30 minutes at room temperature. 100 μL of this
avidin:biotin-HRP complex was added to each slide and allowed to sit for 30 minutes at
room temperature.
The slides were washed twice with PBST, and developed with 3,3’-diaminobenzidine
(DAB Vector; https://vectorlabs.com; cat: SK-4100). DAB developing solution was added
drop-wise to each slide, which were then allowed to react for 2 to 10 minutes, until staining
was clearly visible in positive control samples. At this point the reaction was stopped
by rinsing the slides with tap water. Slides were then counterstained by submerging in
hematoxylin for 45 seconds. Slides were then rinsed thoroughly with tap water. Slides were
then dipped 4 times in a blueing solution, and then washed again with tap water. The
slides were dehydrated by reversing the rehydration procedure from above. Finally slides
were mounted using Permount (Fisher; https://ﬁshersci.com; cat: SP15-100) and a glass
coverslip.
3.2.11 Histological Scoring of Brains
48 hours post-infection, mice were anesthetized with isoﬂurane and euthanized by exsan-
guination. Brains were dissected and stored in Bouin’s Fixative Formula (Fisher Scientiﬁc,
Pittsburgh, PA) for 24 h. Each brain was cut into 4 coronal sections, paraﬃn embedded,
sectioned, mounted and stained with hematoxylin and eosin (H&E) by the histology core
at University of Massachusetts Medical School, Worcester, MA. To quantify the severity
and the extent of pathologic inﬂammation in the brains of HSV-1 infected mice, a histologic
inﬂammation scoring system was used. Each of seven regions of the brain was assigned an
inﬂammation score of 0 (no apparent inﬂammation), 1 (minimal inﬂammation), or 2 (moder-
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ate to severe inﬂammation). Inﬂammation was judged on the presence and extent of cellular
inﬁltrate and reactive gliosis. The regions of the brain that were scored were: frontal cere-
bral cortex, posterior cerebral cortex, hippocampus, diencephalon/mesencephalon (which
includes the thalamus, hypothalamus and brainstem), cerebellum, the caudal paraventric-
ular structures (deﬁned as those areas adjacent to the lateral ventricles), and the rostral
paraventricular structures (deﬁned as those areas adjacent to the 3rd ventricle, the cerebral
aqueduct, and the 4th ventricle). Each brain was scored blindly by two observers. The
scores for each of the seven regions were summed to arrive at a total brain inﬂammation
score for each mouse with a maximum possible score of 14.
3.2.12 Preparation of Viruses
HSV-1 strains including viruses expressing ICP8-GFP [185] were generated in the lab-
oratory of Dr. David Knipe. Viruses were added to MEFs and peritoneal macrophages at
an MOI of 10.
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Figure 3.4: Histology scoring system to measure extent and degree of inﬂammation in
the brain. In order to evaluate the extent and severity of inﬂammation within the brain
following intrathecal inoculation with HSV-1, I developed a novel histology scoring system.
I identiﬁed seven regions of the brain that are well dispersed throughout the superﬁcial
and deep regions of the brain, and are themselves well removed from the initial site of
inoculation (labelled 1 to 7). Each region was examined on H&E stained sections, and the
level of inﬂammation was blindly rated on 3-point scale: 0 is no noticeable inﬂammation, 1
is mild or minimal inﬂammation, and 2 is any amount of inﬂammation above minimal (i.e.
moderate to severe). These scores were then added together to get a score that ranges from
0 to 14.
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3.3 Results and Discussion
3.3.1 CD200R1 -/- mice show similar levels of inﬂammation early in infection
In order to assess levels of inﬂammation following infection with HSV-1 via intracranial
injection, brains were collected from infected CD200R1-/- and wild-type mice. These brains
were ﬁrst assessed by H&E staining for histopathological signs of inﬂammation. Both wild-
type and CD200R1-/- mice showed viral inclusions, gliosis, and perivascular inﬁltration and
inﬂammation following infection with HSV-1. In order to quantify the degree and extent
of inﬂammation, I developed a histopathological scoring system that assessed inﬂammation
on a scale of 0 (no inﬂammation), 1 (minimal inﬂammation), or 2 (moderate to severe
inﬂammation). Using this scoring system, 7 diﬀerent superﬁcial and deep regions of the
brain were analyzed. As seen in Figure 3.5, the amount and extent of inﬂammation in the
brain at 3 days post infection, were not noticeably diﬀerent.
While histological analysis of brain inﬂammation revealed no apparent diﬀerences, cy-
tokine expression was analyzed to assess for any inﬂammatory phenotype which could con-
tribute to the HSE protection seen in the CD200R1-/- mice. Inﬂammatory cytokines IL-6,
MCP-1 (CCL2), and RANTES (CCL5) were measured by ELISA from homogenates of
brain samples collected at one day and four days post infection. As shown in Figure 3.6A-
C, the levels of inﬂammatory cytokines IL-6, MCP-1, and RANTES were not signiﬁcantly
diﬀerent between genotypes at either time point. However, IFN-β, measured by ELISA,
was found to be dramatically lower in the CD200R1-/- mice, when compared to wild type
mice, at both 1 and 4 days infection in brain homogenates(Figure 3.6DC), and at 4 days
post infection in the serum(Figure 3.6E).
Despite a lack of clear diﬀerences in brain inﬂammation as assessed both by histology
and by inﬂammatory cytokine production, on histological examination I noticed what ap-
peared to be a diﬀerence in the size and extent of viral inclusions, with wild-type brain
sections having larger and more numerous nuclear ground-glass inclusions when compared
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Figure 3.5: (A) H&E staining of CD200R1+/+ (WT) and CD200R1-/- (KO)- brain sections
prepared on day 3 post-intracranial infection (100×). Data is representative of 2 separate
experiments each with 3–5 mice per genotype (n = 7 WT and n = 8 KO). (B) Total leukocyte
inﬁltration scores from 7 regions of the brain on day 3 post-intracranial infection.
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Figure 3.6: CD200R1+/+ CD200R1-/- and brains have distinct cytokine response proﬁles.
(A-D) Cytokine levels were measured in CD200R1+/+ (WT, open triangles) and CD200R1-/-
(KO, closed circles) brains on days 1 and 4 (D1 and D4) post-cranial injection of 105 PFU
HSV-1. (A) IL-6; (B) CCL2/MCP-1; (C) CCL5/Rantes; (D) IFN-β. The mean of each
group is indicated by a horizontal bar. The statistically signiﬁcant groups, as determined
by Kruksal Wallis test, are linked by bars and have p-values listed. (E) IFN-β levels were
measured in the serum of CD200R1+/+ (WT, open triangles) and CD200R1-/- (KO, closed
circles). Statistical analysis was performed as above. Data includes a total of 5 experiments
each with 3–7 mice per genotype (n = 20 WT and n = 13 KO day 1; n = 7, WT and KO
day 4).
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to CD200R1-/- brain sections. These nuclear inclusions (Cowdry type A inclusions) are
histological signs of viral infection, and here suggested that while the overall inﬂammation
was not altered in the CD200R1-/- mice, the overall amount of virus might have been. In
order to properly assay this ﬁnding, I performed immunohistochemistry for HSV-1 in the
brain. Using a polyclonal antibody against HSV structural proteins, I was able to detect
HSV in the brain sections of wild-type and CD200R1-/- animals 3 days post infection with
HSV-1. As shown in Figure 3.5, the wild-type mice had more infected neurons, spread fur-
ther throughout several regions of the brain, when compared to the knockout mice. While
HSV-infected cells are clearly visible in the CD200R1-/- brain sections as well, the extent
of infection is clearly less. As can be seen in the rightmost panel (400×), many of the
HSV-1-positive cells are neurons, identiﬁable based on their long axonal projections that
are positive for HSV proteins.
In order to assess whether the reduced inclusions correlated with decreased amounts of
viral replication, brain homogenates from mice infected with HSV-1 via intracranial injection
were collected at 1, 3, or 4 days post infection. These homogenates were then assayed for
viral titer by serial dilution on Vero cell monolayers for plaque analysis. As can be seen in
Figure 3.8, at one day post infection, both wild-type and CD200R1-/- mice have roughly
103 to 104 pfu/mL of HSV-1 in brain homogenates. By day 3, however, a clear diﬀerence
can be seen, with CD200R1-/- mice having lower levels of HSV-1 virus than wild-type mice.
Many of the CD200R1-/- mice at this point were found to have no detectable HSV in
their brains, meaning the infection had been cleared. The same pattern is seen again at 4
days post-infection, with CD200R1-/- mice having lower levels of HSV-1 in their brains, as
compared to wild-type.
3.3.2 CD200R1 is important in TLR2 mediated innate immune responses
In order to assess the eﬀect of CD200R1 on cytokine production following stimulation
with HSV-1, peritoneal exudate cells (PECs) were collected and peritoneal macrophages
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were then elicited from wild-type and CD2OOR1-/- mice. The cells were stimulated with
either HSV-1, the TLR2 ligand Pam2CSK4, or the TLR4 ligand LPS. After 24, 48, or 72
hours supernatants were collected and assayed for the cytokines IL-6, RANTES, and MCP-
1 by ELISA (Figure 3.9A). Following HSV-1 infection, wild-type cells secreted roughly
30,000 ng/mL of IL-6 by 24 hours, which increased to 50,000 ng/mL at 48 and 72 hours.
In contrast CD200R1-/- cells produced around 20,000 ng/mL of IL-6, with no apparent
increase as time progressed. With respect to RANTES production, the CD200R1-/- cells
produced about half as much as the wild-type cells at 24 hours post infection. By 48 hours
however, both wild-type and CD200R1-/- cell types appear to reach equivalent levels of
RANTES production. When looking at MCP-1 production following HSV-1 stimulation,
no apparent diﬀerences were observed between wild-type and CD200R1-/- cells at any time
point.
A similar, but earlier pattern is observed when the TLR2 ligand Pam2CSK4 was used to
stimulate PECs. In this case, CD200R1-/- PECs produced around 15,000 pg/mL of IL-6 at
each of the three time points, while wild-type cells generated ﬁve-fold higher levels of IL-6
(around 80,000 pg/mL). The same is true with RANTES production, with the CD200R1-/-
cells producing a signiﬁcantly lower amount at each of the time points tested, as compared to
wild-type. MCP-1 production was not aﬀected in the same way following Pam2CSK4 stim-
ulation, with wild-type and CD200R1-/- PECs generating equivalent amounts of MCP-1 at
24 and 48 hours post stimulation. However, at 72 hours after stimulation with Pam2CSK4,
the CD200R1-/- cells produced signiﬁcantly more MCP-1 than wild-type.
Here, the TLR4 agonist LPS served as a positive control for the inﬂammatory response,
and it demonstrated that both cell types are capable of generating an inﬂammatory re-
sponse via the activation of a diﬀerent TLR molecule. Unlike following TLR2 activation,
LPS stimulation showed similar patterns between the wild-type and CD200R1-/- PECs,
demonstrating that both cell types have active TLR signaling pathway. It should be noted
that at 48 and 72 hours post stimulation with LPS the CD200R1-/- PECs appear to have a
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elevated MCP-1 response, suggesting that CD200R1-/- might be a critical negative regulator
of MCP-1 expression at later points in an infection.
In order to assess whether the defects in IL-6 production seen in CD200R1-/- signaling
aﬀected inﬂammasome activation and IL-1β production we assayed IL-1β secretion following
infection with HSV-1, with a dual stimulation of LPS and ATP as a control (Figure 3.9B).
Wild-type and CD200R1-/- PECs and BMDMs were tested, and in both cell types the
absence of CD200R1 resulted in signiﬁcantly lower levels of secreted IL-1β. All of the cells
tested were capable of wild-type levels of inﬂammasome activation following LPS+ATP
stimulation, suggesting that HSV-1 requires CD200R1 to eﬃciently activate inﬂammasome
signaling and IL-1β secretion. This result was further veriﬁed by assessing the amount of
cleaved and active IL-1β secreted and retained in PECs (Figure 3.9C). The CD200R1-/-
PECs had signiﬁcantly less IL-1β including active IL-β in the culture media, while retaining
a substantial amount of unsecreted pro-IL-β. Together this suggests that CD200R1 is an
important mediator of inﬂammasome activation following HSV-1 infection.
One of the early eﬀects of innate immune activation is the upregulation of TLR2 on the
cell surface. This upregulation is detectable following stimulation of many TLRmolecules in-
cluding TLR2 itself [186,187] and is thought to result from activation of the NF-κB pathway
[188]. In order to assess whether this TLR2-upregulation reaction is aﬀected by CD200R1,
PECs from wild-type, CD200R1-/-, and TLR2-/- mice were stimulated with HSV-1. The
macrophages were then assessed for surface expression of both CD200R1 and TLR2 by ﬂow
cytometry (Figure 3.10). As can be seen in Figure 3.10A, in wild-type cells following in-
fection with HSV-1, CD200R1 is removed from the cell surface. At baseline roughly 12%
of the PECs are positive for CD200R1, with this number decreasing to about 5% following
infection with HSV-1. This downregulation reaction is TLR2-independent, as TLR2KO
PECs still show this downregulation. The amount of TLR2 on the cell surface was also
measured (Figure 3.10B). At baseline, around 1% of both wild-type and CD200R1-/- PECs
were positive for TLR2 on the cell surface. Following infection with HSV-1, the number
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Figure 3.9: (A) CD200R1+/+ (WT) or CD200R1-/- (KO) elicited peritoneal macrophages
were stimulated with either HSV-1 (MOI 10, left column), Pam2CSK4 (100 ng/ml, center
column), LPS (100 ng/ml, right column), or medium for 24, 48, or 72 hours. Levels of IL-
6 (upper row, pg/ml), CCL5/Rantes (middle row, pg/ml), and CCL2/MCP1 (lower row,
pg/ml) were measured by ELISA. Data shown are mean and SD of representative experiment
(total of 3 experiments, n = 4, WT and KO). An unpaired, two-tailed Student’s t-test was
used to determine statistical signiﬁcance of independent experiments, p values: * p < 0.05,
† p < 0.01. (B) Supernatant IL-1β levels from WT and KO elicited peritoneal macrophages
(left panels) or bone marrow macrophages (right panels) 16 hours after infection with HSV-1
(MOI 10) or after a 3 hour stimulation with LPS (100 ng/ml) followed by ATP (1 mM) for
1 h. ELISA results are representative of 3 experiments. (C) WT and KO elicited peritoneal
macrophages were cultured for 20 hours with HSV-1 (MOI 10). Media (left lanes) and
cells (right lanes) were analyzed by SDS-PAGE followed by Western blot for cleavage of
pro-IL-1β to IL-1β. Data representative of 3 experiments (n = 4, WT; n = 5, KO).
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of TLR2-positive cells increased to 12% among wild-type cells, but remained unchanged in
CD200R1-/- cells. This demonstrates that in CD200R1-/- cells, inﬂammatory signaling and
TLR2 expression in response to HSV-1 infection is signiﬁcantly limited.
Based on the in vivo phenotype of decreased viral replication, and the apparent lack of
inﬂammatory signaling present in CD200R1-/- cells following infection with HSV-1, I wanted
to further probe how well HSV replicated in CD200R1-/- cells. Mouse embryonic ﬁbroblasts
(MEFs) were infected with HSV-1, and viral replication was assessed by measuring the
amount of virus present in the culture supernatant 24 hours after infection (Figure 3.11).
The amount of HSV-1 was measured by plaque formation on Vero cells (Figure 3.11A),
and by quantitative PCR of genomic DNA (Figure 3.11B). By both of these measurements,
wild-type MEFs produced ﬁve-fold more virus then CD200R1-/- MEFs. This result once
again demonstrated that HSV-1 replication is severely impaired in CD200R1-/- cells.
The viral replication studies in Figure 3.11 measured total virus production. However,
there are a number of sequential gene expression events that take place during HSV-1
replication (Figure 3.1), with α genes turning on β gene expression, and β genes turning on
γ gene expression. In order to further probe whether CD200R1-/- was aﬀecting viral entry,
viral gene expression, or viral egress, I infected MEFs and PECs with a strain of HSV-1
that expresses an ICP8-GFP fusion protein. ICP8 is a β (early) viral gene that functions
as an important regulator of viral DNA replication [132]. As this gene is highly expressed
midway through the HSV-1 replication cycle, the CD200R1 eﬀect on HSV-1 replication
can be identiﬁed as being upstream or downstream of ICP8 gene expression. I measured
the percentage of ICP8-GFP-positive cells in cultures at various time points post infection.
The replication cycle of HSV-1 in culture is roughly 6-12 hours. I added pooled human
IgG to the culture supernatants after virus adsorption in order to neutralize released HSV
virions and prevent secondary infection (cells infected by virions generated from previously
infected cells). ICP8-GFP expression was measure by ﬂow cytometry at 1 to 144 hours
post-infection. The results, as seen in Figure 3.12 shows that CD200R1-/- cells are much
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Figure 3.10: CD200R1 controls expression of TLR2 in macrophages.(A, B) The expression
of CD200R1 (A) or TLR2 (B) on the surface of WT (circles), TLR2KO (squares), or
CD200R1KO (triangles) elicited peritoneal macrophages (MΦ) before (–, closed symbols)
or after HSV-1 infection (+, open symbols) as determined by ﬂow cytometry. The lack of
expression of CD200R1 or TLR2 on the surface of CD200R1KO or TLR2KO macrophages,
respectively, served as internal controls. Data representative of 3 experiments (preparations
from individual mice n = 3 WT and KO are shown). An unpaired, two-tailed Student’s t-test
was used to determine statistical signiﬁcance of independent experiments.
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Figure 3.11: CD200R1 MEFs show several log decrease in viral titer, after a 24 hour incu-
bation with HSV-1 virus. CD200R1+/+ and CD200R1-/- MEFs were infected with HSV-1
at an MOI of 10 and incubated for 24 hours. Viral replication was measure by assessing (A)
the amount of live virus present in the culture supernatant by plaque assay on Vero cells,
and by (B) quantitative PCR analysis of HSV DNA present within the culture supernatant.
Mean ± SEM is shown.
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less permissive with respect to HSV-1 infection and ICP8 gene expression, compared to
wild-type cells. Wild-type MEFs reached a peak infection rate of over 40% by 12 hours
post infection with ICP8-HSV, but CD200R1-/- MEFs, only reached a peak infection rate
of around 20%. Macrophages, in general, are much less permissive to HSV infection than
MEFs, and I observed that the GFP-positive rates in these cells are much lower than in
MEFs. Despite this, the CD200R1-/- macrophages also have a signiﬁcantly lower percentage
of positive cells by 24 hours post infection, compared to wild-type macrophages. At 24
hours post infection, over 10% of the wild-type macrophages were GFP-positive, but the
percentage of GFP-positive CD200R1-/- macrophages was less than 5% of total cells.
ICP8 is a β (early) gene expressed during the middle of the HSV-1 lifecycle (Figure 3.1).
Given that I observed a marked defect in ICP8-GFP expression in CD200R1-/- cells (Fig-
ure 3.12), this indicated that CD200R1 was aﬀecting some point in the viral replication
cycle at or upstream of ICP8 expression. In order to better understand whether CD200R1,
a cell-surface protein, was aﬀecting viral entry or viral gene expression, I examined the
expression levels of several viral proteins by western blot (Figure 3.13). After infecting
wild-type and CD200R1-/- MEFs with HSV-1, cell lysates were collected at 3 hours or 6
hours post infection and probed for the α (immediate-early) gene ICP4. Lamin and actin
blotting was performed on the same membrane as loading controls. As seen in Figure 3.13
wild-type and CD200R1-/- MEFs express ICP4 to equivalent levels, with both cell types
expressing substantial amounts by 6 hours post infection. Cell lysates were also probed
for ICP27 (another α gene), the β (early) gene ICP8, and the γ (late) gene VP16. At 6
hours post infection I observed signiﬁcant diﬀerences in protein expression, with CD200R1-
/- MEFs showing decreased levels of each of these genes. These results point to CD200R1
aﬀecting HSV-1 replication at a point early in the lifecycle, after virus entry and ICP4
expression but before ICP27 expression.
In order to verify these ﬁndings derived from the CD200R1-/- mice, I ectopically ex-
pressed and knocked down CD200R1 in U2OS cells and bone-marrow-derived dendritic cells
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Figure 3.12: CD200R1 regulates replication of HSV-1 in cells. (A, B) Flow cytometry
to assess GFP expression in CD200R1+/+ (WT) and CD200R1-/- (KO) mouse embryonic
ﬁbroblasts (MEFs; A) and elicited peritoneal macrophages (B) at various time points fol-
lowing infection with ICP8-GFP virus (MOI). Histograms of each sample were generated.
A gate was set on the uninfected control for each condition, which excluded 99% of the
uninfected cells. This gate was then applied to the paired infected samples to calculate the
percentage of GFP-positive cells. Data representative of 3 experiments.
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Figure 3.13: Western blot analysis of several HSV proteins expressed during the course of
infection. CD200R1-/- cells show decreased expression of ICP4 and ICP8, with no noticeable
expression of the proteins VP16 and ICP28. CD200R1+/+ and CD200R1-/- MEFS were
infected with HSV-1 KOS at an MOI of 20. After 3 hours or 6 hours, cell lysates were
collected and analyzed by western blot for the expression of HSV proteins ICP4, ICP27,
ICP8, and VP16. ICP4 and ICP27 are α genes, ICP8 is a β gene, and, VP16 is a γ gene.
Blotting for actin and lamin served as loading controls.
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(Figure 3.14). U2OS cells are a human osteosarcoma cell line that are known to be permis-
sive to HSV-1 infection and replication. Lentiviral vectors were used to transduce these cells
to express ectopic CD200R1, TLR2, or short-hairpin RNA constructs targeting endogenous
CD200R1. As can be seen in Figure 3.14A, the overexpression of CD200R1 or TLR2 re-
sulted in a near two-fold increase in HSV viral replication, as measured by plaques-forming
units in the culture supernatant. Conversely, knockdown of CD200R1 by shRNA resulted
in approximately two-fold decrease in virus production at 24 hours.
In BMDCs a similar result was observed for CD200R1 but not TLR2 expression (Fig-
ure 3.14B). Ectopic expression of CD200R1 in wild-type BMDCs once again resulted in
signiﬁcant increase in viral replication. However, unlike in the U2OS cells, ectopic expres-
sion of TLR2 did not result in higher levels of HSV-1 replication. CD200R1-/- BMDCs
phenocopied CD200R1-/- MEFs and PECs by producing less HSV-1 than wild-type cells.
This defect in HSV-1 replication could be rescued by the ectopic expression of CD200R1
in CD200R1-/- cells, which lead to a dramatic increase in HSV-1 replication to a level well
above that of the wild-type control cells. Additionally TLR2 expression in CD200R1-/- also
rescued the HSV-1 replication phenotype, returning CD200R1-/- cells to a level of HSV-1
replication equivalent to control wild-type cells. The fact that TLR2 was able to rescue
CD200R1-/- BMDCs cells while also resulting in elevated levels of HSV-1 replication in
U2OS cells points to a role for TLR2 downstream of CD200R1 in the HSV-1 replication
cycle.
Since CD200R1-/- cells have a defect in HSV-1-induced and TLR2-induced IL-6 produc-
tion (Figure 3.9), fail to upregulate TLR2 in response to HSV-1 stimulation (Figure 3.10),
and are unable to support wild-type levels of HSV-1 replication following transduction with
ectopic TLR2 (Figure 3.14), I asked whether TLR2 itself is an important mediator of HSV-1
replication in vitro. Using the ICP8-GFP strain of HSV-1, I infected wild-type and TLR2-/-
MEFs for 6 hours and 8 hours, and measured the percentage of ICP8-GFP-positive cells
by ﬂow cytometry (Figure 3.15). Just like the CD200R1-/- MEFs, TLR2-/- MEFs showed
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Figure 3.14: Ectopic expression of either CD200R1 or TLR2 promote HSV-1 replication.
(A) U2OS were transduced with lentiviral vectors expressing CD200R1, TLR2, or a shRNA
targeting CD200R1. After antibiotic selection, cells were plated and infected with HSV-1
for 24 hours. HSV replication was measured by plaque assay on culture supernatants. (B)
WT or CD200R1-/- BMDCs were transformed during diﬀerentiation with lentiviral vectors
expressing control (GFP), CD200R1, TLR2, of shRNA targeting CD200R1. Following
diﬀerentiation and antibiotic selection, cells were plated and infected for 24 hours with
HSV-1. HSV-1 titers in culture supernatants were measured by plaque assay.
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signiﬁcantly less ICP8 expression when compared to wild-type, further suggesting the defect
in CD200R1-/- cells is related to TLR2.
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Figure 3.15: TLR2-/- MEFs, like CD200R1KO MEFs, do not support robust HSV-1 replica-
tion, as measured by GFP-expressing gene expression. C57BL/6 and TLR2-/- MEFS were
infected with an ICP8-GFP-expressing strain of HSV-1 for 6 and 8 hours, then ﬁxed and
analyzed for GFP expression by ﬂow cytometry. Grey background represent negative (un-
infected control MEFs of each cell type). GFP-positive gates were set at the 99th percentile
of GFP-positive cells in the uninfected control sample for each cell line. This gate was then
applied to the HSV-infected sample for that cell line. Percent GFP-positive samples based
on these gates are reported on each panel.
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3.4 Conclusions
I have found that CD200R1 is an important host factor supporting HSV-1 replication
early during infection. I also found CD200R1 is an important factor in TLR2 signaling
and TLR2 upregulation in macrophages. Additionally I have found that the expression of
TLR2 can rescue in CD200R1-/- cells the ability to support HSV-1 replication. In vivo the
collective results of these ﬁndings are that CD200R1 is required for eﬃcient viral replication
and dissemination with in the CNS, and a lack of CD200R1 is protective in a mouse model
of herpes simplex encephalitis.
Taken together, these results point to CD200R1 playing a role in promoting TLR2 upreg-
ulation and TLR2-mediated inﬂammatory signaling early in the replication cycle of HSV-1.
HSV-1 depends on some amount of inﬂammatory signaling to turn on the expression of
several host factors required for eﬃcient replication. Our results suggest that this processes
involves CD200R1- and TLR2-mediated gene expression. Without the activation of these
signaling pathways during viral replication, the expression of certain early viral proteins are
not able to proceed at suﬃcient levels, limiting replication.
This novel pro-inﬂammatory function for CD200R1 stands in contrast to its previously
characterized role as an important anti-inﬂammatory signaling molecule. Future work inves-
tigating how CD200R1 carries out this function and how it interacts with and promulgates
TLR2 signaling would allow for a better understanding of the intricate dynamic interactions
between pro- and anti-inﬂammatory pathways.
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CHAPTER IV: Discussion
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4.1 On the role of PIR1 in antiviral responses in mammals
PIR1 plays a critical role in promoting an eﬀective antiviral small RNA response in the
model organism C. elegans by promoting the eﬃcient production of antiviral RNAs early on
in an infection, allowing the host to eﬀectively restrain viral replication through RNA inter-
ference [94]. We have also known that human PIR1 selectively interacts with the RIG-I-like
receptor LGP2 (Figure 2.3 on page 26), and that in mice infected with EMCV, type I IFN
production is dependent on LGP2. Therefore, we originally hypothesized that mammalian
PIR1 would play an important role in type I IFN signaling in response to EMCV. However,
it is clear from my data that, at least in response to EMCV, this is not the case. Following
infection with EMCV, PIR1KO mice upregulate type I IFN to wild-type levels and show no
signiﬁcant diﬀerences in overall survival or viral replication. As has been reported multiple
times (and in my own unpublished experiments), loss of MDA5:LGP2:MAVS:IFN signaling
in mice leads to a fulminant EMCV infection with rampant viral replication and accelerated
mortality [53,54]. Such phenotypes are not observed in the PIR1KO mouse. These results,
however, do not rule out a role for PIR1 in the IFN response to other viruses that engage
MDA5:LGP2 signaling, and these other viruses should be investigated in the future using
our PIR1KO model.
My results also do not rule out a role for PIR1 in a mammalian small RNA pathway. In
fact several pieces of in vitro data, when combined with other published evidence, suggest
that PIR1 might be functioning in this capacity. While controversial, a growing body of
evidence appears to support the existence of a functional—albeit enigmatic—antiviral RNA
interference (avRNAi) response in mammals [189]. While it appears that such a mammalian
avRNAi pathway does exist, and that it is employed in certain situations in mammalian
systems, it is also clear that the type I IFN pathway is the predominant antiviral response to
pathogenic infections in mammals. Therefore, it seems mammals have two distinct antiviral
pathways: the type I IFN pathways and the avRNAi pathway. While the importance of the
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mammalian avRNAi pathway is still up for debate, it has been shown to interact with the
type I IFN pathway, suggesting that these two disparate defense systems might coexist in
some cells. How exactly they interact is not yet well understood, but PIR1 might play a
role this interaction.
4.1.1 A potential role for PIR1 in the avRNAi anti-viral response
Since immunostimulatory RNA is encountered on a regular basis from endogenous
sources or from non-pathogenic viruses, it would make sense that a certain threshold of
immunostimulatory RNA would be required in order to trigger the broad and disruptive
antiviral type I IFN response. I would hypothesize that an avRNAi pathway which exists
in mammalian cells could process small amounts of foreign RNA on a regular basis. How-
ever, given that RLRs like MDA5 have a threshold of detection for RNA above which they
oligomerize and initiate signaling [190], should the avRNAi pathway prove ineﬀective in
preventing the build up of foreign RNA, this threshold concentration would be achieved,
and type I IFN would be induced. It is also possible that activation of type I IFN would shut
down or suppress any avRNAi pathway, given the fact that mammalian dsRNA-processing
pathways are known to be negatively regulated following stimulation with type I IFN [84].
It could then follow that, as an RNA phosphatase known to interact with Dicer, PIR1 would
aﬀect this balance by promoting the avRNAi pathway when only small amounts of viral
RNA are present. While there is adequate evidence to suggest this model, many questions
remain unanswered, and much work remains to clearly elucidate these dynamic interactions
and test these hypotheses.
Open questions on PIR1 and avRNAi in C. elegans
While the mechanism is not yet fully understood, PIR1 has been shown to be a critical
mediator of the avRNAi response in C. elegans following infection with the worm virus Orsay
Virus [94]. It has been suggested that PIR1 facilitates the eﬃcient production of antiviral
120
RNAs early on in an infection, promoting host defense through RNA interference. During
the processing of primary avRNA molecules, dsRNA molecules are cleaved by Dicer and the
cleavage products are loaded into complexes with RDE-1 as primary avRNAs. These RDE-
1 complexes then detect and target viral RNA molecules for RdRP. PIR1 mutant worms
are able to produce primary avRNAs, but these molecules are less abundant and are not
eﬀective at inducing the synthesis of secondary avRNA molecules. This could be a symptom
of ineﬃcient loading of primary avRNAs into complexes with the argonaute protein RDE-1.
Argonaute loading is a multi-protein process the occurs in concert with Dicing and involves
Dicer as well as other dsRNA-binding proteins [191]. As PIR1 interacts with these proteins,
and as it binds to the 5’-end of RNA molecules, one possibility could be that PIR1 promotes
RDE-1 loading with primary avRNA molecules. Without PIR-1, primary avRNAs would
get produced, but they would be less stable and as a result would not be able to carry
out their antiviral eﬀect. Another possibility could be that PIR1 aﬀects the processing and
maturation of secondary avRNAs. As these RNA molecules are 5’-triphosphorylated, they
likely require dephosphorylation in order to be properly loaded into their respective eﬀector
argonuate complexes. Perhaps an inability to properly produce stable secondary avRNAs
results in the ineﬀective activity of the whole avRNAi pathway. More work is needed to
better understand the true mechanism of PIR1 in these critical processes, and to potentially
reveal new insights and avenues of inquiry for the role of PIR1 in mammals.
Open questions on PIR1 and avRNAi in Drosphila
Recent work in the ﬂy (as reported by Daniel Chaves [94]) has shown that the ﬂy or-
thologue to PIR1 (CG13197) is required for inhibiting ﬂock-house virus replication and
promoting survival, a response that is known to require antiviral RNAi. At this point, how-
ever, as in the worms, a precise mechanism for this phenotype has not yet been uncovered.
Whether PIR1 aﬀects the production of antiviral siRNAs by Dicer-2 or somehow otherwise
promotes the production of secondary avRNA molecules from complementary vDNA is yet
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to be determined. It is possible that PIR1 could be involved in the loading of Dicer products
into their appropriate Argonaute complexes as is hypothesized for the worm. It is also pos-
sible that the maturation of secondary avRNAs requires 5’-dephosphorylation, since these
are de novo RNA transcripts that are missing a 5’ cap. Again, further investigation will be
needed to probe the relationship between PIR1 and the Drosophila avRNAi pathway.
A potential role of PIR1 in a mammalian avRNAi pathway
Two recent studies by Maillard et al. and Li et al. showed that under certain circum-
stances, avRNAi can be detected in human and mouse systems [82,192]. Pluripotent mouse
stem cells were shown to produce signiﬁcant levels of virus-derived small RNAs, which
showed hallmarks of Dicer production, and were bound in Argonaute complexes. This was
also true in very immature weanling mice, where viral replication was limited by the pro-
duction of small RNAs. Interestingly, in stem cells and other progenitor cells—like oocytes
[193]—the avRNAi pathway is readily detectable by deep sequencing [192]. However, upon
diﬀerentiation, the avRNAi pathway appears to go away, and get replaced by type I IFN
signaling. Together these data suggest that the mammalian antiviral RNAi response is
prominent and important only in speciﬁc subsets of cell types or in speciﬁc contexts.
Many mammalian viruses express potent inhibitors to the small RNA pathway, suggest-
ing that antagonizing RNAi is often beneﬁcial for viral replication. In the case of Inﬂuenza
A, when the potent RNAi antagonist NS1 is deleted, antiviral RNAs are readily detected
by deep sequencing of the host cells. These RNA molecules are loaded into Ago complexes,
and do in fact appear to function as antiviral RNA molecules [83].
Intriguingly, worms and ﬂies are now both thought to employ an ampliﬁcation step in
their generation of antiviral RNA molecules. In C. elegans this ampliﬁcation is accomplished
by RdRP. As of yet, no bonaﬁde mammalian RdRP enzyme has been found, and no notable
evidence for RdRP-mediated small RNA ampliﬁcation. However, in D. melanogaster this
ampliﬁcation is accomplished through a complimentary (cDNA) intermediate. Generation
122
of this cDNA is dependent on reverse transcription activity, apparently derived from en-
dogenous reverse transcriptases associated with retrotransposons already present in the ﬂy
genome [79]. Mammalian genomes, including those of mice and humans, contain many ac-
tive retrotransposons, which could play an analogous role in amplifying antiviral interfering
RNA molecules. In fact, the presence of complementary DNA to several RNA viruses has
been previously reported, further suggesting that such a mechanism might exist in mam-
mals [194–196]. Future work should take care to characterize the nature of these cDNAs
and their abundance during infection in both wild-type and PIR1KO mice.
However, even if mammals are not inherently capable of amplifying viral RNA molecules,
this does not exclude the possibility for small RNA ampliﬁcation via a viral RdRP. Many
mammalian viruses encode for an RdRP enzyme, expressed during infection and required
for viral replication. Ectopic expression of the poliovirus RdRP, for example, can lead to the
production of immunostimulatory RNA in the absence of viral RNA [197]. The same is also
true for the RdRP of Simliki Forest Virus [198] and Hepatitis C Virus [199]. Furthermore
viral RdRPs, which usually require a primer to initiate RNA polymerization, are known to
under certain circumstances synthesize RNA in a template-independent manner [200,201].
Together this means that small RNA ampliﬁcation could still occur in infected hosts that
do not themselves express an RdRP enzyme via a viral RdRP.
Taken together it seems reasonable to conclude that mammalian cells have a functional
pathway by which viral RNA can be recognized and processed, in a Dicer-dependent manner,
into small RNAs. However, it also appears that this pathway, which is actively inhibited
by many viruses, and in some cases is co-opted by viruses to facilitate viral replication, will
only be detectable in speciﬁc contexts (such as oocytes, stem cells, and suckling mice). In
contrast, in fully-diﬀerentiated cells and mature animals, the avRNAi pathway becomes less
important to the more robust IFN response.
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A potential role of PIR1 in a mammalian miRNA pathway
Separate from the antiviral response, recent studies by Burke et al. have shown that
human PIR1 plays a role in promoting the stability of certain non-canonical miRNAs [96].
Additionally, preliminary work by Darryl Conte has shown that PIR1 can interact with
human Dicer (Figure 2.3 on page 26). Consistent with these observations, I have found that
PIR1 aﬀects Dicer-dependent miRNA levels (Figure 2.16 on page 68).
While the exact mechanism is not yet understood, it is suggested that the presence of a
5’-triphosphate on a pre-miRNA or small RNAmolecule aﬀects that ability of Dicer:Argonaute
complexes to properly load the 5p-arm of these molecules into an eﬀective silencing com-
plex. The hypothesis that PIR1 promotes the stable loading of certain small RNA molecules
into Argonaute complexes ﬁts with the current model for PIR1 in the worm, as well as my
ﬁndings on the role of PIR1 in the earliest stages of RLR induction (as shown in Figure 2.15
on page 67).
All together, mammals have all the components required to mount an RNAi-mediated
response to a viral infection, and in speciﬁc circumstances do harbor small RNA molecules
during viral infections. While several studies have tried and failed to ﬁnd small RNAs
derived from various viruses [202], certain other viruses can apparently produce small RNAs
[203–206]. However, these small RNAs are not necessary antiviral. In the case of enterovirus-
71, dicer-dependent virus-derived small RNAs were found to be proviral and thought to help
regulate viral replication [207]. Future work characterizing the diﬀerences in small RNAs
in wild-type versus knockout mice, at baseline and under infection, will allow for a more
complete understanding of the role of mammalian PIR1 in small RNA biology.
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4.1.2 Future work and limitations in studying the avRNAi response in mam-
mals
It is well understood that the predominant innate antiviral response pathway in mam-
mals is the type I IFN response. Upon infection with an RNA virus, type I IFN is induced
by the cytosolic RNA sensors RIG-I and MDA5 (as discussed in Section 1.2.1 on page 8). It
is well documented that mice lacking any of the components of the RNA-sensing and IFN
signaling pathway genes are highly susceptible to RNA viruses, often dying rapidly with
higher rates of viral replication and dissemination.
In contrast, many of the components of the avRNAi pathway are required for embryo-
genesis and early development, making them diﬃcult to study by knock-out. To date, no
in vivo studies using transgenic mice carry a knock-out mutation to a component of the
avRNAi pathway have demonstrated an eﬀect of the avRNAi pathway no survival to a viral
infection. This might suggest that in a mature animal responding to a pathogenic infection,
this pathway is not critical, but more work is need to conﬁrm this.
In the context of the commonly studied pathogenic infections, type I IFN is the critical
mediator of antiviral signaling and is responsible for hampering viral replication, while the
avRNAi pathway is not considered an equivalent or redundant antiviral pathway. It is still
possible that the avRNAi pathway plays a role in complementing the type I IFN response
or responding to RNA that would not otherwise engage the type I IFN pathway.
The complex interaction between the type I IFN and avRNAi responses
The type I IFN pathway and the avRNAi pathway appear to interact with each other
signiﬁcantly during the course of an infection. Perhaps the best evidence that these path-
ways coexists, interact, and potentially complement each other is the fact that the former
has been shown to negatively regulate the later. There is growing evidence that the type
I IFN pathway, upon activation, negatively regulates many parts of the avRNAi response
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by directly ribosylating the Argonaute proteins, reducing their activity [86]. Cells lacking
in type I IFN signaling, show an enhanced ability to process dsRNA into functional siRNA.
When type I IFN was added back to these cells, this elevated dsRNA-processing activity
is lost [84], suggesting that upon activation type I IFN signaling shuts oﬀ the avRNAi
pathway.
There also are a number of molecules that are directly involved in both pathways, aﬀord-
ing an opportunity for cross-talk. The dicer-partner protein PACT, which is an important
co-factor in miRNA processing, coordinates with the RLR RIG-I to facilitate IFN signaling
in response to certain viral RNA ligands [208,209]. The other dicer-partner protein TRBP,
which helps promote dsRNA processing, interacts with the RLR LGP2 to facilitate IFN
induction following infection with EMCV [210].
Additionally, a number of recent studies have suggested that the RIG-I-like receptors do
not simply function as sensors for viral RNA, but instead might help facilitate an antiviral
response independent of IFN induction. RIG-I has been shown to inhibit viral protein and
enzyme binding to to IAV and HBV viral RNA in an IFN-independent manner [211,212].
RIG-I and MDA5 also actively remove viral proteins from dsRNA in an ATP-dependent
manner allowing the viral RNA to be bound to dsRNA-binding protein PKR [213]. Together
these ﬁndings support the hypothesis that RLR-pathways are interacting with an alternative
antiviral response, independent of IFN induction.
Given the feed-forward nature of the the type I IFN response—where small amounts of
IFN-β or IFN-α signal in an autocrine or paracrine manner to further induce the production
of more IFN cytokines—initial activation leads to an ampliﬁcation and ramp up of the
antiviral response until negative regulatory processes can kick in to shut it down hours to
days later. Therefore, it would seem reasonable that there exists a threshold amount of
foreign RNA beyond which IFN release is triggered. It is already understood that such
a threshold exists, at least at the ligand-binding level. Certain mutations in the dsRNA-
sensor MDA5 result in an increased aﬃnity for dsRNA resulting in a greater tendency
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for signaling complex association and signal initiation even when encountering endogenous
dsRNA species that are otherwise non-stimulatory [190].
If mammalian cells have two functional antiviral pathways—the avRNAi pathway and
the type I IFN pathway—foreign RNA could be detected by either. However, viral RNA
that is shuttled into the the avRNAi pathways would get processed and cleaved into small
RNA molecules, neutralizing this RNA and eﬀectively decreasing the amount of foreign
RNA available for IFN induction. If in certain circumstances this shuttling of viral RNA
into the avRNAi pathway for cleavage is inhibited, then MDA5 signaling might get triggered
sooner, as there would be more viral dsRNA available for MDA5:LGP2 complex formation.
I would hypothesize that in a naive cell, both antiviral pathways exists simultaneously.
I would also hypothesize that during the earliest moments of a viral infection or following
the introduction of dsRNA into the cytoplasm the avRNAi has precedence, being allowed
to cleave the foreign RNA and to render it inactive. The cleaved molecules could then be
loaded into Ago complexes as a temporary protection mechanism against subsequent viral
RNA molecules. However, if the virus is able to replicate eﬀectively despite this process,
a dsRNA threshold is reached, at which point IFN signaling is initiated, cytokines are
produced, and the ineﬀective avRNAi pathway is turned oﬀ.
Separating the overlapping pathways of avRNAi and miRNA synthesis
While complicated, the above mechanism allows for the coexistence of both antiviral
pathways, at least early on, and ﬁts much of the current literature. In order to test this
hypothesis one could further investigate the dose-response of the type I IFN pathway, with
and without an avRNAi response. Blocking the avRNAi response is diﬃcult however, since
so many of the components of this pathway also function in the miRNA pathway, helping
to regulate countless other vital biological processes. As such, disruption of these pathway
components would have countless secondary eﬀects upon a given cell. Therefore, some
way to distinguish and diﬀerentiate the miRNA pathway and the avRNAi response will be
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required. Such a distinction has been found in C. elegans and D. melanogaster, and has
allowed for better characterization of an antiviral-speciﬁc pathway. A proteomic analysis of
Dicer-associated proteins following stimulation with viral RNA and synthetic dsRNA might
provide a clue, as this was how DRH-1 was discovered to be an important cofactor to Dicer
in worms [93].
Other techniques would include the use of labelled RNA, which could be followed by mi-
crocopy or co-IP as it gets shuttled into the diﬀerent antiviral pathways and interacts with
the speciﬁc RNA-binding proteins of each. A long synthetic or virus-derived RNA molecule
could be multiply-labelled with radiation or high-quantum-yield ﬂuorophores and trans-
fected into the cells. These molecules could then be UV-crosslinked to whichever proteins
they are bound, and then precipitated out. Mass spectrometric analysis or western blotting
of the bound proteins could demonstrate which pathways are being engaged immediately
after detection.
Alternatively, as has been shown previously, blocking type I IFN activity in vitro with
a neutralizing antibody against the type I IFN receptor IFNAR is a possible solution. In
the context of an inactive type I IFN response, I would expect that any avRNAi activity
would persist longer, and perhaps allow for the small RNA hallmarks of this pathway to
reach detectable levels.
Single-cell pathway analysis
As my proposed mechanism involves studying the binding and processing of a small
number of RNA molecules within a given cell, other single molecule imaging techniques
could be employed. For RNA ligands like polyIC or viral RNA being transfected into cells,
the direct labeling of RNA molecules with high-quantum-yield ﬂuorophores could allow for
detection of single RNA molecules by confocal microscopy. If these RNA molecules are
then processed, a decrease in signal would be evident. Another possibility is to use Click-It
technology (dispersed ethynyl uridine) to label newly synthesized viral RNA during the
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Figure 4.1: A proposed model for the role of PIR1 in the innate antiviral immune response.
PIR1 aﬀects the kinetics of dsRNA sensing via the RLR:MAVS signaling pathway. PIR1
antagonizes this pathway in the minutes to hours after the introduction of a stimulatory
RNA molecule. At 2 hours, PIR1KO cells show increased IRF3 phosphorylation and in-
creased type I IFN signaling. PIR1KO and wild-type cells appear equivalent by 4 hours.
There are a number of mechanisms by which PIR1 could be aﬀecting the several compo-
nents of this pathway, and discovery of the exact mechanism will be the focus of future
investigation. (A) Reconciling my results with current evidence of a complementary role
for antiviral RNA interference (avRNAi) in mammalian cells, and the evidence put forward
by Daniel Chaves that PIR1 is a critical component of an eﬃcient and eﬀective avRNAi
response in C. elegans, my model hypothesizes that PIR1 promotes an avRNAi response at
the earliest moments of infection. Upon the introduction of viral dsRNA into a cell (step
1), this RNA is ﬁrst shuttled into the avRNAi pathway (step 2), where it gets processed
and employed as antiviral molecules (step 3). If the avRNAi mechanism proves unsuccessful
and enough dsRNA accumulates within the cell, the MDA5:LGP2:IFN pathway is activated
(step 4). The type I IFN response, then negatively regulates the avRNAi response (step
5). (B) In the case of a PIR1KO cell, since PIR1 is not present to promote early avRNAi
processing, the activation of MDA5:LGP2:IFN signaling (step 2) occurs earlier.
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course of an infection. Watching the fate of these RNA molecules during infection and
assessing their length based on signal intensity might allow for the detection of dsRNA
cleavage in real-time.
Various deep sequencing techniques might also be used to shed light on this problem.
Single-cell sequencing would allow for the identiﬁcation and characterization of ligand and
ligand-derived RNA molecules during the course of stimulation. When IFN is neutralized in
culture, an immunostimulatory RNA could be transfected and then at speciﬁc time points
post transfection, cells could be isolated and used to generate a single-cell-labelled library
of small RNAs. Another approach might include targeting the sequencing of speciﬁc RNA
motifs. CAP-Seq [214] would allow for the isolation of 5’-triphosphorylated RNA, and
dsRNA-Seq could allow for the isolation of dsRNA molecules.
Furthermore, crosslinked-immunoprecipitation experiments, as have been done with var-
ious RNA-binding proteins in the past, could be carried out with a panel of RNA-binding
proteins involved in both of these pathways. PACT, TRBP, Dicer, and LGP2, should each
be investigated, and studied for which RNA molecules are bound to each, and where they
are localized in relation to the RLR and avRNAi components. It might be that a high-
throughput proteomics approach, as has been applied to the type I IFN pathway [215],
could be employed to probe the RNA processing pathways as a network with and without
IFN antagonism, in a more systematic manner.
4.1.3 Finding the relevance of avRNAi in mammals
A ﬁnal question is why an alternative, less potent, suppressible, antiviral pathway would
persist in mammalian systems. One reason could be to protect the cell from endogenous
retroviruses—also known as retrotransposons—and other endogenous sources of dsRNA
that if left unchecked could aﬀect genome stability. Another possibility is that avRNAi
may help respond to the multitudes of nonpathogenic viral RNA that we encounter daily.
RNA phages present in the gut and on skin have been recovered in various organs including
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the spleen, suggesting that while they are not able to trigger productive infections, phages
can expose host cells to foreign nucleic acids [216]. Even plant viruses, which are regularly
consumed along with their hosts, could present foreign RNA to our cells.
Additionally, it has been shown that some pathogenic viruses are recoverable from oth-
erwise healthy people. Various rhinoviruses, coronaviruses, and adenoviruses are found in
the nasopharnyx of children who exhibit no signs of an illness or infection [217], suggesting
that we are constantly exposed to many viruses. Perhaps an avRNAi response could serve
as a early defense in these situations where cellular processes do not need to be disrupted
and cytokine signaling does not need to be induced.
Also worth considering is the phenomena of chronic or latent infections, in which a virus
is able to withstand or shut down the host’s defenses and persist for extended periods of
time. A viruses might be able to utilize the antagonism between the avRNAi pathway
and the type I IFN pathway to negatively regulate both, allowing it to remain in a cell
undetected. Perhaps better understanding of the role of avRNAi here could lead to new
treatments for chronic infections.
Finally, arboviruses are a group of arthropod-borne viruses that are able to productively
infect both insects and mammals. These viruses include west-nile virus, chikungunya, and
zika virus, all of which are transmitted by mosquito. As the mosquito is related to the
fruit ﬂy, it possesses many of the same antiviral mechanisms that are so well studied in D.
melanogaster. As arboviruses have adapted a genome and set of proteins that are able to
inhibit and circumvent insect avRNAi, they could be doing the same while infecting their
human hosts.
Overall, a better understanding of how viruses interact with RNA-processing pathways
will allow for a better understanding of virus:host interactions, and hopefully will uncover
new mechanisms for antiviral therapies.
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4.2 On the role of CD200R1 and TLR2 signaling in HSV replication
In the isolated and critically-sensitive environment of the central nervous system, there
exists a delicate balance between the anti-inﬂammatory pathways protect the brain in case of
aberrent inﬂammation and the pro-inﬂammatory pathways ready to defend against against
pathogenic infections. In herpes simplex encephalitis, this balance is disrupted, leading to
inﬂammation and viral replication, both of which lead to damage.
After infecting a cell, HSV-1 initiates an intricate series of signaling events that ulti-
mately leads to viral replication. At the same time the infected host cell detects the viral
pathogen and triggers antiviral and inﬂammatory responses. Here we have shown that in
order for HSV-1 to replicate optimally, a certain amount of host detection and inﬂammation
is required.
In studying the role of the anti-inﬂammatory signaling receptor CD200R1, I discovered
that HSV-1 requires CD200R1 to properly replicate within the CNS. I further demonstrated
that CD200R1 actively promotes TLR2 signaling, and in this way facilitates eﬃcient viral
gene expression during the viral replication cycle. My data show that CD200R1 is required
for TLR2 upregulation in macrophages and for TLR2-dependent signaling leading to the
production of speciﬁc inﬂammatory cytokines and chemokines. Without this signaling,
HSV-1 replication appears to stall at the stage of α (immediate-early) gene expression.
Finally, I showed that this HSV-1 replication phenotype in CD2001-/- cells can be rescued
by either ectopic CD200R1 expression or TLR2 expression, suggesting that TLR2 functions
downstream of CD200R1, and is required for eﬃcient HSV-1 replication.
4.2.1 NF-κB signaling and HSV replication
During the course of infection, HSV-1 interacts extensively with innate immune signaling
pathways. Frequently, HSV-1 proteins will actively antagonize defense pathways, but in
the case of NF-κB signaling, HSV-1 actually promotes its activation. NF-κB signaling
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during HSV-1 replication is known to increase levels of viral replication by delaying host
cell apoptosis [218,219]. HSV-1 activates NF-κΒ signaling by engaging TLR2 on the cell
surface [8]. Additionally HSV-1 can also activate NF-κB via the viral protein UL37, which
signals through TRAF6 to turn on NF-κB [220]. Several studies in vivo have found that
inhibition of pro-inﬂammatory pathways actually limits disease and replication following
infection with HSV-1 [221]. Additionally, a lack of TLR2 has also been shown to result in
better disease outcomes following infection with HSV-1 in the brain [179].
With respect to CD200R1 and HSV, my data show that CD200R1 is required for HSV-
1 induced production of IL-6 and IL-1β. In CD200R-/- mice, the defect in inﬂammatory
signaling is likely the cause of defective HSV-1 replication via the decreased capacity for
HSV-1 viral gene expression.
The mechanism by which CD200R1, an anti-inﬂammatory signal receptor, promotes
this pro-viral inﬂammatory signal following infection with HSV-1 is still not know but the
most promising explanation, based on my data, is through an eﬀect on TLR2 expression.
4.2.2 TLR2 upregulation
TLR2 upregulation is a well documented phenomena observed following the activation
of many TLR molecules, including TLR2 itself [186,187]. The exact mechanism of TLR2
upregulation is not fully characterized, and is likely cell-type and signaling pathway speciﬁc.
It has been shown that TLR-mediated upregulation of TLR2 is dependent on MyD88 [186]
and NF-κΒ [188], with the TLR2 promoter having two NF-κB sites, two CCAAT/enhancer
binding protein sites, one cAMP response element-binding protein site, and one STAT
consensus sequence site. The importance of each of these sites in the TLR2 promoter is
cell-type speciﬁc, but frequently the two NF-κB binding sites are critical in turning on TLR2
gene expression [188].
CD200R1-/- cells are unable to upregulate TLR2 following infection with HSV-1, and
produce signiﬁcantly reduced levels of IL-6 following stimulation with HSV-1 or the TLR2
133
agonist Pam2CSK4. Since TLR2 upregulation is NF-κΒ driven, this TLR2 signaling phe-
notype present in CD200R1-/- cells possibly could be caused by reduced levels of NF-κΒ
activation during early viral infection. Since we found that the induction of TLR2 fails in
CD200R1-/- cells, but also that TLR2 over expression is suﬃcient to rescue the HSV-1 repli-
cation phenotype, it seems reasonable that might be that CD200R1 is a critical upstream
factor for TLR2-mediated NF-κΒ activation and TLR2 upregulation. Further investigation
of NF-κΒ activation in CD200R1-/- cells would allow us to better understand whether this
is true. It is also possible that NF-κB activation during HSV-1 infection is a result of an-
other innate immune pathway (TLR3 or an intracellular DNA receptor like cGAS), with
that pathway leading to CD200R1-dependent upregulation of TLR2. However, the fact that
CD200R1-/- PECs failed to generate IL-6 following stimulation with Pam2CSK4 indicates
that CD200R1 is directly aﬀecting some part of the TLR2 pathway. Taken together, it
seems most plausible that CD200R1 facilitates TLR2-driven TLR2 upregulation.
As the TLR2 promoter contains binding sites for other transcription factors, it is possible
that CD200R1 exerts its eﬀect on TLR2 upregulation via one of these other transcription
factors instead. Future investigation of TLR2 promoter region activity, during HSV infection
could yield additional components involved in the C200R1:TLR2 pathway.
Finally, one limitation of my work is that I only measured TLR2 upregulation based
on the surface expression of TLR2. It is possible that CD200R1 is aﬀecting TLR2 protein
localization instead of gene expression. TLR2 has been found in the endolysosome [222],
and so the localization of TLR2 before and after stimulation in wild-type and CD200R1-/-
cells should be studied to clarify this point. By using confocal microscopy, it might be
possible to show if CD200R1 is responsible for shuttling TLR2 receptors to the cell surface
following stimulation.
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4.2.3 HSV signaling and TLR2
Certain strains of HSV-1 are known to be potent activators of TLR2. The glycopro-
teins on the viral envelope can be direct ligands that engage with and activate TLR2 [8].
Furthermore, TLR2 has been found in mouse models of HSE, to be a critical mediators of
neuroinﬂammation. TLR2-/- mice were found to have a less severe disease, with less brain
inﬂammation when compared to wild-type animals [179]. Here I have found that TLR2,
like CD200R1, is an important host factor for viral replication in vitro (Figure 3.15 on
page 115). TLR2-/- MEFs have reduced levels of ICP8 expression, suggesting a defect in
the expression of certain viral genes, presumably due to a lack of TLR2-mediated activation
of transcription factors, such as NF-κB, required for eﬃcient viral gene expression.
More recently, TLR2 has been shown to activate type 1 IFN signaling in cooperation with
the integrin αvβ3, following stimulation with HSV-1 or soluble HSV glycoproteins gH/gL
[10,11]. These results suggest that TLR2 has a role in IFN signaling independent of its role
in NF-κB activation. The engagement of TLR2 during an HSV-1 infection might have more
wide-spread eﬀects on inﬂammatory and antiviral signaling than previously thought. Inves-
tigations into whether integrin-associated TLR2-induction of type 1 IFN is also impaired in
CD200R1-/- cells might help identify how CD200R1 is aﬀecting TLR2 signaling.
4.2.4 How does CD200R1 aﬀect TLR2 signaling and upregulation?
CD200R1 has been most studied for its anti-inﬂammatory activity. Binding of CD200R1
on macrophages with the ligand CD200 is well known to lead to suppressed production of
pro-inﬂammatory cytokines [223]. How CD200R1 transmits this signal after binding it
ligand is less clear. Upon engagement with it ligand, CD200R1 becomes phosphorylated
on several tyrosine residues within its cytoplasmic tail. This phosphorylation event then
leads to the recruitment and phosphorylation of the adaptor molecules Dok1 and/or Dok2
[20]. These Dok molecules subsequently recruit SH-2 domain protein SHP-1 [19]. SHP-
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1 then activates RasGAP which functions as a negative regulator of Ras signaling. In
macrophages Dok1 and RasGAP are critical mediators of CD200R1 signaling [19]. Inde-
pendent of CD200R1 signaling, following LPS treatment of macrophages, Dok1 and Dok2
were found to be negative regulators of TNF-α and NO production through the negative
regulation of the kinase ERK [22]. In fact Dok1-/- or Dok2-/- macrophages have increased
levels of TNF-α and NO without stimulation, suggesting that these Dok proteins negatively
regulate pro-inﬂammatory signals at baseline [224].
Ras and ERK are both MAP kinases that are thought to facilitate the activation of many
pro-inﬂammatory processes in macrophages and other cell types by promoting the produc-
tion of certain cytokines. Dok1 and/or Dok2 aﬀect RAS and ERK signaling presumably
via RasGAP activation, with RasGAP being a well-documented negative regulator of these
kinases [225]. Interestingly, RasGAP has been found to directly regulate NF-κB activity as
well. RasGAP has been shown to facilitate the retention of IκBα and NF-κB complexes in
the cytoplasm, aﬀecting nuclear tranlocation and potentially NF-κB activation [23]. It is
possible that CD200R1 is able to promote TLR2 signaling or TLR2 upregulation via Dok
and RasGAP signaling,
Some evidence already exists linking the CD200R1 pathway with the TLR2 pathway
speciﬁcally in the CNS. Astrocytes and microglia—two types of glial cells in the brain—
express TLR2, and respond to TLR2 stimulation. Following TLR2 stimulation in these cells,
Dok1 and Dok2 are phosphorylated. Additionally, knockdown of Dok1 or Dok2 in astrocytes
cells leads to increased levels of IL-6 production following with the TLR2 ligand Pam2CSK4
stimulation. In microglia, a similar result was seen with Dok2 knockdown, while knockdown
of Dok1 was found to be anti-inﬂammatory [226]. The fact that TLR2 stimulation leads to
the activation of the Dok proteins, which themselves limit TLR2 signaling, again support
the connection between CD200R1 and TLR2.
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4.2.5 A general model for how CD200R1 aﬀects TLR2 signaling and HSV-1
replication.
Synthesizing our results and the current literature on TLR2 and CD200:CD200R1 sig-
naling, I have developed a model for how CD200R1 might aﬀect TLR2 activation and
HSV-1 replication (Figure 4.2). In this model, HSV-1 stimulates TLR2 activation during
infection. This signaling activates NF-κB and other inﬂammatory processes which result
in the production of inﬂammatory cytokines, the eﬃcient expression of certain viral genes,
and the upregulation of TLR2. CD200R1, via its intracellular domain and its signaling
partners Dok1 and/or Dok2, presumably promotes this initial NF-κB activation. Without
CD200R1, TLR2 mediated NF-κB activation is severally limited, resulting in lower levels
of inﬂammation, and also lower levels of viral replication.
However, further work is required to precisely identify where in this process CD200R1
or CD200R1 signaling exerts its eﬀect. It is possible that baseline activity of CD200R1
and its signaling partners directly aﬀect NF-κΒ activity. This could be tested by assaying
NF-κΒ activation following HSV-1 infection in wild-type and CD200R1-/- cells. IκB levels
in the cytoplasm and NF-κΒ levels in the nucleus could be assayed to determine whether
CD200R1-/- cells have more or less activation of this transcription factor. Additionally, since
CD200R1 is implicated in the regulation of certain MAP kinases via its aﬀect on RasGAP,
and ERK signaling has been shown to be an important mediator of TLR2 signaling ([227–
230]. The activity levels of Ras and ERK should be assayed in wild-type and CD200R1-/-
cells to assess their requirement in this pro-viral process.
It is important to consider that baseline levels of CD200R1 activity do exist, as does
baseline activity of Dok1 and Dok2 [224]. Therefore these molecules might be signaling
to some degree without any pathogenic stimulus. As a result, the downstream signaling
molecules Dok1 and Dok2 are excellent candidates for future studies. If ectopic expression
of either or both of these molecules rescues the HSV-1 and TLR2 phenotypes of CD200R1-/-
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Figure 4.2: A model for the role of CD200R1 is TLR2 signaling and HSV-1 replication.
HSV-1 is activates TLR2 on the cell surface early on in the infection. This signaling re-
sults in both an upregulation of TLR2 and the eﬀective expression of various HSV-1 genes.
CD200R1 facilitates this TLR2-mediated upregulation and inﬂammation process. The di-
rect mechanism by which CD200R1 exerts this eﬀect is open to further investigation.
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cells, this would suggest that these proteins are part of the direct link between CD200R1
and HSV-1 replication.
Further studies could also pinpoint if the primary eﬀect of CD200R1 signaling is on tran-
scription, translation, or localization of TLR2 following stimulation. TLR2 is also know to
localize to several diﬀerent regions within the cell, including the outer membrane, phago-
cytic clefts, and the early and recycling endosome [231–233]. CD200R1 could aﬀect TLR2
signaling by promoting its localization to a compartment where it will it will speciﬁcally be
activated during HSV-1 infection. Investigating the distribution and location of TLR2 in
wild-type and CD200R1-/- cells would allow a better understanding of the dynamics and
importance of TLR2 localization during early infection.
4.2.6 The role of CD200R1 and TLR in herpes simplex encephalitis in vivo
It is clear from our studies that within the CNS, CD200R1 is a critical mediator of
HSV-1 replication. While my in vitro studies suggest that the result of CD200R1 on HSV-1
replication is a result of TLR2 upregulation or signal ampliﬁcation, we do not yet have clear
evidence that this is also true in vivo. The functions of Dok1 and Dok2 are diﬀerent between
astrocytes and microglia, with Dok1 being pro-inﬂammatory in both, but Dok2 being anti-
inﬂammatory in microglia and pro-inﬂammatory in astrocytes [226]. Subtle diﬀerences like
these, and all of the other unique features of the CNS, demonstrate why further work is
required to generalize our in vitro ﬁndings to the HSE model, and to conclude that TLR2
in vivois responsible for decreased HSV-1 replication in the CNS of CD200R1-/- mice.
Finally, previous studies in our lab have shown the TLR2-/- mice survive better when
compared to wild-type mice following intraperitoneal [145] or intracranial [179] infection
with HSV-1, however, neither of these studies showed signiﬁcant diﬀerences in viral titer
in TLR2-/- mice when compared to wild-type mice. This discrepancy might be a result
of diﬀerences in study design, but it might also suggest that the eﬀect of CD200R1 on
HSV-1 replication speciﬁcally within the CNS involves a mechanism separate from its eﬀect
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on TLR2 signaling. In order to better understand this apparent diﬀerence, CD200R1-/-
mice could be injected intracranially with TLR2 ligands to test whether TLR2 is active in
the CNS of these mice. Additional studies could include examining cultured neurons and
microglia from CD200R1-/-, TLR2-/-, and wild-type mice for their ability to support and
respond to HSV-1 replication. Lastly, the ex vivo infection of brain sections with HSV-
1, a technique previously used to assess the regional tropism of HSV-1 within the CNS
[234], could be valuable to tease out CNS-speciﬁc eﬀects of CD200R1 and TLR2 on HSV-1
replication.
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4.3 Conclusion
The work presented here ultimately demonstrates the role of two proteins on two dis-
parate facets of the innate immune system. PIR1, being an ancient protein that is shared
between humans and nematodes, potentially oﬀers a key into better understanding how the
evolutionarily conserved small RNA antiviral pathways interact with the newer type 1 IFN
pathways found in vertebrates.
CD200R1, in contrast is a signaling molecule that plays an important role in modulating
cellular immunity, however it appears to promote the replication of Herpes Simplex through
the potentiation of TLR2 signaling.
Taken together, the cases of PIR1 and CD200R1, highlight how intricate and intertwined
host pathways and viral replication are. This is not surprising given that we have evolved
together for millennia. Common pathogenic viruses have evolved to replicate eﬀective within
the context of our immune systems, meaning that while our immune systems are generally
good at clearing an infection in time, it is not good at preventing the virus from successfully
replicated itself and spreading to our family and friends. What this does mean however is
that perturbations to this delicate homeostasis can be fatal, either to the virus or to the
host. It also means that perhaps some of the most worrisome pathogens are not those that
are well known to infect humans like the ﬂu, but are those that have not yet been discovered.
New and emerging viruses are likely to surface with increasing frequency, as has already
been seen with Ebola, SARS, MERS, Chikungunya, Zika, and others. These new viruses,
which are not adapted to human hosts, are likely to interact with our immune systems in
novel ways.
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Appendix I: Additional PIR1KO data
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A.1 Introduction
The following data are from experiments conducted with partially backbred mice (N=6).
Any results herein should be veriﬁed in the fully backbred strain of PIR1KO mice. At N=6,
the PIR1KO mice still carried many 129-derived SNPs in chromosome 4, which is the
home if the type 1 IFN locus where many type 1 IFN genes include IFN-β and IFN-α are
located. The use of littermate control whenever possible, should have mitigated much of the
variability introduced by the mixed background, but as littermate are siblings they do not
share their entire genome. It is likely that mixed background diﬀerence would still exists
between littermate mice.
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A.2 Materials and Methods
A.2.1 Inﬂuenza A virus infection of mice
The Inﬂuenza A strain used was the mouse-adapted strain PR8. For infection, an aliquot
of virus was thawed on ice, and then diluted in sterile PBS. Mice were then inoculated at
a dose of either 2000 pfu/mouse or 4000 pfu/mouse by an intrapharangyeal inoculation.
Mice were infected in the morning. For the weight-loss study, mice were weighed prior to
infected, and then weighed once a day at same time each morning for 10 days. For the
survival study, mice were check for every 12 hours for death or moribundity.
A.2.2 Listeria monocytogenes infection and bacteria recovery from organs of
infected mice
L. monocytogenes stock preparation
The streptomycin-resistant, wild-type 10403s strain of L. monocytogenes was generously
donated by Kate Fitzgerald Ph.D. (University of Massachusetts Medical School; Worcester,
MA, USA). A BALB/c mouse was inoculated intravenously with 400μL of 1×104 cfu of
this bacteria. After 24 hours, this mouse was euthanized, the spleen was dissected out and
place into 2 mL of H20 with 0.02% Triton-X. The spleen was then lysed mechanically using
the Qiagen TissueRuptor. This lysate was diluted and streaked onto a Tryptic Soy Broth
(TSB) agar plate with 50 μg/mL of streptomycin, and growth overnight at 37°C.
A single colony was picked, and grown in 5mL of TSB overnight. The next day, this
inoculum was added to 95mL of TSB and grown to an optical density (OD) at 600 nm
was around 0.2-0.4 (generally an OD of 0.2 yields a titer around 5×107 cfu/mL). Once the
target OD was achieved, the culture was spun down at 10,000×g for 15 minutes. Pelleted
bacteria were resuspended in TSB with 15% glycerol, dispensed into 1mL aliquots in 2 mL
cryogenic vials, and immediately placed into a -80°C freezer. After a day or two at -80°C,
2 to 3 aliquots were thawed for titer determination. Each aliquot was thawed on ice for 30
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minutes, added to 9 mL of TSB, placed into a 125 mL Erlenmeyer ﬂask, and grown at 37°C
with shaking at 200 rpm for 1 hour. This culture was then centrifuged at 10,000×g for 10
minutes, the supernatant was removed, and the pellet was resuspended in 1 mL of sterile
PBS.
Inoculation of mice with L. monocytogenes
A 1 mL aliquot of stock with a known concentration of bacteria was thawed on ice for
30 minutes, added to 9mL of TSB in a 125 mL Erlenmeyer ﬂask, and incubated for 1 hour
at 37°C with shaking at 200 rpm. This culture was centrifuged at 10,000×g for 10 minutes,
the supernatant was removed, and the pellet was resuspended in 1mL of sterile PBS. The
stock was diluted further with sterile PBS to a concentration of 1×105 cfu/mL.
Mice were then inoculated by tail-vein injection with 300 μL of the 1×105 cfu/mL, 3×104
cfu/mouse.
Recovery of L. monocytogenes from infected animals
At the speciﬁed time point post inoculation with L. monocytogenes tissue samples were
collected in order to assay the bacterial burden. Organs were collected into pre-weighted 5
mL round-bottom polystyrene tubes containing 1.5 mL of sterile H2O with 0.02% Triton-X
and kept on ice.
The mice were euthanized and liver and spleen were collected and placed into the 5mL
tubes on ice. These tubes were weighed once again to determine the mass of tissue collected.
The tissues were then mechanically lysed using the Qiagen TissueRuptor. The Tis-
sueRuptor probe was washed and equilibrated by submerging and running it in 80% ethanol,
H2O, then H20 with 0.02% Triton-X between each sample.
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Measuring L. monocytogenes concentration
To determine the concentration of L. monocytogenes in tissue lysates or bacterial stocks,
samples were serially diluted 1:5 in H2O in a 96-well round-bottom plate. 5 μL of each dilu-
tion was then dropped onto duplicate TSB agar plates with streptomycin. After incubating
these plates overnight at 37°C, colonies were counted, and cfu/mL values of the original so-
lution were calculated. For tissue lysates these cfu values were then calibrated by dividing
the mass of tissue from which each sample was derived, to arrive at a cfu per mL per gram
of organ value (cfu mL-1 g-1).
A.2.3 HITS-CLIP
HITS-CLIP analysis was performed on with mouse pan-Ago pulldown, on samples gen-
erated from bone-marrow-derived-macrophages stimulated with EMCV for 6 hour. The
HITS-CLIP protocol was carried as described in [235] and [236]
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A.3 Results
A.3.1 Investigating the role of PIR1 in other models of infection
Mouse model of infection with Listeria monocytogenes Listeria monocytogenes is an
intracellular facultative anaerobe that can cause enteritis and encephalitis in children,
adults, and especially fetuses. It is know that L. monocytogenes, since it is an intracel-
lular pathogen, activates several intracellular PRRs as it infects a cell. In particular, L.
monocytogenes has been shown to activate the type 1 IFN pathways via LGP2 and MDA5
[237]. Having evolved to grow inside human cells, L. monocytogenes has actually adapted
to using the type 1 IFN response to its advantage, with decreased type 1 IFN signaling
leading to slower bacterial replication and lessened disease.
To test whether PIR1, which is known to interact with LGP2 (see Figure 2.3), has any
role in L. monocytogenes infection, I inoculated littermate control and PIR1KO mice with
L. monocytogenes by intravenous injection, and assessed bacterial growth at 24 hours and 48
hours after infection. Spleen and liver samples were collected from each mouse, lysed, and
live bacteria collected. The bacteria was then titered by serial dilution on TSB/streptomycin
plates.
As can be seen in Figure A.1, at 48 hours post infection, the PIR1KO mice show a
marked decreased in recovered L monocytogenes colonies from both the liver and spleen.
This result suggests that PIR1KO plays an important role in promoting L monocytogenes
infection in the mouse. Future studies should investigate whether this phenotype is a results
of a lack of type 1 IFN signaling—as I originally hypothesized—or whether PIR1 is playing
a diﬀerent role.
Type 1 IFN is critical for supporting L. monocytogenes replications [238], and is stimu-
lated by the activation of the RLR receptor LGP2 [237], presumably by the production of im-
munostimulatory RNA from bacterial DNA via cytosolic RNA polymerase III [155,237,239].
As this pathway for type 1 IFN involves RNA polymerase III (RNApolIII) products—known
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ligands of PIR1 [96]—it stands to reason that PIR1 would likely play a role. However, the
data presented in Figure A.1 would suggest that the removal of PIR1 limits type 1 IFN
production. It is possible that the RNApolIII products, being fundamentally diﬀerent from
virus-derived RNAs, requires some amount of dephosphorylation or shuttling into the RLR
pathway in order to properly stimulate an IFN response.
Mouse model of infection with Inﬂuenza A Virus Inﬂuenza A virus ([IAV]) is a human
pathogenic orthomyxovirus (negative sense ssRNA), which elicits a robust innate immune
response upon entering a cell. Since IAV is know to produced triphosphorylated RNAs
during the course of infection, I chose to investigate whether PIR1 plays a role. PIR1 is
hypothesized to function in processing viral RNAs, so I thought that PIR1KO mice would
show more severe disease following inoculation with IAV.
We infected littermate control and PIR1KO mice with IAV by intrapharangyeal inoc-
ulation, and monitored death and weather loss. As can be seen in Figure A.2, the PIR1
KO mice do show some diﬀerences in disease progression. While the littermate control and
PIR1KO mice show similar mortality rates, the PIR1KO actually exhibit signiﬁcant less
weight loss, and actually begin gaining weight as the disease progresses.
This is a counterintuitive result, and suggests that the mechanism of weight loss (which
is often used as a surrogate measure for IAV disease severity) might be separate from the
infectious processes ultimately responsible for mortality. The cause of IAV-induced weight
loss in the mouse models is thought to be a consequence of cytokine-induced anorexia (which
can be partially rescued by administration of a cyclooxygenase-2 inhibitor) [240], meaning
that a decrease in circulating inﬂammatory cytokines without a concomitant decrease in
lung damage and edema could theoretically lead to a less severe weight-loss phenotype
without any observable diﬀerence in survival.
If PIR1 modulated viral progression, aﬀecting the infection eﬃciency in certain tissues
or cell types, its possible that the damage and lung dysfunction responsible for mortality
could persist, while the mechanism for weight loss is mitigated, whether it be diﬀuse cy-
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Figure A.1: PIR1-deﬁcient mice show decreased rates of L. monocytogenes growth fol-
lowing infection. PIR1KO (N=6) and littermate control mice were each infected with L.
monocytogenes by intravenous injection and organs were collected at 24 and 48 hours post
infection. The burden of bacteria was then measured in each organ. Each represents a
control mouse, each represents a PIR1KO, and for each group the geometric mean is also
displayed. Control and PIR1KO groups were analyzed using the Mann-Whitney U test.
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Figure A.2: PIR1-deﬁcient show less weight loss, but similar survival kinetics following
infection Inﬂuenza A. PIR1KO (N=6) and littermate control mice were infected with IAV
PR8 by intrapharangyeal inoculation. Five mice per genotype were infected with 4000
pfu of inﬂuenza A virus (PR8 strain). (A) The represents the mean weight loss of the
littermate control mice, and represents the mean weight loss of the PIR1KO mice. Error
bars represent SEM.
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tokine production, immobility. Future studies should look to repeat these experiments while
monitoring for serum cytokine levels and assessing mouse mobility over the course of the
infection. Additional studies to collect lung samples from IAV-infected mice and measure
inﬂammation cytokine production and/or IAV replication in the lungs should also be done.
I would hypothesize that there would not be much of a diﬀerence in the lung, as this would
contradict the lack of a survival phenotype, as seen in Figure A.2.
A.3.2 High-throughput sequencing of argonaute-associated RNA molecules
Performing HITS-CLIP (high-throughput sequence cross-linked immunoprecipitation)
with a pan-Argonaute antibody, I isolated and sequenced the RNAs fragments associated
with an argonaute protein following infection with EMCV. Following sequencing the ago-
associated sequences were aligned to the EMCV genome. As can be seen Figure 4.3, there
does appear to a diﬀerential levels of EMCV-derived small RNAs bound to argonaute pro-
teins, with PIR1KO showing substantially higher levels of RNA derived from certain regions
of the EMCV genome, particularly in and round the L region.
While this experiment needs to be repeated, it does suggest that PIR1KO cells generate
and load into RISC a diﬀerent repertoire of virus-derived RNA molecules. As reads were
normalized to all aligned reads, and I have previously seen by direct probe ligation that
PIR1KO cells at baseline
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Figure 4.3: Analysis of argonuate-associated RNA molecules by HITS-CLIP. (A) An
overview of the HITS-CLIP protocol. (B) all ago-associated RNAmolecules which aligned to
the EMCV genome were stacked along the genome. Reads were normalized to total mapped
reads (mapped to the mouse or EMCV genomes). Blue tracks are aligned RNAs isolated
from wild-type cells and red tracks are aligned RNAs isolated from PIR1KO cells. Positive
and negative sense sequences are shown (positive sense above the x-axis and negative sense
below the x-axis), but almost no negative sense sequences were found.
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